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SUMMARY 
It is estimated that 115 million animals are used in experimental testing each year. Hence, 
shifting efforts toward alternative methods for toxicity assessment is essential. However, slow 
regulatory acceptance of new approaches is governed by knowledge gaps in toxicity modes of 
action. In this thesis, I describe these challenges and the use of in vitro screening as an 
alternative of animal testing. I also discuss common data-based methods to derive hypotheses 
about toxicity modes of actions, and the associated limitations in capturing multiple biological 
perturbations. 
 I applied novel data-based workflows, using rule models, to prioritize in vitro assays predictive 
of toxicity as well as to detect significant polypharmacology profiles. I explain how constraints 
were applied to rule-based models to inform meaningful mechanistic interpretation for two 
toxicity endpoints: rat hepatotoxicity and acute toxicity.  
I compared assays selected, by rules, for predicting hepatotoxicity with endpoints used in in 
vitro models from commercial sources. An overlap was observed including cytochrome 
activity, mitochondrial toxicity and immunological responses. However, nuclear receptor 
activity, identified in rules, is not currently covered in commercial setups. I also demonstrate 
that endocrine disruption endpoints extrapolate better into in vivo toxicity when a set of specific 
conditions are met, such as physicochemical properties associated with good bioavailability.  
Next, I examined synergistic interactions between conditions in rules describing acute toxicity. 
I gained novel insights into how specific stressors potentiate the perturbation by known key 
events, such as acetylcholinesterase inhibition and neuro-signalling disruption. I show that 
examining polypharmacology profiles is particularly important at low bioactive potencies. 
Further, the overall predictive performance of rules describing acute toxicity was tested against 
a benchmark Random Forest model in a conformal prediction framework. Irrespective to the 
data type used in the training, the models were prone to bias over compounds promiscuity, by 
which high promiscuous compounds were more likely to be predicted as toxic.  
Overall, the studies conducted in this thesis provide novel insights into molecular mechanisms 
of toxicity, namely hepatotoxicity and acute toxicity, and with regards to chemical properties 
and polypharmacology. This knowledge can be used to improve the utility and design of 
alternative methods for toxicity, and hence, accelerate the regulatory acceptance.  
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INTRODUCTION 
 
 
According the Cruelty Free International, 115 million animals are used in experimental testing 
each year, where the USA, Japan and China top the list.1 A worldwide movement against 
animal testing resulted in number of regulatory changes including the animal ban in the EU on 
cosmetic products since 2013.2  Yet, the adoption of animal free drug testing is still far from 
common practice, as the number of animals tested each year is not declining.1 The demand for 
banning animal tests does not only arise from ethical pressures but also the lack of efficiency 
and reliability of animal models as representatives of effects in human. Research have shown 
low concordance between outcomes from preclinical animal experiments and human effects.3,4 
This partly explains why 90% of drug candidates which were found promising in animal tests 
fail in clinical trials.5 Rectifying the current situation requires broad-scale actions from the 
regulatory and scientific communities to define alternative measures, as well as from the 
general public to raise awareness. 
 
In the first part of this chapter, we address challenges of animal testing and discuss alternative 
toxicity testing methods, giving great attention to in vitro methods. In part 2, we explain how 
data can be used to generate hypotheses about toxicity modes of action, as well as how to 
predict toxicity with confidence using conformal models. 
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PART 1: THE USE OF IN VITRO SCREENING IN 
TOXICOLOGY 
 
1.1 Current status in toxicity testing and the need to reduce, refine and 
replace animal testing 
 
In order to fulfil the requirements by regulatory agencies for compounds produced or used at a 
large scale, stakeholders are obligated to provide information about substance properties, 
exposure and risk management measures.6 As defined by the United States Environmental 
Protection Agency (EPA), risk assessment is the characterization of “the nature and magnitude 
of health risks to humans and ecological receptors (e.g., birds, fish, wildlife) from chemical 
contaminants and other stressors, that may be present in the environment”.7 Risk assessment 
and toxicity profiling are key steps in the regulation and legalization of chemicals. Safety 
profiling is also a vital part in the drug discovery process, which runs as early as stages of hit 
identification and optimization. Suboptimal safety profiles contributes to the high attrition rates 
of drug candidates reaching the market, due to unwanted adverse effects.5  
 Chemical safety requirements in both pharmaceutical and environmental industries demand 
extensive repeated-dose animal testing for a wide range of endpoints. Consequently, a 
considerable of animals battery is consumed to assess acute and chronic toxicity effects.8 For 
example, reproductive, developmental and carcinogenic endpoints require long-term animal 
exposure to chemicals on two or more species.9,10 Moreover, toxicity profiling of compounds 
involves conducting pharmacological safety tests to survey all organs for any adverse effect 
using various toxicity measures; such as lethal doses (LD50) and no observed adverse effect 
level (NOAEL).11 The timeline of animal-based safety assessment during the drug discovery 
process is presented in Figure (1-1). The reader can refer to relevant reports on the protocols 
of in vivo testing for drugs12 and environmental chemicals.13  
Animal-based testing is inefficient and raises considerable economical and ethical concerns, 
resulting in global pressures.14 Large numbers of potentially hazardous chemicals are not yet 
tested because current traditional methods are economically unfeasible. The estimated cost to 
legalize 68,000 compounds (in 2009) under the REACH (Registration, Evaluation, 
Authorisation and Restriction of Chemicals) regulations is $9.5 billion using 54 million 
 3 
vertebrate animals, which is difficult to handle. Additional limitations are the lack of 
mechanistic information on the toxicological modes of action15 as well as the difficulty in 
extrapolating results from animal models to estimate effects in human. From the 
pharmaceutical industry’s perspective, the vast majority of potential drug candidates are still 
failing during late stages of clinical trials due to insufficient safety evidence, despite passing 
preclinical safety testing.5 Therefore, actionable steps are to be conducted in order to fill the 
gaps in traditional methods. 
 
Figure (1-1) The timeline of animal-based safety assessment during drug discovery and development.16 
GLP: good laboratory practice, IND: investigational new drug, NDA: new drug application.  
 
The first step towards reducing the reliance on in vivo testing methods is to reduce the number 
of animals used. The 3Rs principle, which stands for Replacement, Reduction and Refinement 
of the use of animals in testing and research, was first introduced by Russell and Burch in 
1959.17 Since then, efforts to apply the 3Rs principles in the pharmaceutical sector resulted in 
reducing the number of animals used for testing through improving study design and 
coordinating projects.18 The most common and accepted animal testing guidelines, which is 
described by OECD documentation, has already entitled a significant reduction in the number 
of animal used to assess systemic toxicity.19  
The second step, to facilitate the aspirations of the 3Rs, is to develop and validate non-animal 
testing methods, which can be used to integrate with or replace in vivo approaches.20 The most 
common alternative methods are in vitro screening and in silico models, as will be discussed 
subsequently in this chapter. Several in vitro tests have already been validated and accepted in 
toxicity profiling as exemplified in Table (1-1). The set of validated assays represent endpoints 
Drug Discovery Preclinical Studies Human clinical trials
• Exploratory non-GLP
single and repeated 
dose studies in 2 species
• Safety Pharmacology
• Hepatotoxicity 
• Embryotoxicity
• GLP and non-GLP 
28 days repeated dose 
in 2 species
• GLP safety 
pharmacology
• GLP Genotoxicity
• GLP chronic toxicity
for 3-12 months in 2 
species
• GLP reproductive 
toxicity 
• GLP carcinogenicity for 
24 months in 2 species
IND NDA
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that can directly translate into in vivo effects. However, this may not be the case for complex 
endpoints such as toxicities in the liver and the nervous system, where multiple pathways and 
mechanisms are involved. In order to address this, a broad scale in vitro approach is adopted, 
as will be reviewed next. 
Table (1-1) Examples of accepted in vitro assays to predict in vivo toxicity.  
 
1.2 Large scale In vitro methods as a potential alternative for animal 
testing  
Driven by the need for an in-depth understanding of the molecular basis of toxicity events, and 
parallel to the calls for reducing animal testing, several technologies have been proposed and 
studied to characterize and predict adverse effects.25 The vision of toxicology in the twenty-
first century is motivated by shifting the standard and predefined battery of toxicology tests 
into hypothesis-driven methodologies which are adapted to the specific characteristics and use 
of chemicals.26 With the wealth of in vitro screening methods that have been proposed for 
Endpoint In vitro assay examples 
OECD 
document 
number 
Adopted 
Genotoxicity21 
 
Bacterial reverse mutation assay 
In vitro mammalian chromosomal 
aberration test 
In vitro mammalian cell gene mutation 
test 
In vitro mammalian cell micronucleus 
test 
In vitro gene mutation assays using the 
TK locus  
 
471 
473 
 
476 
 
487 
 
490 
 
1983 
1983 
 
1984 
 
2010 
 
2015 
 
Acute toxicity22 
 
 
- Skin corrosion 
 
- Phototoxicity 
 
 
 
In Vitro Skin Corrosion: Human Skin 
Model Test 
In Vitro 3T3 NRU phototoxicity test 
 
 
 
431 
 
432 
 
 
 
2004 
 
2004 
 
 
Endocrine 
disruption23,24 
 
ER binding assay 
Steroidogenesis 
TG 493 
TG 456 
2015 
2011 
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toxicity profiling,27,28 our focus in this chapter will be on in vitro approaches aimed for broad 
biological space screening.  
The special attention towards large-scale screening methods has arisen due to the 
unprecedented advances in biotechnology, genetics and engineering which have created an 
enriched environment for the rapid screening of chemical compounds for their gene expression 
profiles and biological activities via high-throughput screening (HTS) technologies.14,29,30 
Within the scope of drug discovery, HTS has not only allowed for the identification of hits and 
lead optimization, but also facilitated the success of some drug candidates in reaching the 
market.31,32,33  Following this success, several projects such as the Tox2115 (Toxicity testing in 
the 21st century) and ToxCast16 programs have been launched to evaluate toxicity via HTS 
techniques and consequently generate large in vitro data. 
Typically, HTS involves the screening of chemical entities in high-quality assays that capture 
biological functions at various degrees of complexity ranging from interaction with pure 
biological macromolecules, such as proteins and DNA, up to whole cellular systems and 
tissues. HTS is performed in an efficient automated manner using 96, 384, 1536 or 3456 
microtiter wells with the aid of high-performance detection techniques and followed by data 
processing and chemical profiling.30 Assays can be categorized as target-based, or phenotypic-
based according to readout complexity (Figure (1-2)). The measured phenotype can be an 
alteration in a biomarker or cellular components, such as changes in cell morphology and 
physiology. In contrast, target-based assays measure the direct or indirect interactions of 
compounds with specific predefined targets.  The hypothesis behind the utilization of HTS in 
toxicity assessment is that the chemical-induced toxicity is initiated by an interaction between 
the chemical and biological targets, by which one or multiple pathways are perturbed.34 
Several repositories were created to store measurements from in vitro screening, such as 
PubChem,35 ChEMBL,36 DrugBank37 and ChemBank.38 We will focus on two examples where 
broad scale in vitro screening is conducted for toxicity assessment purposes. The first example 
explains the use of secondary pharmacology profiling for drug development projects. Then, 
considerable attention will be given to the US EPA ToxCast initiative, which forms the 
backbone of data used for the analysis in this thesis. 
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Figure (1-2) Target-focused screening versus phenotypic screening. Target-focused assays are simpler 
and explain specific molecular functions. On the other hand, phenotypic assays involve at least a cellular 
biological system and can also extend to tissues of various cell types. Adapted from 
http://www.sulsa.ac.uk/research-facilities/uk-npsc/phenotypic-screening. 
 
1.2.1 Secondary pharmacological screening 
During the drug development process, secondary pharmacology screening, often termed off-
targets profiling, is conducted to identify possible bioactivities against targets other than the 
intended therapeutic target.39,40 It is reported that around 75% of adverse drug reactions can be 
attributed to the pharmacological profile of drugs, and hence, these unwanted effects can be 
predicted early on.41  Secondary pharmacological profiling involves screening against a range 
of targets types including enzymes, nuclear receptors, ion channels and transporters. A list of 
targets commonly used by four major pharmaceutical companies have been reviewed by Bowes 
et al.41  
Data from secondary pharmacology screening can be used to assess the promiscuity of 
compounds.42 Promiscuity is defined as the percentage at which a compound show activity at 
a given concentration (for example 1µM) against multiple pharmacological targets.43 Despite 
controversial reports, high promiscuity has commonly been associated with a higher likelihood 
of adverse reactions.44 Some marketed drugs show high promiscuity, yet tolerable effects.45 
Hence, disregarding promiscuous compounds in drug discovery projects may not be the best 
approach to address the risks of potential clinical effects.46 In Chapter 6, we will address the 
confounding effect of promiscuity on the classification of toxic compounds. 
Bowes et at argued that the associations between hitting particular targets can have higher 
relevance to human effects in comparison to animal models. Hence, these profiles provide 
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mechanistic insights about side effects observed in human. The secondary pharmacology 
profiling data can also be used to prioritize potential drug candidates as well as to inform 
subsequent tests. For example, if a hit target is identified, further experiments should be 
conducted to determine the selectivity across the target family and the potency in dose response 
assays. Also, target activity can guide the design and selection of in vivo studies relevant to the 
detected activity.  
One of the key off targets is potassium voltage-gated channel subfamily H member 2 (hERG), 
which is responsible for cardiovascular effects upon inhibition through the prolongation of QT 
interval of the electrocardiogram.40  Due to the high impact of inhibiting hERG, a regulatory 
requirement in drug submissions in first in human trials is including results of screening against 
this ion channel.47 One way to improve risk assessment using off-target activity is estimating 
safety margins by calculating the ratio of in vitro off-target potency (IC50) to the maximum 
plasma concentration Cmax.48 Several studies have shown how incorporating Cmax can improve 
the predictivity of clinical effects (see section 1.4.1). Yet, the limitation of this approach is 
overlooking the consequences of polypharmacology profiles of low potencies. The later will 
be addressed in Chapter 5 for chemicals inducing acute toxicity. 
1.2.2 ToxCast in vitro screening 
ToxCast is a chemical prioritization research program launched by the EPA in 2007 in 
collaboration with the National Toxicity program and the National Institute of Health Chemical 
Genomic Centre.15,49,50 One of the EPA's goals is to effectively manage and regulate 
environmental chemicals that are likely to cause harm to humans. However, such regulations 
require the assessment of large numbers of chemical entities. Inspired by the vision of the 
National Research Council for measuring perturbations in toxicity pathways as signatures to 
predict adverse effects in vivo,15,51 the EPA's  ToxCast program has adopted high throughput 
screening as a tool to assist in toxicity profiling by incorporating mechanistic in vitro assays50. 
Moreover, the advances in toxicogenomics, transcriptomics and proteomics have made a  great 
contribution in the determination of toxicological pathways and targets responsible for 
inducing diseases in vivo25. Hence, the toxicity biomarkers identified by transcriptomics have 
been utilized as assay endpoints, in conjunction with conducting a large scale screening 
approach for building the ToxCast database.  
The wealth of ToxCast assays ranges from cell-free biochemical to physicochemical and 
phenotypic endpoints. These are contributed by several platform sources in collaboration with 
 8 
the EPA.49 An overview of the core screening platform within the ToxCast project is given in 
Table (1-2), describing the various technological screening systems.  This shows the diversity 
of assays in the ToxCast assay pool, and hence, the potential of that data to derive novel 
mechanistic information associated with in vivo toxicity. The platforms providing the largest 
number of assay measurements are Apredica, Attagene, Bioseek and NovaScreen52, in addition 
to Tox21 using NCGC technology53 (see Table (1-2) for assay details).  
The ToxCast chemical library was designed by selecting compounds using specific activity 
and physicochemical criteria. First, the environmental compounds that have the potential of in 
vivo toxicity were selected (e.g. as pesticides, insecticides in addition to drugs).50 In addition, 
the ToxCast chemical library shows variable scaffold structures in order to assure as much 
chemical and bioactivity diversity as possible.49 Figure (1-3) represents the number of 
compounds screened in different phases of the ToxCast project. The Tox21 phase cover 
measurements for over 8000 compounds against a subset of endpoints including cell viability 
and nuclear receptor disruption.53 Overall, the number compounds with the broadest assays 
screens is around 1061.52 
Table (1-2): Description of HTS screens in phase I of the ToxCast project, adapted from Kavlock et 
al., Chem. Res. Toxicol., 2012.49 
 
Technology 
platform source 
 
Description 
ACEA 
 
Real time cell electronic sensing (RT-CES) of growth of A549 cells 
Apredica 
 
Cellular high content screening (HCS) evaluating cellular markers such as 
stress pathways, mitochondrial involvement, cell cycle, cell loss, mitotic arrest, 
and the cytoskeleton in HepG2 cells 
 
Attagene 
 
Multiplexed transcription factor profiling in HepG2 cells 
Bioreliance Gene mutation and DNA and chromosomal damage assays 
 
Bioseek ELISA based readouts of interactions of co-cultures of primary human cells 
  
Continued Table (1-1) 
CellzDirect qNPA on select genes relevant to xenobiotic metabolism in primary human 
hepatocytes 
 
Gentronix GreenScreen genetic toxicity assay using GADD45a GFP in TK6 cells 
 
NCGC qHTS profiling of nuclear receptor function in agonist and antagonist mode by 
reporter genes using a variety of cell types 
 
NovaScreen Biochemical profiling, largely using human proteins, of receptor binding, 
enzyme assays, GPCRs, and ion channels 
 
Odyssey-Thera Protein complementation assays for a wide variety of intracellular signalling 
networks. 
 
Vela Sciences High content multiparameter assays providing quantitative digital imaging of 
cultured cells as well as information on a variety of cellular 
proteins/structures/function 
 
Zebrafish Zebrafish embryonic development assay 
 
Mouse embryonic 
stem cells 
Mouse embryonic stem cell cytotoxicity and differentiation 
	
Technology 
platform source 
 
Description 
ACEA 
 
Real time cell electronic sensing (RT-CES) of growth of A549 cells 
predica 
 
C llular high con ent scr eni  (HCS) evaluating cellular markers such as 
stress pathways, mitochondrial involvement, cell cycle, cell loss, mitotic arrest, 
and the cytoskeleton in HepG2 cells 
 
Attagene 
 
Multiplexed transcription factor profiling in HepG2 cells 
Bioreliance Gene mutation and DNA and chromosomal damage assays 
 
Bioseek ELISA based readouts of interactions of co-cultures of primary human cells 
  
Continued Table (1-1) 
CellzDirect qNPA on select genes relevant to xenobiotic metabolism in primary human 
hepatocytes 
 
Gentronix GreenScreen genetic toxicity assay using GADD45a GFP in TK6 cells 
 
NCGC qHTS profiling of nuclear receptor function in agonist and antagonist mode by 
reporter genes using a variety of cell types 
 
NovaScreen Biochemical profiling, largely using human proteins, of receptor binding, 
enzyme assays, GPCRs, and ion channels 
 
Odyssey-Thera Protein complementation assays for a wide variety of intracellular signalling 
networks. 
 
Vela Sciences High content multiparameter assays providing quantitative digital imaging of 
cultured cells as well as information on a variety of cellular 
proteins/structures/function 
 
Zebrafish Zebrafish embryonic development assay 
 
Mouse embryonic 
stem cells 
Mouse embryonic stem cell cytotoxicity and differentiation 
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Figure (1-3) Number of compounds tested and assay endpoints screened in the key ToxCast and Tox21 
phases. 
 
 
1.3 ToxCast for Integrated Approaches in Testing and Assessment 
(IATA) 
 
The new toxicology approach, commonly referred to as the Integrated Approaches in Testing 
and Assessment (IATA), is mainly intended to reduce, refine and replace animal use for 
toxicity evaluation (3R measures).26 These approaches are used to prioritize testing, identify 
and characterize hazard, as well as to assess risk according to exposure measures. The aim 
through IATA is to provide a mechanistic oriented system for an efficient and 
human/environmental relevant safety evaluation.54  The IATA approach is designed to tailor 
the specific chemical and its exposure level. The components of IATA can be categorized into 
i) mode of action and adverse outcome pathways, ii) in vitro in vivo extrapolation (IVIVE) and 
iii) data-based methods55 (see Figure (1-4). These are performed by integrating two or more of 
the following; physicochemical properties, in vitro assays, mode of action analysis (MOA), 
human epidemiology data, animal test data, kinetic models and in silico models.56 These 
components, however, are not discrete. For example, data methods can be used to derive 
hypotheses about modes of action and also to predict kinetic parameters in IVIVE.  
 In vitro methods form a key pillar in the IATA paradigm.  In the following sections, each 
component will be explained followed by examples of how ToxCast assays has been 
implemented.  
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Figure (1-4) Integrated Approaches in Testing and Assessment (IATA) which consists of three main 
components, namely Mode of Action/ Adverse Outcome Pathway (MOA/AOP), in vitro in vivo 
extrapolation (IVIVE), and data mining. 
 
1.3.1 Mode of Action/ Adverse Outcome Pathway 
 
1.3.1.1 Overview of MOA/AOP framework 
 The mode of toxicity can be defined as a set of physiological signs that characterize adverse 
responses in the biological system.57 It is associated with identifying the perturbation in the 
biochemical pathway as well as the resulted physiological changes produced by that 
perturbation. A more recent term for the concept, which is the adverse outcome pathway 
(AOP), was first described by Ankley et al.58 The AOP can be defined as the conceptual 
framework which reflects the existing knowledge linking the initial triggers at the molecular 
level and the adverse outcome at the organizational level58,59 (see Figure (1-5) and Table (1-
1)). The AOP can be viewed as a series of sequential events reflecting a gradual increase in the 
complexity of the biological levels. These key events are linked via causal, mechanistic or 
inferential connections termed as key event relationships (KERs).59,60 The downstream adverse 
outcomes commonly describe effects which are relevant to regulatory testing requirements. 61  
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Figure (1-5) Adverse outcome pathway (AOP) framework. 
 
Table (1-3) Components of AOP. 
Key Event (KE) • Represent the nodes in the AOP  
• Describes measurable endpoints in the biological state 
Molecular initiating event 
(MIE) 
• Specific type of key events and the starting node in the AOP 
• Describes the interaction between chemical and biological 
targets, chemical reactivity, such as the formation of a hapten 
conjugate 
Key Event Relationship 
(KER) 
• Directional relationship between adjacent key events 
• Describes the weight of evidence which supports the functional 
or structural relationship between upstream and downstream key 
events 
Adverse Outcome (AO) • Key event at the biological organization level • Describes an apical endpoint usually of a regulatory relevance or 
part of guideline test 
 
High throughput and high content screening methods combined with computational modelling 
have provided useful tools for predicting adverse reactions and identifying measurable 
biomarkers. However, in order to incorporate this knowledge in the regulatory decision 
making, the mechanistic framework has to be validated and verified.62 The AOP not only 
provides a means for mechanistic verification and approval but also outline the current 
knowledge on how initiating events progress into adverse outcomes. Another advantage of the 
AOP system is reducing the complexity of the biological signalling pathways involved in the 
toxicological events.59 This is achieved by identifying measurable markers in the pathway in 
form of key events (KE). Hence, each key event in the pathway captures an upstream effect 
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which induces the relevant downstream effect if sufficient magnitudes and durations of 
perturbations were reached.  
In an attempt to promote the utility of the AOP framework as a predictive tool in risk 
assessment, the Organization for Economic Co-operation and Development (OECD) has lead 
initiatives towards guiding and promoting AOP development. The OECD formulated a set of 
guidelines for the development and evaluation of AOPs in 201363 followed by a revised version 
in 2017.54 Additionally, the OECD constructed an assembly of the accumulated knowledge in 
AOPs, namely the AOP-knowledge base (AOP-KB) which was made publicly available in 
2014.60 The AOP-wiki module of the AOP-KB represents a documented source of key events 
and associated adverse outcomes. The OECD has also organized workshops to encourage the 
collaboration and harmonization in the AOP community across the academic, governmental 
and private sectors to accelerate the acceptance of AOP in regulatory toxicology.61 Next, we 
will explore examples to derive molecular initiating events and early key events in the AOP 
captured as chemical substructures, i.e. structural alerts, and biological activities from in vitro 
assays. 
1.3.1.2 Structural alerts to understand initiating events 
Structural alerts are molecular substructure patterns that are associated with adverse 
reactions,64,65 also known as toxicophores. These molecular features are popular in elementary 
evaluations of the possible adverse effects because of their simplicity and interpretability.66 
The application of structural alerts can be in a form of a rule, which is described as; if alert X 
present in a molecule then it will have Y activity. The use of these alerts can be used for a 
specific in vitro assay activity67 or a complex adverse effect such hepatotoxicity.68 Structural 
alerts can be derived from expert knowledge and literature as well as from data-derived 
methods.69 However, the boundaries between these approaches are not fixed, and rather a 
spectrum where expert knowledge can be integrated to refine and curate substructures detected 
from large datasets.70  
Structural alerts resources include Derek71, Toxtree72 and ToxAlerts73, which are derived from 
curating literature. Data-based methods used to prioritize these alerts vary in complexity and 
enrichment methods. For example, with univariate methods, alerts are represented as 
independent substructural features for a given endpoint, such as the case of calculating the 
binomial distribution in a dichotomous fashion.74 Other methods such as emerging patterns 
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rather identify a set of one or more substructural features as a unit of enrichment.67,75 In such 
case, the rule involves one or more substructural conditions. These methods will be further 
discussed in part 2 of this section. 
The success of structural alerts is dependent on the type of endpoint used. Hence, in cases 
where the effect originates from a specific pharmacophore or chemical reactivity, i.e. 
electrophilicity, structural alerts are successful in flagging active compounds. This is 
particularly evident for effects such as mutagenicity75  and carcinogenicity67,76. Yet, the use of 
structural alert as a sole predictor can come with limitations. There is a probability to 
incorrectly label flagged compounds as toxic, encountering for false positives.66 Also, the use 
of structural alerts on their own is not enough to capture modes of actions in toxic compounds, 
and hence the integrating bioactivity data can be highly beneficial.77  
1.3.1.3 Using ToxCast to derive important key events 
The Toxcast in vitro project provides a wealth of bioactivity data for hundreds of compounds, 
for many of which in vivo toxicological data are available. These bioactivity measurements 
represent key events at the molecular and cellular levels which can be used to elucidate 
statistical links with adverse outcomes,61 and hence, understand the associated modes of action. 
The Toxicity Reference Database78 (ToxRefDB) has commonly been used as a source of 
animal-based in vivo toxicity endpoints generated in compliance with standard guidelines. For 
example, Martin et al. evaluated the effects of 309 environmental chemicals on the gene 
regulatory network by targeting nuclear receptors and transcription factor response elements 
in 73 assays.79 The authors were able to detect 133 significant univariate associations between 
ToxCast in vitro assays and 77 rodent in vivo endpoints and rabbits from the ToxRefDB.  In 
this study, significant associations were reported for Peroxisome proliferator-activated 
receptors; PPARa and PPARg, with liver tumors in rats, whereas, estrogen receptor (ERa) and 
its response element (ERE) had associations with reproductive effects such as decreased 
fertility. Additionally, Hu et al. utilized Comparative Toxicogenomics Database to explore the 
annotated toxicities and adverse reaction in humans induced by ToxCast chemical set.80 The 
annotated adverse effects and toxicities were grouped into four major toxicological categories; 
cardio-, hepato-, neuro- and renal-toxicities. The authors identified significant associations, by 
calculating the proportional reporting ratio (PRR), between the annotated toxicities and some 
genes mapped by ToxCast in vitro library. The analysis has shown that assays for modulating 
androgen receptors (AR) and glucocorticoid receptors (NR3C1) appeared repeatedly as 
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significant predictors of the four toxicological categories. Svensson et al used ToxCast assays 
to prioritize key events in structural cardiotoxicity (morphological damage of cardiac cells).81 
In this study, ToxCast compounds were mapped with drugs reported in the FDA Adverse Event 
Reporting System (FAERS). This resulted in identifying 22 adverse events-assays associations, 
involving estrogen receptors, PPARa/g and androgen receptors. Additionally, the authors 
developed two adverse outcome pathways, namely, downregulating tissue factor (TF) and 
modulating translocation protein (18 kDa) TSPO as key events for heart failure and mitral 
valve incompetence, respectively. Overall, the data-based enrichment of important in vitro 
activities has shown that nuclear receptor disruption, such as ER, AR and PPARs, frequently 
and significantly correlated with a broad range of in vivo toxicities.  
However, the insights gained from in vitro assays are limited to the biological space of the 
input data. Some of the chemical-gene interactions, which are important in toxicological 
events, were missing from the ToxCast assay library. For example, the catalase gene (CAT), 
which encodes for a vital antioxidant enzyme is missing from the ToxCast in vitro set. 80  The 
retinoic acid signalling pathway is involved in development toxicity,82 for which several 
endpoints have been screened in the ToxCast project, such as retinoic acid receptor (RAR) and 
retinoid X receptor (RXR). However, retinal dehydrogenase is missing in the data which 
represent an early key event in the pathological pathway.83 
 It is important when analysing in vitro data of broad biological space, to understand the 
confounders attributed by chemical and biological properties. In vitro bioactivity 
measurements rarely act as independent variables. An observed and reported confounder is the 
cytotoxic-based assay promiscuity of ToxCast activity measurements.84 Chemicals can show 
cytotoxic effects at same concentration ranges where target specific assays are activated. 
Judson et al reported that cytotoxic compounds (up to 100 µM), activated, in average, 12% of 
assays in comparison to only 1.3% of assays activated by non-cytotoxic compounds.85 This 
phenomenon is called the “cytotoxic burst” (CTB) at which intracellular machinery is activated 
due to unspecific effects such as cell stress and disruption of proteins and membranes. Also, 
the authors reported that in vivo toxicity can be explained by either i) specific target activities 
below cytotoxic concentrations or via ii) unspecific cytotoxicity and cell stress pathways. 
ToxCast assays that are frequently activated below CTB concentration were investigated.84 50 
unique targets were prioritized which occupied the top 90th percentile of assays with the 
greatest percentage of hits below CTB. A fraction of these was proposed as novel targets for 
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the development of AOP, such as sodium-dependent dopamine transporter (SLC6A3), 
prostaglandin E receptor (PTGER2) and chemokine ligand 10 (CXCL10).84  Additionally, 
target-specific assays were utilized to map genes and biological pathways. For example, Judson 
et al. mapped 315 unique genes from 467 assays so as to identify the magnitude of perturbing 
biological pathways by chemicals and its relation to toxicity.15 The results revealed an 
association between the number of pathways perturbed by a chemical and the minimum 
bioactivity concentration in a set of 15 cytotoxic assays. There was also an association between 
the concentration that caused pathway perturbation in vitro and the lowest effective dose on rat 
prenatal developmental toxicity.15 Another pattern is the inter-assay correlations of relevant 
biological functions. As will be shown in Chapter 3, assays for endocrine disruption (such as 
ER, AR and GR) broadly correlate with phenotypic and cytotoxic assays. This in part may 
explain why endocrine disruption assays frequently top in vitro readouts that are prioritized in 
data-based approaches as shown in previous examples. We will also report that assays for 
endocrine disruption are key predictive endpoints for hepatotoxicity (in Chapter 4) and acute 
toxicity (Chapter 5). 
Overall, linking in vitro bioactivities to mapped genes and biological pathways is useful to gain 
novel mechanistic information about in vivo toxicity. However, confounders such as inter-
assays correlation, cytotoxicity and promiscuity should be considered when in vitro data are 
interpreted. We will demonstrate in Chapter 4 that potent hepatotoxicants are characterized by 
specific pathway perturbations in contrast to low potent hepatotoxicants which tend to trigger 
more often non-specific phenotypic effects. Additionally, in Chapter 6 we report compound 
promiscuity as a confounder that can bias toxicity prediction in two different models.   
Deriving hypotheses about toxicity modes of action using data-based methods to is the 
backbone of research conducted in this thesis. These approaches will be further explained in 
part 2 of this chapter. Important in vitro profiles of chemicals-inducing hepatotoxicity and acute 
toxicity will be discussed in Chapter 4 and Chapter 5, respectively. 
1.3.2 In vitro in vivo extrapolation (IVIVE)  
Quantitative in vitro in vivo extrapolation (QIVIVE), which is the second component in the 
IATA, is defined as the process of estimating the human dose which achieves concentrations 
at the tissue target equivalent to that observed in in vitro tests.86 As the traditional estimation 
of pharmacokinetic parameters involves in vivo exposure tests to measure plasma 
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concentrations, volume of distribution and clearance rates, QIVIVE provides an alternative 
approach to model the kinetic behaviour of compounds.  The main components in QIVIVE 
rely on i) in vitro screening of biological properties and ii) kinetic parameters of compounds 
which are together incorporated in a physiologically based pharmacokinetic model (PBPK).87 
The biological characterization includes deriving the characteristics of dose-response effects 
and identifying the tissue target. Whereas, in vitro estimation of kinetic parameters includes 
measurements of permeability, plasma protein binding and hepatic clearance. The QIVIVE 
process has also benefitted from the advancement in computational modelling. The use of 
Quantitative Structure Activity Relationship (QSAR) models was proposed as a third pillar in 
QIVIVE in order to aid the prediction of bioactivity effects and kinetic parameters.88 Therefore, 
combining QSAR with in vitro tests and pharmacokinetic modelling has the potential to replace 
quantitative in vivo studies.  
QIVIVE can facilitate time- and cost-effective strategy in risk assessment by improving the 
translatability of in vitro assay results into in vivo effects.89 Wetmore et al used IVIVE methods 
to calculate daily human oral doses that are required for steady state blood concentrations 
equivalent to AC50 or lowest effective level (LEL) of ToxCast assays.90 Assessing the 
possibility of observing adverse effects can be improved when the real exposure dose is 
compared with the estimated dose associated with toxicity. 91  
Despite the significant steps towards replacing animal testing for exposure assessment, 
limitations still exist in modelling the pharmacokinetic parameters. This is particularly evident 
in the case of estimating compound clearance, at which models fail short to provide accurate 
predictions because of the complexity of this parameter.88 Wambaugh et al argued that the 
assumptions and approximations in common IVIVE methods can result in false estimation of 
equivalent in vivo doses when using in vitro derived kinetics.87 The authors reported that 
inaccurate estimation (up to 10 fold of underestimation or overestimation) results from 
excluding or improper incorporation of active transport, secretion and reabsorption in bile, and 
extra-hepatic metabolism.  
In Chapter 4, and in order to avoid assumption about estimating plasma and tissue 
concentrations, the approach we applied uses physiochemical properties as conditions to 
extrapolate important in vitro activities into in vivo hepatotoxicity. We demonstrate how some 
physicochemical properties can act as simple proxies for exposure, such maximum plasma 
concentrations, because they reflect properties of good bioavailability. 
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1.3.3 Applications of data-based methods 
 Data-based statistical mining on ToxCast can be categorized into i) understanding toxicity 
modes of action by linking in vitro activity to in vivo toxicity (see section 1.3.1.3 for examples), 
ii) identifying chemical categories using bioactivity profiles as well as iii) using assay 
measurements as toxicity predictors in machine learning models. We report below examples 
of studies where ToxCast data were used to achieve the latter two goals. 
The ToxCast data were explored for their ability to detect compound clusters of similar 
bioactivity and phenotypic properties. MacDonald et al. analysed the chemical-induced 
changes on Protein-Protein Interactions (PPI) by 107 ToxCast phase I compounds across 49 
high-content protein fragment complementation assays.92 Ward clustering of compounds 
showed that structurally similar entities clustered together, as well as compounds modulating 
the same therapeutic target classes. The authors, therefore, reported that known structure 
activity relationships were reproduced and suggested the mechanism of action of four drugs 
with unknown biological interactions. Moreover, the bioactivities of 976 compounds (ToxCast 
phase II) were analysed against 311 biochemical-target binding assays in cell-free 
environments. The results also demonstrated co-clustering of compounds sharing similar 
scaffolds as well as related targets.93 309 environmental94 chemicals and later 776 
environmental and pharmaceutical compounds95 were screened against BioAMAP system as 
part of the phase I and phase II ToxCast program, respectively. The results demonstrated that 
the BioMAP screening system was able to classify compounds according to major toxic and 
therapeutic mechanisms upon clustering bioactivity profiles. These studies show that ToxCast 
assays can be successfully used in grouping chemical classes and providing insights into some 
mechanistic information about modes of action.  
However, several studies have shown the negligible benefit of incorporating in vitro 
measurements to improve the predictive power of machine learning models.96,97 For example, 
Abdelaziz et al. used chemical descriptors, ToxCast in vitro readouts and the corresponding 
perturbed biological pathways to predict 61 toxicity endpoints via various classifiers.98 The 
authors concluded that only 10 endpoints, including rat developmental and hepatic toxicity, 
actually significantly benefited from using in vitro measurements as predictors in multi-domain 
predictive models98. Similarly, Thomas et al. applied more than 600 ToxCast in vitro assay 
readings for constructing predictive models against 60 in vivo endpoints.99 It was reported that 
bioactivities from assays had a limited effect on the overall predictive power, with the 
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exception of cholinesterase inhibition. Dix et al, however, argued that using statistical models 
without incorporating chemical and biological knowledge will result in poor predictivity from 
in vitro measurements.100 The authors recommended selecting relevant assay endpoints, 
applying relevant data aggregation and ensuring a sufficient size of compound data. For 
example, Lui et al reported a good overall accuracy when data of relevant hepatotoxicity 
endpoints were aggregated, and grouped into hypertrophy, injury and proliferative lesions. 101 
It is often seen that building predicting machine learning models from in vitro measurements, 
in general, performs better when chemical properties are incorporated.102 Yet, standard 
predictive models, especially non-linear models, provide little insight into the complex 
conditional associations between input data and toxicity outcomes.103  
1.4 Case studies: in vivo endpoints of regulatory importance 
1.4.1 Hepatotoxicity 
 
Hepatotoxicity is an adverse effect manifested in liver injury induced by drugs or chemicals. 
Drug-induced liver injury (DILI) resulted in the withdrawal of several drugs postmarketing, 
such as troglitazone in 2000 and sitaxentan in 2010. Between 2005 and 2010, hepatotoxicity 
attributed to 14% and 12% of the termination of AstraZeneca’s drug discovery projects due to 
unsatisfactory safety in preclinical and clinical studies, respectively.104 Liver injury can be 
induced by the parent compound or its reactive metabolites in a predicted dose-response 
fashion, as in paracetamol, or unpredictable (idiosyncratic) such as the case of phenytoin.105 
One way drugs can initiate liver injury is via chemical reactivity, by forming covalent bonds 
with intracellular components, eg proteins, or by depleting reduced glutathione (GHS) content 
at which cells are incapable of averting oxidative stress. As a result of these chemical reactions, 
cytotoxic immune responses and mitochondrial toxicity can be induced. Additionally, injury 
can result from specific interactions that perturb biological targets and signalling pathways, 
such as inhibiting bile acid pump, eg BSEP, resulting in blocking bile flow, i.e. cholestasis.106 
Russmann et al have reviewed a three-step model for mechanisms in DILI, which involves one 
or more of the three initial injuries, namely, cell stress, mitochondrial impairment and induction 
of immune reactions.107  These can further lead to inducing cell death pathways and severe 
mitochondrial dysfunction. Given the regenerative and detoxification capabilities of the 
liver,108 capturing mechanistic pathways in chemical-induced hepatotoxicity is challenging. 
In order to detect hepatotoxicity via in vitro models, relevant mechanistic endpoints are 
prioritized. However, this is not a straightforward task, primarily because hepatotoxicity 
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involves complex pathological pathways. Based on expert knowledge and known mechanisms 
of hepatotoxicity, several in vitro models have been developed, such as cytotoxicity, bile salts 
pump inhibition, mitochondrial impairment109, Cytochrome P activity,110  and covalent 
binding.111 Alternative models consider immunological activity through changes in cytokines 
profiles.112 Another in vitro technique used to screen for hepatotoxic compounds is high content 
screening (HCS), which utilizes multiple cellular measurements, such as changes in nuclear 
size, cell count, mitochondrial mass and cell membrane integrity, as biological responses.113–
115 Considering this diversity in biological mechanisms leading to hepatotoxicity, it is not 
surprising that in vitro assays which adopt a fraction of this bioactivity space would suffer from 
relatively low detection rates, with sensitivity ranging from 40 to 60%.95,113–115 It has been 
hence recommended that in vitro models for hepatotoxicity should involve a broad range of 
bioassay endpoints that cover wider biological perturbation points and cellular phenotypes, in 
order to increase overall sensitivity.114,116  However, which endpoints to consider, and how to 
combine their readouts, is not clear. 
The second important parameter for an efficient in vitro – in vivo translatability is exposure, 
i.e. to what extent the compound actually reaches the site where it exerts its action86, which is 
related to physicochemical properties.117,118 This parameter poses considerable difficulties in 
predictive toxicology modelling, mostly because this information is difficult to obtain for large 
sets of compounds. As a proxy for exposure, parameters such as maximum plasma 
concentrations (Cmax) and administered dose levels have shown improvements in the prediction 
of compounds in vivo toxicity. 109,114,115 For example, compounds had significant odds ratio for 
liver injury when levels of maximum plasma concentrations, Cmax, are greater than 1.1µM 
combined with a set of three bioactivities, namely cytotoxicity with an IC50 below 100µM, bile 
transport inhibition with an IC50 below 30µM, and mitochondrial impairment assays IC50 below 
25µM.109 It has also been recommended, as a rule of thumb, to have 100-fold separation 
between the concentration at which compounds are toxic in in vitro HCS assays and Cmax value 
in vivo.114,115 Additionally, some studies used total daily dose as an estimate for hepatotoxic 
liability combined with lipophilicity levels of compounds or in vitro bioactivity. For example, 
“the rule of two” states that the drug is likely to be hepatotoxic (with an odds ratio of about 
3.9) if the lipophilicity expressed as logP is greater than 3 and the daily dose is higher than 
100mg.119,120 Dose was also combined with in vitro covalent binding to generate a zone 
classification system which has shown a clear separation of drugs causing idiosyncratic 
toxicity.121 Another study has also shown that the likelihood for observing hepatotoxicity is 
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significantly higher when the administrated daily dose is higher than 100mg and the drug i) 
forms active GHS adduct, ii) has 5-fold IC50 decrease in Cytochrome P450 metabolism-
dependent inhibition, or iii)  binds covalently to proteins at levels higher than 200 pmol eq/mg 
protein.111 These studies demonstrate how incorporating daily dose or Cmax can be powerful in 
improving the predictivity of hepatotoxicity. Obtaining these measurements from in vivo 
experiments, however, is generally not feasible at early stages of drug development, or for 
profiling large number of compounds.  
In conclusion, early assessment of hepatotoxicity can be challenging for two factors. Firstly, 
how to capture the minimum biological space in assays for maximum compound coverage, and 
secondly, how to account for exposure when in vivo parameters are unavailable. We attempted 
to address these challenges in Chapter 4 using ToxCast in vitro data and physicochemical 
properties.  
1.4.2 Acute toxicity 
Acute toxicity is a key adverse outcome required in registration and legalization of chemical 
compounds used in industry.19 According to the R.7.4 documentation by European Chemicals 
Agency (ECHA)122, it is defined as “health adverse effects following short-term exposure” 
upon oral or dermal administration as well as the inhaled route. These effects include 
irritability, changes in organ weight, sensitization or mortality. The conventional method for 
assessing systemic acute toxicity is via measuring doses in oral and dermal exposure, or 
concentrations in inhalation route, at which mortality occurs for half of the tested animals, 
namely (LD50) and (LC50), respectively.6 The most common and accepted animal testing 
guidelines, which are described by OECD documentation, have already allowed for a 
significant reduction in the number of animals used to assess systemic toxicity.19 In 1981, 30 
animals per chemical were needed to derive a LD50 for the oral acute toxicity and 20 animals 
for dermal systemic toxicity.19 The current protocol was fewer than 10 animals for both oral 
and dermal toxicities according to adjusted OECD guidelines.123,124  
In order to reduce and replace traditional animal testing for acute toxicity in concordance with 
the 3Rs principles, alternative in vitro methods have been proposed. The current state of art for 
alternative approaches include in vitro assay for basal cytotoxicity using neutral red uptake 
(NRU) to identify starting doses in animal testing.125 Another method uses embryo-larval fish 
models, which has shown high correlations with acute systemic toxicity in rodents.126 Recent 
efforts have shifted into target-based bioactivities and chemical features to understand the 
underlying molecular mechanisms. Some of the key mechanisms identified for acute toxicity 
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include the interference with neurotransmission, ion channels, energy haemostasis, antioxidant 
pathways and cellular integrity.6 The description of toxic effects through adverse outcome 
pathway (AOP) frameworks provides, in conjunction with computational models, a realistic 
application of mechanistic data in risk assessment. Several AOPs were proposed around these 
key events (KE) to describe acute mortaltity127–129, which are published in the AOP database. 
These include the modulation of ionotropic GABA (gamma-Aminobutyric acid)129 and 
ionotropic glutamate receptors128, and the inhibition of acetylcholinesterase.130  
The key element to fully utilize the AOP framework is to understand how to implement 
mechanistic information at the molecular level to capture an endpoint with complex and diverse 
pathological pathways as in acute toxicity. Current efforts focus on understanding the 
complications of each key event separately. However, a more plausible approach is to 
investigate the toxicity triggered by multiple key events, which is more realistic given the 
polypharmacology nature of bioactive compounds. Experimental validation of multiple target 
activities can be laborious. For example, knockout mice are used to inactivate an existing gene 
by altering its sequence.131  When a knockout mouse of a specific gene is exposed to bioactive 
compounds, phenotypic effects can be compared with a control group which helps to form 
hypotheses about the effects of combining multiple activities. A study reported that aryl 
hydrocarbon receptor (AhR) activity, as a single variable, correlates with in vivo acute 
toxicity.132 AhR knockout mice have shown a higher expression of a1D-adrenergic receptors 
and an increase in the maximal effect in aorta contraction by a-receptors agonists; 
noradrenaline and phenylephrine.133 This indicates that combining AhR disruption with a-
receptors modulators have greater implications as compared to single bioactivities. While this 
approach is very informative to understand the effects of multiple targets, it is not feasible to 
explore all possible interactions that can lead to observable toxicological effects.  
In alignment with this concept, the AOP networks integrate multiple intersecting AOPs in order 
to explain and anticipate complex toxicological pathways.134,135 AOP networks allow for two 
key objectives to be achieved. First, to anticipate the actual critical path in which molecular 
initiating events (MIE) eventually result in the observed outcome. Second, to understand the 
possible effects when multiple MIE/KE are combined for which their AOPs have downstream 
intersections, leading to additive, synergistic or antagonistic interactions.136 The current 
challenge to fully utilize the AOP network framework is the incomplete information about 
KE/MIE linked by key event relationships (KER) resulting in either known or unexpected 
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phenotypic outcomes.135–138 Therefore, it likely that the current state of knowledge will not 
capture all possible risks in cases where multiple stressors exist in the occasion of bioactive 
mixtures or compounds’ polypharmacology.138  
Thus data-based approaches, which consider statistical interaction of variables, can offer an 
alternative way to investigate significant polypharmacology as will be proposed in Part 2 of 
this chapter, and investigated in Chapters 4 and 5. 
1.5 Filling knowledge gaps in toxicity modes of action can accelerate 
regulatory acceptance of new methods 
 
Despite the rapid advancement in new testing technologies, the acceptance of these methods 
by regulatory bodies is still slow. In the US, regulatory acceptance and utilization of non-
animal methods vary in formal legislative requirements.6 For example, the guidance on 
nonclinical safety studies for the conduct of clinical trial recommends obtaining data from 
animal studies including lethality tests, as described in the  ICH 2009.139 Whereas,  the EPA 
Office of Pollution Prevention and Toxins (EPA OPPT) would accept and recommend non-
animal test such as QSAR models and in vitro tests.19 In the EU, the Cosmetics Directive has 
implemented regulations in 2009, which imposed an animal testing ban on cosmetics 
ingredients.2 Given the large numbers of chemicals yet un-tested in traditional animal studies, 
REACH has also recommended implementing non-testing methods including QSAR, read-
across and physicochemical methods.  
Although regulatory bodies in environmental industries have recommended the use of 
alternative methods, the approval of these methods for drug regulation to substitute animal 
testing is yet hindered by a number of factors.140 For example, the lack of clarity in applying 
weight of evidence, as well as concerns about robustness and reproducibility, are some of the 
obstacles slowing regulatory acceptance.140 The purpose of alternative methods is not to 
reproduce outcomes of animal studies, but to provide insights into possible risks relevant to 
human.55 Given the large number of potential mechanistically-based models, effort should be 
streamlined for international harmonization. One way to accelerate this process is by using data 
to derive novel hypotheses about modes of action and use these insights to rationalize toxicity 
assessment. We will next review some data-based approaches used to derive mechanistic 
hypotheses about in vivo toxicity, then propose rule models as a potential method to address 
 23 
challenges in capturing important mechanism of toxicity as well as significant 
polypharmacology profiles.  
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PART 2: DATA-BASED METHODS TO UNDERSTAND 
TOXICITY MODES OF ACTION USING IN VITRO 
DATA 
 
This section will address data-based methods used to generate hypotheses about toxicity modes 
of action. While generating hypotheses from data is a broad topic, our focus will be on how to 
prioritize molecular and cellular key events in the toxicological pathway using large scale in 
vitro data. Examples of studies reporting important key events from data were given in section 
1.3.1.3. In this section, we will first review some the most common methods to find significant 
associations between in vitro activity and in vivo toxicity. Then we will explore the potential 
of rule models to prioritize key events, as well as to understand conditional associations, such 
as significant polypharmacology profiles and important physicochemical conditions. Finally, 
we will address how to classify toxic compounds with confidence using the conformal 
prediction framework.    
2.1 Common data-based methods to prioritize key events  
In order to generate hypotheses about modes of action, interpretable feature space and 
algorithms are to be used. With regards to data, common sources include in vitro bioactivity 
measurements such as assay readouts and gene expression, as well as substructures and 
physicochemical properties. Some of the popular methods for exploring key events, including 
univariate association and regression methods, are reviewed below.  
2.1.1 Univariate associations 
Data-based endpoint prioritization has until this stage, been commonly performed by 
analyzing significant univariate associations and correlations between in vitro readouts and in 
vivo observations. These associations are frequently performed in a dichotomous manner to 
link a binary activity call in an assay, i.e. active or non-active, against a two-class toxicity label, 
i.e. toxic or non-toxic. The counts of these flags can be summarized in a contingency table, as 
presented in Figure (2-1). When the activity in assays is captured as continuous variables, such 
as IC50 (concentration at half maximum inhibition), a discretization step is performed by setting 
an arbitrary value as a threshold for activity.  
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Figure (2-1) 2 ´ 2 contingency table used to calculate dichotomous associations between in vitro 
activity and in vivo toxicity. 
Examples of algorithms commonly used to mine univariate associations are summarized in 
Table (2-1). Prioritization of key events in this way is useful to identify predictive in vitro 
assays as well as enriched structural alerts. This process can also be performed during 
exploratory analysis as a primary step to select important features prior to advanced statistical 
modelling. The limitations of these methods, however, arise when important key events may 
not be predictive on their own and need to be accompanied by other conditions such as specific 
chemical space, permeability requirements or multiple biological perturbations. As a result, 
key events of toxicity importance may not top the rankings and hence, excluded or overlooked.  
The analysis in this chapter attempts to overcome this limitation by using rule models. Rules 
will be used to mine conditional associations using chemical and biological properties, as will 
be explained in section 2.2 and demonstrated in the subsequent chapters. 
 
2.1.2 Multiple linear regression  
Linear regression describes the relationship between a response variable and predictor variable 
using linear parameters. 141 The simplest regression can be described as follows: y=	wo+w1x1+w2x2	+	...	+	wnxn  [1] 
where y is the numeric response, wo is the intercept, (w1,	w2,	…,	wn) are the coefficients for x1,	x2,	…,	 xn variables. The advantage of the linear regression is interpretability given that the 
absolute numeric values of the coefficients reflects the importance of the corresponding 
variables.  
  Toxic effect 
  Toxic 
Non-
toxic 
Assay 
activity 
active a b 
inactive c d 
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Table (2-1) Examples of common algorithms to estimate univariate associations for key event 
prioritization  
 
Univariate 
method Equation Comment 
Relative 
Risk/Positive 
Reporting 
Ratio  
RR/PRR = 11 + 2 33 + 45  
a,b,c,d correspond to values 
in Figure (2-1). This measure 
was used to prioritize 
ToxCast assays against 
multiple in vivo and human 
toxicity endpoints.79,80 
Odd Ratio OR	 = 12 345  a,b,c,d correspond to values in Figure (2-1). 
Fisher test 7 = (1 + 2)! (3 + 4)! (1 + 3)! (2 + 4)!1! 2! 3! 4! ;!  
a,b,c,d correspond to values 
in Figure (2-1), N is the sum 
of a, b, c and d. P value for 
significance of association 
(probability of observing 
values as random). A 
threshold of 0.05 or lower is 
usually used to describe 
significance. Fisher test was 
used to identify ToxCast 
assay associated with tumors 
in rat.15 
Mutual 
information I(X; Y) = @@A(B, C)DEF A(B, C)A(B)A(C)G∈IJ∈K  
Mutual information between 
two variables X and Y of 
discrete values, where xÎX 
and yÎY. mutual 
information was used to 
prioritize ToxCast assays 
associated with structural 
cardiotoxicity in human.81 
Binomial 
distribution 
P=  ∑ 	MNOPQN ((n'!)/(i!	(n'-i)!))	×	(m/n)i	×																										(1-(m/n))(n	'	-i) 
P value is derived from the 
probability density function 
of a binomial distribution. 
This measure is used to 
identify substructures that 
are enriched in active or 
toxic compounds.74,142 n is 
the total number of 
compounds, m is count of 
active/toxic compounds, n’ 
is counts of compounds with 
substructure and m’ is count 
of active compounds with 
the substructure. 
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In cases where the response is dichotomous, i.e. a label accounting for 2 classes, such as toxic 
and non-toxic, the response (y) can represent the probability P of observing one class variable. 
In order to fit the probability estimates between 0 and 1, a sigmoidal function (s) is used as: 
A = 	s	(y) = 	 WWXYJZ[\      [2] 
As linear regression can capture multiple features at a time, this model has been applied to 
assess drug toxicity by combining in vitro activity and exposure. For example, assay 
measurements for covalent binding in hepatocytes and daily dose were used to predict 
idiosyncratic drug reactions.121 Using regression analysis, the authors reported a three zone 
system that classifies multiple safety categories. 
Additionally, linear regression equation can also capture feature interactions when the variables 
used are mutually dependent.143 For a response y described by variables x and z with an 
interaction, the regression equation can be represented as follows: y	=	wo+w1x+w2z+w3	(x×z)   [3] 
where w1, w,2, w3 are the coefficients and (x´z) is the interaction variable. Lazic et al used 
hERG potassium channel activity from in vitro measurements as well as clinical Cmax 
(maximum plasma concentrations) to derive probabilities of observing QT elongation on an 
electrocardiogram.144 The authors used a linear model and considered an interaction between 
hERG activity and Cmax. Additionally, the authors controlled the direction of association 
between hERG activity and QT elongation assuming a positive monotonic association between 
these variables.144 Combining hERG activity and Cmax has shown improvement in capturing 
cardiotoxicity in comparison to using hERG in vitro activity alone. 
Although linear models help understand the contribution of multiple variables towards the 
target endpoint, they are sensitive to noise and may not perform well using highly correlated 
variables. A prior pre-processing step is to be conducted, most importantly, to capture the most 
important and causal predictor variables.145 As shown in the example above, when few 
variables of direct association with the endpoint are used, the linear regression model can be 
very informative. However, these models may not be able to capture toxicity endpoints 
characterized by highly diverse underlying mechanisms.101 High dimension feature space can 
be captured by nonlinear models such as Random Forest146, support vector machines147, and 
deep neural networks148, which have shown high performance, but at the cost of 
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interpretability. In order to derive interpretable associations between large scale in vitro activity 
and toxicity, we used rule models. Rules can capture both conditional associations and allow 
for the description of toxic compounds that exert diverse modes of action. In the next section, 
we will explain generic rule models and algorithms. Additionally, we will propose 
modifications so as to overcome limitations of conventional rule models when capturing 
toxicity data. 
2.2 Rule models to understand polypharmacology of toxic compounds 
Rules can be defined as sets of feature conditions that are commonly associated with another 
variable and presented in if-then statements.149 Hence, unlike univariate associations, rules find 
a set of features, when are all present (using an AND operator), the association with the 
response label is stronger. Here, we will define different rule types, and algorithms used to 
generate these rules. Then we will explore the limitations of conventional rule methods and 
how to overcome these limitations so as to extract meaningful in vitro-in vivo associations as 
well as to identify significant polypharmacology profiles.  
Rules are meant to be simple representation of data. They can run in a supervised or 
unsupervised manner. The notion, association rules, run in an unsupervised fashion where one 
or more features are associated frequently with another feature, i.e. finding the frequent 
itemset.150 Whereas, classification rules use a predefined response label to find discriminating 
condition sets in a supervised fashion. Table (2-2) compares classification rules with 
association rules. 
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Table (2-2) Comparison between association rules and classification rules. 
 
 
Association rules‡1 
 
Classification rules 
 
Mining approach 
 
Unsupervised 
 
Supervised 
Most common searching 
score 
Frequency Entropy or Gini index 
Data representation Transactions binary matrices 
Matrices of categorical or 
continuous variables (rules) 
Transactions/binary matrices 
(emerging patterns) 
Left hand side (LHS) Combination of feature items 
Combination of feature values 
(rules) or feature items (emerging 
patterns) 
Right hand side (RHS) One feature A class label 
Algorithm example 
 
Apriori 
 
C4.5, CPAR 
 
 
2.2.1 Classification rules versus emerging patterns 
Emerging patterns are a form of contrast data mining techniques which identify feature sets 
frequent in one class of the data, but not the others.151  Rules and emerging patterns are 
describing the same concept. However, during the construction of conventional rules models, 
a discretization process is usually involved especially when continuous features are used. In 
contrast, emerging patterns take as input features described in true/false or categorical values. 
Hence, data are discretized beforehand and prior the generation of emerging patterns. For a set 
of binary variables, the common input structure for classification rules is a binary matrix as the 
left representation in Figure (2-2), whereas, emerging patterns handle transaction 
representation of data as an input (right in Figure (2-2)).  
Given a dataset of X samples where Xi Î X described by feature set Y, where Y= {A, B, C, 
…, Z} and class C, where C = {1, 2}. A rule R can be represented as follows: 
 
‡ Associations rules can be used for classification by pruning all rules not describing the class label as the RHS 
variable. An example for this implementation is the CBA383 algorithm (Classification Based on Association). 
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IF predictor A > 0.1 AND predictor B < 0.5   THEN   class C=1 
The example above describes a rule for data samples that are described by continuous variables. 
Each rule condition in this case is represented by two segments, which are the feature and a 
corresponding split. For example, the first condition in the rule entitled the predictor A and 
split specification at values greater than 0.1. 
 
 
Figure (2-2) Pseudo dataset of binary features and class labels represented as a conventional binary 
matrix (left) commonly used to derive classification rules, and transactions lists (right) which are used 
to generate emerging patterns. 
 
Emerging patterns aim to find combinations of discriminating features in a supervised 
classification problem.149 For each entry in the data (a compound in the training), the features 
are described as ‘s’, where s Ì S, and label c Í C, where S are all feature set and C are all 
labels. An itemset is a subset of features which are present in one or more entries.  If an itemset 
of features is present frequently among entries in the data set, such itemset is called a frequent 
pattern.  
Measures to describe the performance of rules and emerging patterns are the same. The 
frequency of a pattern (i) or a rule R is described by the support (Suppi), which is the count or 
fraction of entries in the dataset that support this patterns. In other words, the support is the 
count of entries where a pattern or a rule is fulfilled. The minimum support level, for an itemset 
to be frequent, is set by the user. Another key measure for the performance is the confidence 
(Conf) which describes how accurately a pattern or a rule can predict the class label of fulfilling 
entries. Confidence is presented in Equation [4] for a rule i describing label c: 
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Conf(a	Þ	c) 	= 	Supp(a	Ç	c)	/		Supp(a)       [4] 
Where i  Í S and c  Í  C, S is the group of all feature set, and c is a class label in all labels C. 
2.2.2 Algorithms to generate discriminating rules 
Many algorithms were developed to generate rules. Here we will focus on two algorithms, 
which are C50 for classification rules and CPAR for emerging patterns. These algorithms were 
used in Chapter 4 and Chapter 5, respectively. For comparison purposes, we applied a Random 
Forest model in Chapter 6 to evaluate the predictive performance of emerging patterns. Hence, 
the Random Forest algorithm was also reviewed below.  
2.2.2.1 C5.0  
C5.0 algorithm was developed by M. Kuhn152 based on the C4.5 algorithm introduced by 
Quinlon in 1992.153  Rules, in the C4.5 algorithm, are constructed by collapsing an unpruned 
decision tree. The decision tree, in a classification problem, consists of nested if-then 
statements of predictors to describe a class label. A simple tree can be represented as follows: 
IF predictor A > 0.1 then 
|      if predictor B < 0.5   THEN   class C=1 
else class C=2 
 
This tree can be converted into the following rules: 
IF predictor A > 0.1 AND predictor B < 0.5   THEN   class C=1 
IF predictor A <= 0.1   THEN   class C=2 
 
As each rule represents a unique path in the tree (a route to a terminal node), the number of 
conditions in a rule is equal to the number of nodes in that path. 
 The first step in constructing a tree is finding the feature set and split points that achieve 
maximum discrimination between classes (highest purity).  To find the best split, searching 
measures quantify the purity in order to rank the generated splits. C4.5 uses the information 
statistic, entropy, which is originated from the information theory154. First, the information 
statistic is calculated before and after the split using Equation [5]. afgE = 	−[	7	 logl 7 + (1 − 7) logl(1 − 7)	]           [5] 
Where info is the information statistic, p is the probability of the first class and (1-p) is the 
probability of the second class.  
 To estimate the improvement in purity, the difference in the information statistic before and 
after the split is calculated and represents the entropy, Equation [6]. The higher the entropy, 
the higher the ability of the condition to discriminate between the classes. 
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afgEno1paEf	F1af	(qfpnE7C) = afgE	(2qgEnq	r7Dap) − 	afgE(1gpqn	r7Dap)             [6] 
The splits are gradually added, in a nested tree, to eventually create homogenous partitioning 
of data classes. 
The second step is collapsing the tree into rules. Then, rules are pruned using a pessimistic 
pruning approach to remove conditions with the least improvement in rule accuracy. The error 
is estimated for the unpruned rule (baseline error) as well as for the rule except for one 
condition. The condition with the highest error rate is removed iteratively, given that the error 
rate is greater than the baseline error. This is repeated until the maximum error rate of any 
conditions is greater than the baseline error or until all conditions are removed, i.e. the rule is 
removed. The remaining rules are then prioritized to select the minimum representative set. 
The minimum description length (MDL) metric selects the simplest rule combination using 
search methods such as simulated annealing. Finally, the rules are ordered by accuracy. C5.0 
algorithm adds on to the C4.5 features such as boosting and unequal cost.141,152 Also in C5.0, 
rules are not ranked. Instead, predictions are made according to a voting system which is 
weighted by confidence. 
2.2.2.2 CPAR (Classification based on Predictive Association Rules)  
CPAR is an emerging pattern algorithm developed by Yin and Han,155 extended from the PRM 
(Predictive Rule Mining) and FOIL (First Order Inductive Learner) algorithms. FOIL156, which 
was developed by Quinlan, uses gain (Equation [7]) as the searching measure to build rules. 
The best feature in gain is added, one by one, until the maximum rule size is reached.  
Gain	 = |A∗|	(log |w∗||w∗|X	|x∗| 	− 		 log |w||w|X	|x|)          [7] 
Where |P*| and |N*| are the counts of positive and negative instances after adding the feature 
condition to the rule, whereas, |P| and |N| are the counts of positive and negative instances 
before adding the feature.  
A key feature in the FOIL algorithm is that example entries are removed from the training data 
as soon as a fulfilling predictive rule is generated. PRM (Predictive Rule Mining) extends from 
FOIL by applying a decay factor to the used examples instead of removing these instances. 
CPAR adds up to these features by considering multiple options in the gain-based feature 
selection, which results in generating multiple rules simultaneously. For example, if the top 
gain feature co-occurred with other features with 0.99 gain similarity, multiple rules are 
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produced considering these options. Therefore, CPAR can be seen to combine the properties 
of the exhaustive association classification and the conventional greedy rule-based algorithms. 
2.2.2.3 Random Forest 
Random Forest as described by Breiman (2001)157, is an ensemble of m number of unpruned 
tree models, each producing an independent prediction. Using m number of trees, m number of 
predictions are then aggregated for each instance, i.e. via number of votes in classification or 
average prediction in regression. The Random Forest is based on the CART158 algorithm, 
originally developed by Breiman et al in 1984, which uses Gini impurity as the search metric 
for the best split. Gini index which was introduced by Breiman et al158 is presented in Equation 
[8]. Fafa	af4qB = 	71	 (1 − 71) +	 72	(1 − 72)           [8] 
where p1 and p2 are the probabilities of class 1 and class 2, respectively. In two class data, the 
Gini index is equivalent to 2p1p2. At equal distributions of the two labels, i.e. p1=p2, the Gini 
index value is maximum and equal to 0.5. Therefore, as the purity increases the value of the 
Gini index decreases.  
The random component in the Random Forest algorithm is introduced by training trees on a 
random subset of predictors/features P, referred to as mtry using random bootstrap samples. 
This randomness prevents the low variance in predictions as a result of highly correlated trees, 
i.e. trees of similar structures. The recommended value for mtry is 1/3 P for regression and √A 
for classification, where P is the number of features.157 The higher the number of trees, the 
lower the error rate of the ensemble model. However, as a rule of thumb, a recommended 
number of trees is between 500159 and 1000.141 
2.2.3 Limitations of conventional rule models  
Rules are useful to understand patterns within data and can be highly interpretable. They find 
conditions at which high purity of a label class is achieved. In other words, rules with sufficient 
discriminating power can be useful to extract the combination of related features which 
together can translate better into the outcome property.  
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Despite the interpretability of rule models, they suffer from two key limitations that may hinder 
their applicability for extracting meaningful information from toxicity data. Firstly, 
conventional rule algorithms do not imply any constraints on the direction of the association 
between activity in vitro and toxicity in vivo. The general assumption in the relationship 
between the activity in an in vitro assay and the in vivo effect has often been a positive direction. 
In other words, in vivo toxicity is related to activity against a target or perturbation of a pathway 
rather than inactivity. This assumption is applied when in vitro – in vivo associations are 
interpreted or univariate correlations are derived.80,101 Also, this directional association is 
fundamental in developing AOPs from a series of key events (see Figure (1-5)).   
In this thesis, constraints were applied in rule models to preserve a positive direction for the 
association between in vitro activity and in vivo toxicity. Hence, the presence of toxicity is 
linked to the presence, (but not absence) of in vitro activity. Whereas, the absence of toxicity 
is related to the absence of in vitro activity. These constraints were applied in two ways, i) 
pruning rule space generated by C50 algorithm in Chapter 4, and ii) pruning the data space 
prior to running CPAR algorithm in Chapter 5. 
Secondly, when a high dimensional feature space is used against a toxicity label of complex 
mechanistic pathways, the number of generated rules can be large and difficult to interpret. 
This was handled in two ways: i) selecting the most representative rules which have the 
maximum assay diversity and maximum compound coverage, and ii) combining rule models 
with network analysis to visualize and extract important patterns. The first approach was used 
in Chapter 4 for hepatotoxicity and the second was used in Chapter 5 for acute toxicity. 
2.3 Using Conformal prediction framework to assess uncertainty in toxicity 
classification   
The main challenges for accepting alternative methods in regulatory toxicology are the low 
interpretability of common statistical models, as well as the uncertainty level of predictions 
made.  
One of the most common data-based approaches in predictive toxicity is QSAR models. QSAR 
is a mathematical model that associates molecular representations of compounds with an 
important chemical property or biological endpoint.160 The development of efficient molecular 
representations, such as 2D molecular fingerprints by Klopman, has also assisted in the 
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growing utilization of QSAR models.161 The reader can refer to published articles for detailed 
accounts of molecular representations and machine learning algorithms used for 
QSAR.160,162,163 
In order to improve model interpretability, the QSAR framework in toxicity prediction has 
evolved to incorporate knowledge in biological pathways and perturbation points.100 The so-
called MoA QSAR (Mode of Action QSAR) combines biological assay results with structural 
features as predictive descriptors.160 For example, readouts from ToxCast in vitro assays were 
used with chemical descriptors to predict hepatotoxicity in rats.101 It is argued that associating 
in vivo phenotypic effects of compounds from their biological information alone can be 
limiting.146 In fact, utilizing chemical information in addition to bioactivity data can be critical 
in deriving meaningful mechanistic interpretations.146  
A key step in the generation of QSAR models is defining the applicability domain, which 
assesses the chemical space where reliable predictions can be made.164 In concordance with 
this principle, the OECD has determined a set of specific criteria for the use of QSAR in 
toxicity prediction in regulatory applications.165 These criteria include defining the 
applicability domain, and the ability to provide mechanistic interpretation.  
 The applicability domain aims to assess the similarity of the test points with those used in the 
training the model.166 Yet, a more practical assessment of the model performance should 
address the uncertainty or confidence of each prediction. In this context, the conformal 
prediction framework has been proposed as a technique to allow predictive models to only 
generate valid predictions within a given level of confidence.167 This framework has a great 
potential in the field cheminformatics167 and drug discovery168  where a robust measure of 
uncertainty is required for decision making. The level of confidence is set by the user and it 
controls when a model can assign a prediction to a new instance. Svensson et al have applied 
conformal prediction using a Random Forest model to predict the compound cytotoxicity in 
different cell lines.169 The conformal models achieved 80% average accuracy and 87% average 
coverage at a confidence level of 80% despite the significantly unbalanced cytotoxicity labels.  
Moreover, Ji et al have developed a web server, eMolTox, to predict 174 in vitro and in vivo 
toxicity endpoints for compounds under a conformal prediction setting.170 Hence, evaluating 
the reliability of predictions made by models is very insightful in toxicity assessment. 
In order to have an unbiased evaluation for the confidence of the conformal model, a reference 
dataset which is independent to the training set is used, i.e. the calibration set. Figure (2-3) 
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represents a basic workflow for conducting a conformal predictor using Random Forest. The 
training data are split into proper training and calibration sets. The proper training set is used 
to develop the underlying model, whereas, the calibration set is used as a reference to rank the 
test samples. 
The conformal predictor uses a non-conformity measure (NCM) to make predictions and 
estimate the confidence. This numeric measure correlates with the likelihood of the class label 
in question. In other words, the NCM represents a way to describe the similarity of new 
instances in comparison to the training set. Some of the commonly used NCM include the class 
probabilities from machine learning models such as Random Forest169 as well as similarity 
measures used in applicability domain evaluation.171 With respect to the calibration set, test 
instances are ranked.  The level of accepted rank is determined by the confidence level set by 
the user. For example, a confidence level of 80% means that the models will only give a valid 
class label for the new instances if its NCM rank falls within the top 80% of the calibration 
data. On the other hand, if the NCM of new instance does not fall within that region, the model 
fails to assign a valid label, and hence, it is considered outside the confidence level of the 
conformal model. 
When the data set is significantly unbalanced, it is preferred that the rankings are performed 
for each class label independently as in the Mondrian conformal prediction, which was 
introduced by Vovk et al.172 In a binary classification problem, conformal predictor models 
produce four types of outcome for each instance. For example, given arbitrary class labels of 
A and B, the possible outcomes are either ‘A’, ‘B’, ‘Both’ or ‘None’. In terms of a conformal 
predictor, a correct classification is achieved when the correct label is assigned, hence ‘A’ or 
‘B’ in addition to ‘Both’. The latter label represents cases where the instance satisfies the 
model’s requirements of both classes for a given confidence level. Whereas, the ‘None’ label 
means that the model cannot assign a confident classification for an instance because it does 
not satisfy the model characteristics for either class.  
The performance of conformal models is evaluated by the validity and efficiency. Validity 
represents the accuracy of the conformal model, i.e. the rate of correct classification including 
the ‘Both’ label. Whereas, the efficiency represents the percentage of single class predictions, 
i.e. the ability of the models to discriminate between classes with confidence.  
In Chapter 6, the conformal prediction framework was applied to evaluate the uncertainty of 
predictions made by rule models in comparison to a benchmark Random Forest model.
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Figure (2-3) Mondrian conformal prediction using Random Forest as an example for the learning 
algorithm. The first step is to split the data into training and test set, where the training data is further 
split into proper training and calibration sets (step A). The proper training is used to build the machine 
learning model (Random Forest in step B), whereas the calibration set is used as an unbiased reference 
for the test set. A key component in the conformal model is the non-conformity score, which is a 
continuous variable that measures the similarity of the predicted instance to the calibration samples 
with regards to each class label. In the case of Random Forest, the probabilities are used as the 
nonconformity score (step C). Two rankings for a test point are obtained for the two class labels (ai, 
bi). Based on a predefined level of confidence and the two obtained rankings, a prediction is made or 
rejected. 
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2.4  The application of data-based methods in this thesis 
The aim of this thesis was to improve our understanding of chemical-induced toxicity by 
extracting meaningful knowledge from data. A better understanding of the mechanistic basis 
of toxicity allows to utilize in vitro methods more efficiently, and eventually accelerates the 
regulatory acceptance of the alternative methods. The conventional data-based approach in 
deriving mechanistic information on toxicity is conducted from interpreting univariate 
associations between molecular bioactivities and in vivo observations. The novelty, in this 
thesis, extends this approach by extracting important interacting stressors, which together have 
greater associations with in vivo toxicity, namely hepatotoxicity and acute toxicity. These 
interacting stressors may represent significant polypharmacology profiles or combinations of 
biological activities and chemical properties. 
While in vitro – in vivo associations are often directional and involve multiple conditions, there 
is a shortage in studies that consider these constraints in a multivariate non-linear level. The 
analysis here is first to explore these associations using i) rule models with constraints over in 
vitro readouts, and ii) in combination with chemical properties in order to capture chemical 
reactivity and kinetics. This approach allows to inform meaningful conditional associations 
with regards to predictive bioactivities and chemical properties. 
First, the ToxCast dataset will be explored in Chapter 3, as it represents the backbone of in 
vitro data used throughout the thesis. Here we explained the key patterns observed in target-
based and phenotypic assays, and how these patterns relate to the cytotoxic burst phenomenon 
reported in literature,85 and mechanisms of hepatotoxicity and acute toxicity, explored in 
Chapter 4 in Chapter 5, respectively. In Chapter 4, we will prioritize assays predictive of 
hepatotoxicity, as this adverse effect significantly contribute to failures of drug discovery 
projects. Current in vitro models have low detection rates due to incomplete biological 
coverage.95,113–115 Hence, we will compare assays prioritized by rules with endpoints used in 
four commercial in vitro setups for hepatotoxicity. Additionally, we will explore how 
physicochemical properties used in rules can act as proxies for exposure and can help improve 
the translatability of in vitro-in vivo associations. Next, in Chapter 5, we will investigate modes 
of action in compounds which induce acute toxicity, given that the in vitro mechanistic 
screening for this remains immature. Significant polypharmacology profiles of toxic 
compounds will be explored by combining rules and network analysis. Next, to examine the 
predictivity of rules generated in Chapter 5, we will compare the performance of rules with a 
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benchmark Random Forest model in Chapter 6, using a Mondrian conformal prediction 
framework. 
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3      EXPLORING CORRELATION PATTERNS OF 
SPECIFIC AND UNSPECIFIC PATHWAY 
PERTURBATIONS IN TOXCAST ASSAYS 
 
3.1 Introduction  
In order to properly utilise bioactivity data in toxicity assessment, it is important to 
understanding in vitro-related biases and confounders. For example, an observed phenomenon, 
“cytotoxic burst” (CTB) is reported in which cytotoxic compounds show high promiscuity by 
activating a broad range of target specific assays.84 While 1.3% of assays are activated by non-
cytotoxic compounds, 12% of assays are activated by cytotoxic compounds.85 This indicate 
that observing cytotoxicity at a given concentration can bias the measurements of target-
specific assays, and hence any interpretation from these can be misleading.  A list of ToxCast 
assays that are frequently activated below CTB concentration were investigated by Fay et al.84  
It is argued that toxicity in vivo can be explained by either i) specific target activities below 
cytotoxic concentrations or via ii) unspecific cytotoxicity and cell stress pathways. In order to 
examine the associations between specific and non-specific in vitro effects, we analyse the 
variance and similarity within the ToxCast assay library. We group the assays into target and 
phenotypic based according to the intended target type. The target focussed assays were 
designed to capture major biological pathways that have known relevance to toxicological 
events, either by direct chemical-protein binding or indirect effects on up- or downstream 
proteins. Phenotypic assays screen a broad-spectrum of cellular changes, with focus on 
cytotoxicity, proliferation and the cell cycle as well as other intracellular changes related to 
organelles and proteome production. 
We will show that cytotoxicity assays have shown broad correlation with target specific 
readouts, which align with the CTB phenomenon. Also, we report that assays predictive of 
toxicity show specific patterns in the bioactivity space.  
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3.2 Materials and Methods 
3.2.1 Dataset 
The ToxCast in vitro data173 were used to extract bioactivity measurements for 673 compounds 
against 821 assays in concentrations at half maximum activity (AC50). The matrix was curated 
by removing chemical mixtures and inorganic constituents. The overall percentage of complete 
AC50 readouts in the matrix was 9%. Therefore, in order to increase data density, a subsets was 
retrieved by keeping assays with at least 20% complete AC50 measurements. An overall of 109 
assays were selected for this study. Then assays were categorised into two parts: target-based 
and phenotypic-based assays, according to the “type of intended target” in the ToxCast assay 
annotation file. If the intended target is a protein, the assay is classified as target-focussed, 
otherwise, it was considered to be a phenotypic assay.  The target-based and phenotypic-based 
assay matrices contained 56 and 53 assays, respectively. The AC50 readout values ranged from 
as low as fractions of nM up to just below 1 mM concentrations (Appendix A, Figure (A-1) 
and (A-2)). Detailed information on some targets is given in Appendix A, Table (A-1). 
3.2.2 Analysis of variance using principal component analysis (PCA) 
Principal component analysis converts original dataset variables into their uncorrelated linear 
combinations, which are called principal components.141 To test the diversity of the assays 
matrices, a PCA was performed. First, the data were pre-processed via scaling and centring 
using the caret174 and e1071175 packages in R176 environment (version 3.3.3). The data were 
sclaed by converting measurements into Z-scores (subtracting the mean from the values, then 
dividing by the standard deviation). Then the normalized values were centred via Box-Cox 
transformation statistic. Next a PCA was then conducted using the FactoMineR177 R package. 
The percentage of variance explained by each principal component for both target and 
phenotypic assays were visualised. 
3.2.3 Cluster analysis 
Clustering is a multivariate technique that assembles apparently unrelated objects into fewer, 
similar or homogenous groups called clusters.5,179 Hierarchical clustering was performed on 
Spearman coefficients derived similarity matrices using the complete linkage method. 
Spearman correlation is a non-parametric rank method 180, derived from the following 
equation:          r  = 1 − z∑{|	M(M|}W)                [9] 
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The results were visualized in a heatmap plot. Clustering and visualization were conducted 
using the function ‘heatmap.2’ in the (gplots)181 package under R programming environment 
in default settings. 
 
3.3 Results and Discussion 
3.3.1 PCA shows high diversity among phenotypic assays in ToxCast data 
 
In order to examine the variance in ToxCast assays, we performed PCA analysis on 109 assays 
as well as on subsets of 56 and 53 target and phenotypic assays, respectively. The percentage 
of variance was plotted for assays in Figure (3-1). The PCA on the overall set had shown that 
70% of the variance was described by 33 components, meaning that the ToxCast assays are 
diverse and highly dimensional. The Figure also show that variance is higher among 
phenotypic assays in comparison to target-based assays. The first principal component of 
phenotypic and target assays explains around 15% and 25% of the total variance, respectively. 
Therefore, we can conclude that phenotypic assays carry higher overall variance and can 
provide novel insights on toxicity which may not be captured by target assays. Recent efforts 
were directed into understanding specific target and pathways perturbation.58 However, it is 
argued that in vivo toxicity may also result from non-effects such cytotoxicity and cell stress.84
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Figure (3-1) Percentage of variance captured by principal components with regards to: a) 109 ToxCast 
assays, b) 56 target-based assays, c) 53 phenotypic assays. In (a) the accumulated variance of 70% 
require 33 principal components. Capturing variance in a large number of principal components 
indicates the low variance described by principal components and, hence, high diversity within the 
ToxCast data. The first two principal components in target-based assays explain around 25% and 12% 
variance respectively, whereas the first and second components of phenotypic assays explain around 
15% and 6% of variance, respectively. Therefore, phenotypic measurements are more diverse than 
readouts from target-based assays.  
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3.3.2 Assays relevant to toxicity show specific patterns in cluster analysis 
 Given the challenges in analysing in vitro data for toxicity assessment due to the confounding 
effect of cytotoxic burst, we were motivated to examine the assay space of ToxCast with 
regards to correlation patterns between target and phenotypic assays. A similarity matrix 
between the two classes was created by calculating the Spearman correlation coefficient 
between each target and phenotypic assay pair. The count of mutual readouts for each assay 
pair are presented in Figure (3-2). The number of complete pairwise measurements between 
target and phenotypic assays ranged from 25 up to 244, with a mean of 90 common data points. 
This means that there were enough mutual data points for each assay pair to generate 
meaningful and informative similarity values.  
 
  
 Figure (3-2) a) The frequency of complete pairwise measurements between target- and phenotypic-based 
assays. b) The frequency of mutual hits counts in assay pairs where both possess AC50 activity ≤ 10µM. 
Figures show that there were sufficient mutual readouts to generate informative similarity scores. 
 
 Unsupervised hierarchical clustering was performed on the Spearman-derived similarity 
matrix and visualized as a heatmap in Figure (3-3). Assays of similar activity profiles, co-
cluster. The horizontal axis in Figure (3-3) illustrates the co-clustering of similar target-target 
assays, whereas, the vertical axis illustrates co-clustering of phenotypic assays. We found that 
assays correlation values ranged from -0.44 to 0.71. The average Spearman correlation 
coefficient was 0.2, whereas only 25% of the assay pairs had shown magnitudes above 0.34. 
These results align with findings from PCA and indicate assay diversity.  
 
a b 
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Figure (3-3) Heatmap plot of the hierarchical clustering of target- and phenotypic-based ToxCast 
assays along the horizontal and vertical axes, respectively. The colours in the heatmap plot were set to 
visualize correlation magnitudes that are under -0.3 in blue or over 0.3 in red. Clustering divides the 
matrix into four major sectors describing the chief biological classes of assays. Assays for cell loss and 
cell cycle arrest correlate broadly with target specific assays used in this analysis, aligning with the 
cytotoxic burst phenomenon. Tox21 nuclear receptor assays have wide correlations with the majority 
of phenotypic assays. ATG nuclear receptor assays, however, have weak correlations with most 
phenotypic assays. The arrow point to stress kinase assay which broadly correlates with targets assays 
in the dataset. 
 
The biological-dependent clustering was seen for assay families as well as individual assays. 
Phenotypic assays clustered roughly into two major groups; assays for cytotoxicity and assays 
for changes in intracellular content. For example, the first phenotypic cluster involved in 
screening for cell loss, oxidative stress, cell cycle arrest, mitotic arrest as well as increases in 
nuclear size and mitochondrial mass on various cell lines. The second sub-cluster included 
assays involved toxic effects on microtubules and mitochondria, as well as changes in the total 
protein content. Target-based assays also clustered into two groups; the first related to DNA 
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and nuclear receptors binding, while the second mainly consisted of assays that screen changes 
in cell adhesion proteins. Details on some of these targets can be found in Appendix A, Table 
(A-1).  
In general, the heatmap in Figure (3-3) shows three key bioactivity patterns: i) broad-scale 
correlations in bioactivity space of assays relevant to toxicity, ii) co-clustering of assays of 
relevant biological pathways, and iii) co-clustering of assays conducted by the same platform.  
First, the broad-scale correlation can be seen for three groups, namely, cytotoxicity (cell loss 
and cell cycle arrest), endocrine disruption and the stress kinase assay. We can observe from 
the heatmap in Figure (3-3) that phenotypic assays describing cell loss and cell cycle arrest 
have shown broad correlations with the set of target assays used in this study. This observation 
agrees with the cytotoxic burst phenomenon reported in literature,85 which is defined as broad 
intracellular machinery activation due to unspecific effects. 
Additionally, assays for endocrine disruption, listed below, correlated broadly with phenotypic 
measurements at an overall magnitude of 0.32 up to a maximum of 0.67 Spearman coefficient. 
- Tox21_GR_BLA_Antagonist_ratio (glucocorticoid receptor) 
- Tox21_ERa_LUC_BG1_Antagonist (estrogen receptor)  
- Tox21_AR_LUC_MDAKB2_Antagonist (androgen receptor)  
- Tox21_AR_BLA_Antagonist_ratio (androgen receptor)     
- Tox21_TR_LUC_GH3_Antagonist (thyroid hormone receptor)  
These  nuclear receptors control a variety of metabolic and developmental functions by sensing 
steroids and thyroid hormone.182–185 In vitro screening for endocrine disruption is classically 
used to predict reproductive and developmental toxicities.186 However, endocrine disruption is 
also associated with a broad range of chronic effects including cardiovascular diseases, 
neurodevelopment disorders, carcinogenicity and cognitive functions.187 In a data-derived 
approach, Hu et al investigated the associations between ToxCast in vitro measurements and 
human effects from Comparative Toxicogenomics Database (CTD).80 The authors reported 
significant associations between assays for endocrine disruption and four major toxicity 
categories in human, namely, hepato-, cardio-, renal- and neuro-toxicities. Our analysis of 
mechanisms in hepatotoxicity in Chapter 4 and acute toxicity in Chapter 5 have reproduced 
these patterns. As will discussed in Chapter 4, endocrine disruption represented a key 
independent cluster of hepatotoxic compounds, which included activities against estrogen, 
androgen and glucocorticoid receptors. In Chapter 5, disruption of thyroid hormone receptor 
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had shown significant synergistic links with key events in chemical-induced acute toxicity.  
Despite the broad correlation of these assays in the bioactivity space, seen here, as well as in 
the disease space, reported in literature,80,187 their utility as predictors for organ-specific effects 
is limited.  
Another assay that had shown a unique pattern was the stress kinase assay on Hep G2 cell lines 
(APR_HepG2_StressKinase_1h_up). This assay had a broad-spectrum correlation with target-
based assays, at an average of 0.41 Spearman coefficient up to a maximum of 0.66. 
Additionally, as will be described in Chapter 4, the stress kinase assay has the strongest 
correlation among the pool of ToxCast assays with in vivo hepatotoxicity. Upon environmental 
stimuli, such as exposure to toxins, stress-activated protein kinases are activated and 
consequently phosphorylate a range of transcription factors.188 Eventually, a variety of gene 
expression events are initiated in response to the external stimuli. This explains why the stress 
kinase up-regulation assay broadly correlated with the majority of target-based assays, 
including nuclear receptors. Overall, assays that show broad correlations in the bioactivity 
space seem to act as key predictors for in vivo toxicity. 
Besides global correlations, the second observation is the co-clustering of assays of relevant 
cellular pathways co-clustered. For example, phenotypic assays associated with changes in 
organelle conformation, such as APR_HepG2_NuclearSize_72h_up, 
APR_HepG2_MitoMass_72h_up and APR_HepG2_MitoMass_24h_up, correlated with a 
large number of DNA and nuclear receptor binding assays. Such observation can be explained 
by the fact that nucleus size is proportional to the compactness of chromosomes.189 Similar 
behaviour is likely to occur in mitochondria during the Mitochondrial DNA expression for 
energy production.190 Also, changes in cell adhesion molecules correlated with a broad range 
of cytotoxicity assays, oxidative stress screens and reduction of cellular protein content screens. 
Cell adhesion molecules are responsible for attaching cells together to maintain tissues 
integrity, cellular functions and anti-inflammatory responses.191 Inhibition of cell adhesion 
molecules may be associated with cytotoxicity via the disruption of cellular integrity and 
communication. BSK assays that screen for chemical-induced changes in the regulation of cell 
adhesion molecules, were associated with renal toxicity.80 Our results demonstrated the co-
clustering of CIS and TRANS regulatory elements assays of the same transcription factor. This 
is evident by the alignment of ATG_PXR_TRANS_up next to the ATG_PXRE_CIS_up, 
ATG_ERa_TRANS_up and ATG_ERE_CIS_up as well as ATG_PPARg_TRANS_up and 
ATG_PPRE_CIS_up. CIS and TRANS acting elements are DNA sequences that regulate the 
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transcription of a specific gene. However, transcription factor response elements, CIS, regulate 
gene expression by acting as binding sites for transcription factors.192 TRANS regulatory 
elements are DNA sequences that encode the transcription factors.192 The co-clustering of CIS 
and TRANS assays is a pattern previously in the literature.79 Therefore, the similarity between 
relevant assays validates the bioactivity content of ToxCast measurments. 
The third key observation in Figure (3-3) implies that assays supplied by the same platform 
cluster together. The majority of APR assays clustered together, especially HepG2 screening 
for cell loss, oxidative stress, cell cycle arrest and mitotic arrest. Both phenotypic- and target-
based assays, from the Bioseek platform, co-cluster together as well as mutually correlate at 
Spearman score of over 0.5. Moreover, Bioseek’s target-based assays show moderate, albeit 
weaker, correlations with APR-HEPG2 assays. It is clear that not only does the BSK platform 
co-clustered together but also the assays performed on the same type of cell line were adjacent 
to each other. For example; fibroblasts, mixtures of peripheral blood, mononuclear cells, 
endothelial cells and endothelial cell lines co-clustered. Given that each platform performs 
specific assay setups with regards to cell lines, solvents and detection techniques, it is possible 
to achieve similar profiles within the same platform. Another factor is the relatively limited 
space of modes of action and cellular pathways in each platform. This is exemplified by BSK 
cell adhesion molecules assays and DNA and nuclear receptor binding assays by ATG. Overall, 
the similarity within platforms can be attributed to the conserved biological space as well as 
the bias from the assay setup. 
3.4 Conclusions 
The similarity and variance of the ToxCast bioactivity space were investigated. The diversity 
and biological patterns in the ToxCast in vitro measurements indicate its utility to explore key 
events in adverse outcome pathways and to understand toxicity modes of action. The higher 
variance among phenotypic assays, compared to target assays, demonstrate that these assays 
capture complex bioactivity profiles. Hence, phenotypic measurements can be useful 
predictors of toxicity key events which may not be captured by specific target interactions.  
The results also agree with the cytotoxic burst phenomenon. Assays for cell loss and cell cycle 
arrest correlated broadly with target specific assays used in this analysis. We also observed that 
assays for endocrine disruption show unique patterns in the bioactivity space as evident by 
broad correlations with phenotypic readouts. The utility of these assays to predict organ-
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specific toxicities is limited, as will be discussed in Chapter 4 regarding commercial in vitro 
setups for hepatotoxicity. It is argued that the manifestation of endocrine disruption into 
adverse effects is influenced by a number of genetic and environmental factors.187 The 
endocrine disruption-cytotoxicity cluster, seen here, will also be observed among assays 
predictive of hepatotoxicity (Chapter 4) and acute toxicity (Chapter 5). In the following 
chapters, we demonstrate that in vitro activities, including endocrine disruption, can translate 
better into in vivo effects if specific chemical and bioactivity conditions are considered. We 
suggest that initiators of toxicity at the molecular level occur as a result of multiple chemical 
conditions as well as compounds’ polypharmacology rather than single initiating events. 
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4   UNDERSTANDING CONDITIONAL 
ASSOCIATIONS BETWEEN TOXCAST IN VITRO 
READOUTS AND HEPATOTOXICITY USING RULE-
BASED METHODS  
4.1 Introduction 
 
  Hepatotoxicity is a complex adverse effect which is associated with diverse biological 
perturbations, at molecular and cellular levels. Several in in vitro endpoints were proposed to 
capture the key perturbation points.109–112  It has been reported that using a subset of the relevant 
bioactivity endpoints would result in relatively low detection rates, with sensitivity ranging 
from 40 to 60%.95,113–115 
In general, for an efficient translatability of in vitro outcomes in to in vivo effects, two key 
factors are to be considered. First, to design and select the assay set up and endpoints relevant 
to the toxicological effect in question.15,100 Second, to understand and incorporate relevant 
conditions such as multiple bioactivity stressors,193 as well as exposure and 
bioavailability.86,194114,116  With regards to which endpoints to consider, and how to combine 
their readouts, is by no means clear. Parameters such as maximum plasma concentrations 
(Cmax) and administered dose levels are commonly used to improve translatability of in vitro 
activity in to in vivo hepatotoxicity. 109,114,115 Yet, obtaining these measurements from in vivo 
experiments is generally not feasible at early stages of drug development, or for profiling large 
number of compounds.  
A possible alternative for exposure measures are physicochemical properties, which are 
associated with pharmacokinetic parameters117,118, and can be used as proxies to 
exposure.195,196 Yet, the mechanistic understanding of how these properties influence the 
concordance between in vitro measurements and in vivo effects, to our knowledge, has not been 
investigated. Therefore, understanding and prioritizing biological effects of hepatotoxic 
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compounds with respect to chemical properties should involve a holistic approach which 
combine background knowledge as well as data driven methods. 
The current study is, to the best of our knowledge, the first to apply rule-based models on 
ToxCast in vitro measurements and ToxRefDB in vivo hepatotoxicity data with the 
incorporation of physicochemical properties. Rule based classifiers describe each class label 
by a combination of conditions using the input property set. As such, rules can facilitate 
prioritizing significant assays, as well as the interpretation and analysis of multivariate 
associations between in vitro activity and in vivo toxicity. However, conventional rule models 
do not consider directional associations which may occur between input features and outcome 
class, leading to associations that are either spurious or difficult to interpret. Therefore, we 
modify rules according to two key assumptions: 1.) Positive bioactivity in an assay (and not 
absence of an activity) potentially contributes to hepatotoxicity; and 2.) Multiple conditions 
influence in vitro–in vivo associations, which means for an assay to extrapolate well into in 
vivo outcome, number of other conditions have to be met. These conditions can be a 
combination of bioactivities and/or physicochemical properties (related to exposure). With 
those two key assumptions in mind, we manually modify the rules for hepatotoxicity to 
enhance interpretability and biological relevance. The framework we describe here can also 
generally be used to optimize in vitro models for toxicity by selecting significant assay 
combinations, as well as identifying relevant physicochemical conditions.  
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4.2 Materials and Methods 
The steps followed to generate and prioritize rules for hepatotoxic compounds are 
summarized in Figure (4-1).  
 
Figure (4-1) Dataset and workflow for extracting biologically relevant rules for hepatotoxic 
compounds. Firstly, ToxCast bioactivity measurements and an interpretable set of physicochemical 
properties were used as descriptors against hepatotoxicity labels. Rat hepatotoxicity endpoints, from 
the ToxRefDB, were converted into binary labels by setting two maximum exposure thresholds for 
lowest effective level (LEL), 500mg/kg/day and 15mg/kg/day (step 1). The dataset was used to generate 
rule-based classifiers via the C5.0 algorithm (step 2). At each threshold level, rules capturing toxicity 
were pruned by removing inactive assay statements (step 3). Next, in step 4 the modified rules were 
reassessed in terms of balanced accuracy and number of correctly classified compounds (true coverage). 
Prioritization of biologically relevant rules was conducted in multiple steps. The primary selection in 
step 5 involved performance measures, keeping rules that exerted at least 70% accuracy and median 
value of coverage (50 at 500mg/kg/day and 20 at 15mg/kg/day). The secondary selection (step 6) was 
performed based on overall compound coverage, by prioritizing the combination of most accurate rules 
that describe 80% of toxic compound set. The final set of prioritized rules were analyzed in terms of 
contributing bioactivity and physicochemical conditions. 
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4.2.1 Data collection 
 (Figure (4-1), step 1) 
 
Hepatotoxicity endpoints. Rodent hepatotoxicity measures were extracted from the 
Toxicity Reference Database (ToxRefDB, version toxrefdb_v1 released on October 2014)78 . 
Histopathological endpoints (Appendix B, Table (B-1)) from rat studies in liver which were 
observed for chronic, sub chronic, multigenerational and prenatal development were used in 
this analysis, recorded as lowest effective level (LEL) in mg/kg/day for 882 compounds. These 
measurements were converted into a binary format by applying two toxicity thresholds of 
500mg/kg/day and 15mg/kg/day which were subsequently analyzed separately. This 
classification was adapted from Martin et al197 considering the highest and lowest quantile bins 
for toxic effects, corresponding to 15mg/kg/day or less, and 500mg/kg/day or less. 
 
 In vitro measurements. Assay bioactivity data were extracted from the ToxCast 
database173, version December 2014, for 1,057 compounds which represents phase I and II. In 
vitro measurements in ToxCast are recorded as the concentrations at which half-maximum 
activity is reached (AC50), generated from dose-response curves for more than 800 assays in 
units of log10 µM concentration. Assays are annotated by their “intended target type”, in the 
ToxCast assays summary file173 into protein, cellular, pathway, DNA, RNA or unspecified. We 
used this annotation to describe the assays as target-based or phenotypic; if the intended target 
type was described as protein, it was considered target-based, otherwise, for high-dimensional 
readouts, assays are annotated as phenotypic. 
 
Compound set. The compound set used in this study represent the intersection between 
compounds in ToxRefDB and ToxCast, resulting in 673 compounds in total matched by 
ToxCast compound ID. Applying the toxicity threshold of 500mg/kg/day resulted in 395 toxic 
compounds and 278 non-toxic compounds; whereas, at the threshold of 15mg/kg/day 162 
compounds were annotated as toxic and 511 as non-toxic (Step 1 in Figure (4-1)).  
 
Dataset curation. Assay endpoints with empty fields (missing values) were considered 
inactive and an arbitrary (very large) AC50 value of 106 µM was assigned, adapted from Lui et 
al.101 In order to select a data matrix that was as complete as possible (to reduce the bias of 
subsequent analyses) only assays which had valid AC50 measurements for at least 5% of the 
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compounds were selected.  This step resulted in 361 assays which are listed in Appendix B, 
Table (B-2). 
 
Structural preprocessing and calculation of physicochemical properties. Compounds 
were standardized using ChemAxon standardizer198 (version 15.12.14.0) using the parameters 
cleaning 2D, mesomerisation, neutralization, tautomerization (generating the most stable 
tautomer) and removal of fragments. Physicochemical properties were generated using 
RDKit199 via KNIME200 and the Calculator Plugins201 in Instant JChem (version 15.12.14.0)202. 
A subset of 29 physicochemical properties were used in the current analysis which are listed 
in Appendix B, Table (B-3).  
 
4.2.2 Constructing rule-based classifiers  
(Figure (4-1), step 2) 
Multivariate associations between assays and hepatotoxicity endpoints were modelled via 
rule-based machine learning classifiers (Step 2 in Figure (4-1)) as follows. Input variables were 
29 physicochemical properties and 361 ToxCast in vitro AC50 measurements for 673 
compounds against two hepatotoxicity labels of 500mg/kg/day and 15mg/kg/day. The rules 
were generated using the C5.0 algorithm (modified from the C4.5153 algorithms by Ross 
Quinlan) as implemented in the C5.0152 and caret174 R packages using 5-fold repeated cross-
validation with 100 trials and without winnowing. Other parameters are set to default. The 
models with the highest correct classification rate (CCR) at each trial were retained so as to be 
used to generate the rules (accuracy distribution in Appendix B, Figure (B-1)). Throughout 
text, we refer to rules associated with hepatotoxicity as rules predictive or describing toxicity, 
exchangeably.  
 
4.2.3 Rule modification  
(Figure (4-1), step 3) 
Each rule derived from the above procedure consists of one or more conditional statements 
to predict the hepatotoxicity label at a given dose, based on the input variables (ie 
physicochemical properties and ToxCast readouts; Step 3 in Figure (4-1)). In order to extract 
biologically relevant associations between activity in vitro and hepatotoxicity in vivo, rules 
were manually modified to retain interpretable and biologically meaningful patterns. To 
achieve this, modification was applied by removing conditions of inactivity in assays from 
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rules describing hepatotoxic compounds. On the other hand, positive activities in assays and 
physicochemical properties were kept for further analysis as provided by the machine learning 
method. As conventional rule methods that take continuous variables as input can generate 
conditional splits contradicting the assumption stated above, manual curation of rules was 
applied to retain only splits satisfying this assumption.  
Positive activity and inactivity in an assay were discriminated according to the direction of 
the conditional split. Since the compound potency in an assay is inversely related to the 
concentration at which a certain biological response was obtained (such as an IC50 value or 
similar), a bioactivity condition was considered active if the split represent a concentration 
range below a defined cutoff, and vice versa.  
One example of how rules were modified is provided in Figure (4-2) and illustrated in the 
following. For example, in the condition Tox21_p53_BLA_p5_viability <= 0.026, the first part  
 
 
Figure (4-2) An example of rule pruning to retain biologically relevant conditions. Left: unmodified 
rule, describing toxic compounds, as generated by the C5.0 algorithm. This rule consists of five 
conditions, namely two inactive bioactivities (shown in red), one positive bioactivity and two 
physicochemical properties. These represent the increase in mitochondrial membrane potential 
(inactive), heat shock protein agonist (inactive), cytotoxicity assay (active), average molecular weight, 
and number of aromatic heterocycles (physicochemical properties). The rule was then modified by 
removing the inactive bioactivities so as to retain only positive bioactivity readout (cytotoxicity) and 
physicochemical properties (right), which are more meaningful, and biologically more plausible to be 
associated with toxicity. 
 
describes the viability of a human intestinal cell line, and the second part (<= 0.026) represents 
the range of AC50 (in log10 µM concentration) to be less than 0.026 (< ~1.06µM) for the 
condition to be fulfilled. As the statement describes the range below a bioactivity cutoff (split 
point), this example represents a bioactivity condition with positive activity. On the other hand, 
the two conditions, i) APR_HepG2_MitoMembPot_72_up > 2.037 and ii) 
Tox21_HSE_BLA_agonist_ratio > 2, represent respectively the increase of mitochondrial 
membrane potential and Heat Shock Protein (HSP) agonism (both relative to negative control) 
Original rule:
APR_HepG2_MitoMembPot_72h_up > 2.036928
Tox21_HSE_BLA_agonist_ratio > 2.40309
Tox21_p53_BLA_p5_viability <= 0.02595656
AMW > 192.001
NumAromaticHeterocycles <= 1
>>  class toxic  
Modified rule:
Tox21_p53_BLA_p5_viability <= 0.02595656
AMW > 192.001
NumAromaticHeterocycles <= 1
>>  class toxic  
Original rule:
APR_HepG2_MitoMembPot_72h_up > 2.036928
Tox21_HSE_BLA_agonist_ratio > 2.40309
Tox21_p53_BLA_p5_viability <= 0.02595656
AMW > 192.001
NumAromaticHeterocycles <= 1
>>  class toxic  
Modified rule:
Tox21_p53_BLA_p5_viability <= 0.02595656
AMW > 192.001
NumAromaticHeterocycles <= 1
>>  class toxic  
Pruning
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with AC50 values higher than 100µM. The latter conditions were considered inactive, and 
hence removed from rules capturing toxicity during the pruning process. 
 
4.2.4 Performance assessment and rule prioritization  
(Figure (4-1), steps 4 and 5) 
In the current study, the performance of rules was assessed at two levels, for individual 
conditions used in original rule set as well as for rules before and after modification.  
Individual rule conditions were first extracted by collecting the unique set of features used 
by the rules. These were assessed for their association with the hepatotoxicity outcome, at both 
thresholds, 15mg/kg/day and 500mg/kg/day, by calculating the information gain (entropy), 
which is described in Chapter 2 under section 2.2.2. The comparison was conducted with 
respect to condition type, which were categorized into three groups; conditions describing 
positive assay activity, inactivity in an assay and physicochemical properties. 
As the applied modification may change rule performance, the next step was to assess the 
accuracy (confidence) and coverage of rules before and after modification (Step 4 in Figure (4-
1)). Rule confidence, represents the percentage of correctly classified compounds for a given 
class, i.e. here hepatotoxicity. In order to account for the imbalanced distribution of toxicity 
classes, the balanced accuracy of modified rules was calculated by generating 500 randomly 
selected balanced data subsets, each composed of 300 data points, and then averaging the 
accuracy. Rule coverage was calculated for the number of toxic compounds that satisfy the rule 
conditions (true positives).  
As the modification arrived at a rule set that is overall not optimal, a set of prioritization and 
selection steps were conducted. The prioritized rules were subsequently assumed to capture 
biologically meaningful information to the maximum possible extent, given the unavoidable 
limitations of chemical space coverage and bias of the dataset that was available to us. 
The rules predictive of toxicity were filtered based on minimum coverage and accuracy (Step 
5 in Figure (4-1)). Minimum coverage was set to 50 and 20 compounds per rule at thresholds 
of 500mg/kg/day and 15mg/kg/day, respectively. The cutoffs for coverage represented the 
median values after modification, in other words, the best 50% of rules in terms of coverage 
were selected (see Appendix B, Figure (B-2)). Secondly, an accuracy cutoff of 70% was 
applied for both rule sets. Another selection step was undertaken to reduce assay redundancy, 
that is if an assay contributes to multiple rules, then the rule with the highest accuracy that 
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contains that particular assay was selected. Finally, the minimal rule set which covers 80% of 
toxic compounds at each toxicity threshold was selected (see Results and Discussion below). 
To identify the key bioactivity groups captured in toxic compounds in the dataset, the final 
rule sets were clustered according to their similarity in compound membership. This was 
performed by generating a matrix of rules against compounds fulfilling the respective rule 
conditions, from which a rule similarity matrix (based on shared detected and not detected toxic 
compounds) was calculated based on the Jaccard index.203 Hierarchical clustering was applied 
to the similarity matrix using the Agglomeration method Ward.D2204 algorithm via the ‘hclust’ 
function in R (version 3.3.2).176 Visualizations were generated using ‘ggplot2’205 package in 
R. The bioactivity assay conditions under each cluster were examined. 
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4.3  Results and Discussion  
4.3.1 Extracting biologically relevant rules for toxic compounds 
4.3.1.1 Information content of conditions in hepatotoxicity rule-based classifiers 
To have a picture of how original rules were structured, Table (4-1) describes the average 
frequency of each condition type. Overall, on average, rules capturing toxicity include one 
positive assay activity and four inactive bioassay conditions at both toxicity levels. Close to 
one (0.9) physicochemical condition is on average involved in toxic rules at a threshold of 
15mg/kg/day, whereas only on average 0.6 physicochemical conditions are included in rules 
at a threshold of 500mg/kg/day. Hence, although inactive conditions are by themselves not 
very information-rich, they frequently are contained in automatically derived rules. Given that 
inactive assay conditions cannot be mechanistically meaningfully linked to toxic events this 
underlines the need for rule modification as our method of choice (the difficulty of deriving 
toxicity predictors entirely automatically from ToxCast data have also been discussed, using 
different methods, before).99,100 
Table (4-1) Average number of conditions per toxic rule in the original set. Overall per rule, there is 
one positive bioactivity, four negative bioactivities and one physicochemical property. The abundance 
of inactive assay conditions and physicochemical conditions is slightly lower at toxicity threshold 
500mg/kg/day. 
 Condition type in toxic rules 
Toxicity 
threshold 
Active in an 
assay 
Inactive in an 
assay 
Physicochemical 
properties 
15mg/kg/day 1 3.8 0.9 
500mg/kg/day 1 3.6 0.6 
 
  In order to evaluate to what extent individual assays might be able to predict hepatotoxicity 
we firstly examined how much information was gained from each type of conditions in the 
rules. Given the distribution of data points in the classes of the overall dataset, the maximum 
possible information gain was 0.79 and 0.98, at thresholds of 15mg/kg/day and 500mg/kg/day, 
respectively. Figure (4-3) displays the distribution of the information gain (IG), for positive 
bioactivities, negative bioactivities, and physicochemical conditions in toxic rules at toxicity 
levels of 15mg/kg/day and 500mg/kg/day, respectively, and we can observe two key trends. 
Firstly, the maximum observed IG obtained by any split is very low overall, with the maximum 
IG being only slightly higher than 0.04 and the median IG of positive bioactivity conditions 
 59 
being around 0.01. This indicates that single assays on their own have little predictivity for 
hepatotoxicity. 
Figure (4-3) The distributions of the information gain (IG) for each condition type (positive bioactivity, 
assay inactivity and physicochemical properties), in rules capturing toxicity, at two toxicity thresholds, 
LEL= 500mg/kg/day and 15 mg/kg/day. IG is a metric used to describe to which extent particular 
condition (split) improves the homogeneity (purity) of the partitioned data, and which features are hence 
associated with the classes under consideration. To fully discriminate between all toxic from non-toxic 
compounds, IG of variable split should be 0.79 and 0.98, for levels of 15mg/kg/day and 500mg/kg/day, 
respectively. The overall values of IG in the plot are low compared to the maximum possible values. 
Positive bioactivity conditions had the greatest average IG in comparison to other condition types, 
whereas, negative bioactivity conditions had the lowest. This means that the predictive power of a single 
positive activity in classifying toxic compounds is generally larger than single bioassay inactivity and 
physicochemical property conditions. Yet, single assays on their own are not sufficient to fully predict 
compounds in the dataset, which aligns with findings in previous studies.96,97,99 
 
Secondly, the median IG for physicochemical and negative bioactivity conditions is even lower 
and does not exceed 0.005. This means that these conditions on their own are less predictive 
for hepatotoxicity than active assay conditions. Examples of assays that scored the highest IG 
values include the downregulation of CD40 and IP-10 cytokines at the level of 15mg/kg/day 
and the upregulation of stress kinase and AMP response element binding protein (CREB) at 
500mg/kg/day toxicity level (see “prioritizing endpoints for hepatotoxicity detection” below 
for details). 
Although positive bioactivities provide the relatively highest IG overall, their low 
quantitative values indicate that one condition (or assay) is certainly not sufficient to 
discriminate all toxic from non-toxic compounds. This observation can be attributed to two 
factors: Firstly, hepatotoxicity involves diverse and complex mechanisms that cannot usually 
be captured by single endpoints.107,193 Secondly, without considering exposure (or at least some 
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proxies, such as chemical properties),117 assay readout do not translate readily into in vivo 
outcomes,99.206 Our conclusion in this work is hence that, in order to improve our ability to 
predict in vivo toxicity, we need to use rules which, on the one hand, involve a combination of 
assay endpoints to cover wider bioactivity space, and on the second hand incorporate also 
physicochemical conditions.  
4.3.1.2 Rule modification 
To make rules capturing toxicity more biologically meaningful, we next modified them by 
removing inactive assay conditions, and then keeping rules which retain the highest accuracy 
and coverage (as described in Methods).  
The changes in error rates (accuracy) from rule modification are presented in Figure (4-4). 
modification resulted overall in a deterioration in accuracy of 10% and 20% on average for 
rules set at thresholds of 15mg/kg/day and 500mg/kg/day, respectively, as shown in Figure (4-
4). The change in accuracy is broad, ranging between -20% up to +40% at both toxicity levels. 
However, the improvement in accuracy (negative values in Figure (4-4)) can be seen for one 
fifth of rules at the level of 15mg/kg/day and less than a quarter of the rules at level of 
500mg/kg/day (Figure (4-4)).  
 
 
Figure (4-4) The error rate change (accuracy deterioration) in percentage from removing inactive 
bioactivity conditions from rules. The error rate is calculated by subtracting the accuracy of the rule 
after modification (by removing inactive bioactivity conditions) from the accuracy of the original rule. 
The deterioration in rule accuracy after modification is, in general, greater at threshold 500mg/kg/day, 
at an average of 20%, whereas, the overall drop in accuracy at 15mg/kg/day after modification is 10%. 
Simplifying the rules by pruning inactive conditions resulted in a variable level of accuracy 
deterioration. Yet, negative values mean improvement in accuracy which was observed in almost 25% 
of rules.  
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4.3.1.3 Prioritizing predictive rule sets (Figure (4-1), step 6) 
 As some modified rules have shown severe deterioration in accuracy, a selection step was 
introduced to keep only highly performing modified rules, defined as at least 70% minimum 
accuracy, in addition to a minimum of 50 and 20 compounds being covered (corresponding to 
the median in coverage), at the toxicity thresholds 500mg/kg/day and 15mg/kg/day, 
respectively. Finally, rules were ranked by accuracy, then the minimum rule set able to detect 
at least 80% of all hepatotoxic compounds was selected (Step 6 in Figure (4-1)).  
Figure (4-5) shows the relationship between the overall compound coverage, at both toxicity 
thresholds, with i) the minimum rule accuracy in the series of ranked rules and ii) the number 
of unique bioassays used in the rules. Firstly, if higher percentages of toxic compounds are to 
be detected, then more rules (some of which will have lower accuracy) are needed. For 
example, to obtain collectively 80% compound coverage at a threshold of 500mg/kg/day 
requires including 35 rules up to a lower limit of 73% accuracy. On the other hand, in order to 
achieve equivalent coverage at a threshold of 15mg/kg/day 20 rules with a lower accuracy limit 
of 81% is sufficient. Hence, potent toxicants can be captured by rules of higher confidence than 
compounds fall under weaker toxicity levels.  
 
Figure (4-5) Percentage of overall toxic compounds matching rules ranked by accuracy. The x-axis 
represents the percentage of compound coverage as a function of minimum accuracy in ranked rules 
(Y-axis, red) and number of unique bioactivity assays used in rule combination (Y-axis, black). The 
most accurate rule sets sufficient to cover 80% of toxic compounds, at each threshold level, were 
selected as the minimal rule set to describe hepatotoxicity. Fewer numbers of unique assays were 
required at a threshold of 15mg/kg/day in comparison to level of 500mg/kg/day to cover 80% of all 
compounds, namely 24 and 38 assays, respectively. 
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  Secondly, in order to cover larger proportions of compounds, higher numbers of unique assays 
to be used by the rules (Figure (4-5)). It can be seen that up to 50% of compounds, at both 
thresholds, can be described in rules using readouts from 11 assays. For 80% compound 
coverage, 24 and 39 assays are needed in rules, at thresholds 15mg/kg/day and 500mg/kg/day, 
respectively. Further for 90% coverage, 34 unique assays are needed in rules at 15mg/kg/day, 
whereas, more than 70 unique assays are required to cover the same proportion of toxicants at 
500mg/kg/day threshold.  
Hence overall, single assay endpoints, for the dataset employed here, are only sufficient to 
anticipate in vivo hepatotoxicity for rather few compounds individually. Instead, a combination 
of bioactivity measurements is required for enhancing the detection rate of hepatotoxic 
compounds, for which larger numbers of assays (with broader mechanistic coverage) are 
needed. 
 
4.3.2 Prioritizing endpoints for hepatotoxicity detection 
We next interpreted the bioactivity endpoints used in rules predicting hepatotoxicity, as 
determined from the assays used by the best-performing rules covering 80% of the toxic 
compounds at both LELs of 15mg/kg/day and 500mg/kg/day.  
The diversity of the bioactivity space in the prioritized rules was analyzed by firstly 
clustering rules according to compound coverage, and subsequently interpreting the biological 
associations between the selected endpoints and hepatotoxicity. Rules were clustered according 
to the similarity in toxic compound coverage, which means that rules that satisfy similar 
compound sets are grouped together. Tables (4-2) and (4-3) present the rule clusters labelled 
by the major contributing bioactivity described by the assay endpoints used in the rules. At 
both thresholds of 15mg/kg/day and 500mg/kg/day, the rules clustered into three bioactivity 
groups, namely those involving i) Cytochrome P enzymes, ii) immune responses, and iii) 
nuclear receptors and transcription factor elements. 
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Table (4-2) Description of unique bioactivity assays in best performing rules for toxicity, which cover, combined, 80% of toxic compounds, at threshold of 
500mg/kg/day. Rules were clustered according to similarity in compound coverage, which resulted in three major clusters of rules. Each is describing predominantly 
one class of bioactivity assay, namely, Cytochrome P activity, immunological responses and nuclear receptor activity. The information gain was calculated for 
individual conditions (split points) and highlighted for values higher than median (0.02), whereas, accuracy represents the rule in which the bioactivity was used. Some 
rules used two assay conditions at a time, and assays in the table. are linked by the symbol; ë. 
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 Table (4-3) Description of unique bioactivity assays in best performing rules capturing toxicity, which cover, combined, 80% of toxic compounds, at threshold of 
15mg/kg/day. Rules were clustered according to similarity in compound coverage, which resulted in three major clusters of rules. Similar to findings in Table (4-2), 
the predominant assay class used by each rule cluster are Cytochrome P activity, immunological responses and nuclear receptor activity. The information gain was 
calculated for individual conditions (split points) and highlighted for values higher than median (0.022), whereas, accuracy represents the rule which the bioactivity 
was used. Some rules used two assay conditions at a time, and these assays are linked in the table by the symbol; ë. 
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4.3.2.1 Cytochrome P 
Activity against Cytochrome P enzymes is one of the key properties of hepatotoxic 
compounds at both toxicity thresholds (Tables (4-2) and (4-3), cluster 1). There are multiple 
assays in the rules describing activity against different Cytochrome P isoforms, namely against 
CYP3A, CYP2C18 and CYP2C19 at a dose of 500mg/kg/day, and against CYP2A, CYP2C6, 
CYP2C12, CYP2C13 and CYP2C19 at a level of 15mg/kg/day. All Cytochrome P enzymes 
exerted information gain (IG) values higher than average in the selected assay set (Tables (4-
2) and (4-3), cluster 1), i.e. higher than 0.02 and 0.022 at levels of 500mg/kg/day and 
15mg/kg/day, respectively. The average potency in Cytochrome P enzymes as described by 
rules is less than 10µM (Appendix B, Figure (B-3)). Activity against Cytochrome P isoforms 
CYP3A4 and CYP2C19, which are responsible for the majority of drug metabolic reactions207, 
can be linked to liver injury via generating toxic metabolites or interfering with the metabolism 
of co-administered drugs resulting in slow elimination and chemical accumulation.80,101,207  
 
4.3.2.2 Immunological responses 
Multiple assays contribute to immunological responses at both toxicity cutoffs (Tables (4-2) 
and (4-3), cluster 2). Immunological responses in hepatotoxicity rules, in general, had shown 
assay potency requirements lower than Cytochrome P activities, of around 40µM (Appendix 
B, Figure (B-3)). At a threshold of 500mg/kg/day, assays associated with the downregulation 
of cytokines CXCL10 and CD40 were frequently selected for rules, and they also had an 
individual information gain values above the median at values around 0.029, namely the assays 
“A.15”, “A.17” and “A.20”. These cytokines are associated with both proinflammatory and 
regenerative responses depending downstream signaling. 208,209 For example, CD40-mediated 
activation of IL-12 has a proinflammatory effect.210,211 On the other hand, it can also activate 
IL-10 immune response, which primarily participates in regenerating and repairing hepatic 
cells via anti-inflammatory responses.208,212 Similarly, the CXCL10 cytokine can reduce liver 
injury in mice models via upregulating CXCR2.213 Yet, also blocking CXCL10 has a 
regenerative effect after liver damage.209 Hence, hepatotoxicity can be predicted from the 
perturbing the expression of relevant genes, and can be irrespective to the direction of change. 
Similarly, immunological endpoints detected at a threshold of 15mg/kg/day involve the 
downregulation of CXCL10 and CD40, as above, and in addition that of CCL2, captured by 
the assays “B.13”, “B.15” and “B.10”, respectively. At this threshold, downregulation of CCL2 
had a high associated information gain of 0.037, hinting to its importance for hepatotoxicity 
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prediction. CCL-2 expression can increase tissue damage via IL-12  signaling214, but 
simultaneously has a protective effect by activating the hepatoprotective cytokine IL-10.214,215 
A study has shown an overall downregulation of a variety of cytokines (CCL2, IL-10, IL-12 
and IL-16) in primary and liver sinusoidal endothelial (LSEC) cell lines upon the exposure to 
free fatty acids in contrast to hepatocytes. The authors suggested the anti-inflammatory effect 
as a response to overcome liver damage.216 Therefore, assays which detect changes in the 
expression of immunological cytokines, such as CXCL10 and CCL2, are biologically not 
entirely understood, but nonetheless they are statistically informative and hence, can be 
regarded as valuable in hepatotoxicity in vitro models. 
 
4.3.2.3 Nuclear receptors and response elements 
Activity against nuclear receptors contributes considerably to the overall bioactivity profile 
of hepatotoxic compounds (cluster 3 in Tables (4-2) and (4-3)). Compared to the above 
bioactivity groups, lower potencies of approximately 50µM were used in the rules to predict 
hepatotoxicity (Appendix B, Figure (B-3)). Endocrine disruption is seen at both thresholds, 
such as activity against estrogen and androgen receptors, which is captured in multiple assays 
(“A.3”, “A24”, “A.34”, “B.4”, “B.12”, “B18”, “B23”). There are established links between 
estrogen and glucocorticoid receptors (“A.35”) with cholestasis (impairment of bile flow)217 
and steatosis (fatty liver)218, respectively. In addition, androgen receptor antagonism is 
associated with a range of hepatotoxic effects with hepatitis as most commonly reported .219 
Rules obtained at both thresholds for hepatotoxicity also share activity against CAR 
(constitutive androstane receptor), FXR (farnesoid X receptor) and PPAR (peroxisome 
proliferator-activated receptor) which are described by the assays “A10”, “A.11”, “B.24”, 
“A.2” and “B.17”. Both CAR and FXR play a key role in preventing xenobiotic induced 
hepatotoxicity by regulating a number of genes including phase I and II metabolizing enzymes 
and bile acid transporters.220,221 The activity of FXR was found to be correlated with the degree 
of protection from chemical-induced liver injury.221 PPAR-gamma agonist activity, which 
represented by up regulation in A.2, is known to be involved in chemical-induced liver injury. 
222 Whereas, PPAR-delta has a hepatoprotective effects against toxicants223. 
Additionally, there were bioactivities contributing specifically to each toxicity cutoff under 
the nuclear receptor activity class. For example, at 500mg/kg/day, several transcription factor 
response elements were involved in cluster 3 in Tables (4-2), such as the regulation of cyclic-
AMP response element binding protein (CREB), which provided a relatively high information 
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gain, at this dose, of 0.048 in “A.31”. It has been found that the activation of CREB-binding 
protein/b-catenin interaction promotes liver fibrosis.224 Another response element is the 
upregulation of SMAD (“A.28”) , which mediates TGF-b-induced apoptosis and fibrosis via 
downstream immune responses.225,226 
At a toxicity threshold of 15mg/kg/day, bioactivities under the nuclear receptors cluster 
included those against the vitamin D (VDR) and liver X receptors (LXR) in the assays “B.8” 
and “A.21”. Upregulation of the VDR response element (VDRE) is associated with anti-
inflammatory properties and xenobiotic metabolism.227,228 LXR has an anti-inflammatory 
effect227 and can reduce chemical-induced toxicity229. Thus, the activation of these nuclear 
receptors can be linked to triggering protective response against xenobiotics.  
Overall we can conclude that hepatotoxic compounds are frequently associated with multiple 
changes in nuclear receptor activity, with different types of nuclear receptors being activated 
or inhibited at different dose levels, based on dataset and analysis type considered here.  
 
4.3.2.4 Other targets and mechanisms 
Furthermore, the prioritized rules involved a number of phenotypic and less specific 
activities that cannot be attributed to a specific target. These include cytotoxicity, cell cycle 
arrest, oxidative stress and mitochondrial impairment (Tables (4-2)). There are ten assays 
describing cell cycle or cell morphology under the toxicity level of 500mg/kg/day, whereas 
this is only the case for four assays detected by best rules at 15mg/kg/day (Tables (4-2) and (4-
3)). Also, these assays had shown significant difference in the overall assay potencies, of 
around 50µM, between levels of 500mg/kg/day and 15/mg/kg/day. The phenotypic assay 
overlapping between the two toxicity levels include increase in nuclear size and mitochondrial 
mass, represented by “A.1”, “A.25”, “B.19” and “B.20”. Mitochondrial dysfunction is one of 
the key mechanisms of chemical-induced hepatotoxicity.107,212,230,231 Nuclear size increase is 
accompanied by nuclear receptor activity, as a result of activating gene expression. 
Additionally, at threshold of 500mg/kg/day, two assays describe mitochondrial effects with 
information gain higher than the median (0.02 and 0.029), which are associated to changes in 
mitochondrial membrane potential, namely “A.22” and “A.23”. Chemical toxicants can cause 
mitochondrial permeability transition (MPT) via the opening of permeability transition pores 
in the mitochondrial membrane, either directly or indirectly. As a result, mitochondrial 
depolarization takes place which leads to ATP depletion and reactive oxygen species (ROS) 
release, followed by mitochondrial membrane rupture and apoptosis or necrosis.107 Another 
 68 
effect is the increase in stress kinase expression as a response to stress; “A.27”. This assay has 
amongst the highest information gains of all assays (of 0.052) and the accuracy of its rule is 
95%, which indicates that it is highly associated with toxicity at a 500mg/kg/day level. Also, 
rules at this level involve other cell cycle assays which screen for cytotoxicity, oxidative stress 
and cell cycle arrest. Hence, we can conclude that less potent hepatotoxic compounds are more 
likely to have unspecific effects which can be difficult to detect using target-specific assays. 
Judson et al reported a greater likelihood of disrupting target specific pathways when active 
concentrations fall within the range of eliciting cytotoxicity.85 What we observe here is an 
association between potency of toxicity in vivo and specificity of in vitro effects that are 
predictive for toxicity. We also observe that these unspecific effects are embedded more 
frequently in clusters describing nuclear receptor activity and endocrine disruption. This 
observation aligns with findings in Chapter 3, where assays for endocrine disruption have 
shown broad correlations with cytotoxicity assays. Additionally, for compound to be toxic at 
low doses, they are required, according to the rules, to be more potent in assays (see Appendix 
B, Figure (B-3)).  
In addition to the major bioactivity classes, further rules for hepatotoxicity involved other 
target assays. For example, the Novascreen target binding affinity assay (“A.6” and “B.22”), 
which appeared in rule sets at different dose levels, is related to the transporter SLC6A3 gene 
with relatively high information gain of 0.021 and 0.024 (see Figure (4-3) for distributions of 
information gain values) at 500mg/kg/day and 15mg/kg/day, respectively. The SLC6A3 gene 
encodes for the dopamine transporter (DAT). DAT-dependent neurological degeneration is 
linked with hepatic dysfunction related to ROS overproduction and mitochondrial impairment 
in rodents.232 Another endpoint related to the toxicity threshold of 500mg/kg/day is the 
translocator protein (TSPO) (assay “A.9”), which is involved in the transport of cholesterol 
across mitochondrial membrane. The expression of TPSO has also been found to be associated 
with activating macrophages in chemical-induced liver injury and hence leads to cell 
death.233,234 At a toxicity level 15mg/kg/day, upregulation of prostaglandin E2 (PGE2), in assay 
“B.1”, was also used by rules. PGE2 is a lipid autocoid which protects against liver damage by 
downregulating the expression of inflammatory cytokines. 235,236 It has also been reported that 
PGE2 participates in liver regeneration upon injury. 237 
Therefore, we can overall conclude that hepatotoxicity can be initiated by a variety of 
mechanisms (also very likely beyond the ones covered in the assays used here), supporting the 
need for broad range of endpoints when screening for potential hepatotoxic compounds.  
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4.3.2.5 Combined bioactivity readouts 
Our study goes beyond interpreting univariate associations into investigating rules 
constructed from multiple assay conditions. Previous studies has reported the benefit of 
combining multiple pathway perturbations to detect hepatotoxic compounds, but were 
narrowed to specific modes of action.109,193 Some rules for hepatotoxicity involve two 
bioactivities at a time (linked by the symbol ë in Tables (4-2) and (4-3)). There are seven and 
six rules including multiple bioactivity features at toxicity thresholds 500mg/kg/day and 
15mg/kg/day, respectively. For example, multiple rules combined androgen receptor activity 
with a range of bioactivity assays, such as change in mitochondrial membrane potential, at 
threshold 500mg/kg/day, Cytochrome P (CYP2A1) activity at 15mg/kg/day, and PPAR 
activity at both thresholds. AR ligand, dihydrotestosterone, has shown to induce mitochondrial 
membrane potential238, which establish a link between AR modulation and disrupting 
mitochondrial membrane. Additionally, CYP2A1, which metabolizes 90% of testosterone239, 
is subject to inducers leading to a decrease in serum testosterone.240 Hence, the dual activity of 
AR antagonist and CYP2A1 modulation can potentiate compounds to be hepatotoxic.  There 
is an established bidirectional crosstalk between AR and PPAR isoforms by which each can 
influence the expression as well as the transcription activity of the other.241,242 Primary 
hepatocytes of obese male AR-knockout mice had shown hepatic steatosis which is associated 
with altered PPAR-a and PPAR-g expression.243  
Other interactions which are seen at a level of 500mg/kg/day include multiple combinations 
Firstly, CYP2C19 appeared in conjunction with SLC6A3 (dopamine transporter) in rules 
(Table (4-2)). It is found that the antagonists of D2 dopaminergic receptors interfere with the 
regulation if CYP2C enzymes.244,245 This can support the link between interfering dopamine 
transportation and CYP2C19 activity highlighted in the rules. Secondly is the combination of 
CD40 with IL-8 cytokine. Activation of CD40 increases the secretion of IL-8 in hepatic stellate 
cells resulting in an amplification of proinflammatory effects.246  Also, the hypoxia inducible 
factor-1 (HIF-1) was combined with CCAAT/enhancer binding protein B (C/EBPB) (Table (4-
2)).  Studies have shown mutual regulation between these two transcription factors in 
expression and transcription.247,248 Also, HIF-1 is one of the key transcription factors which 
binds to C/EBPB during liver regeneration.249  
At 15mg/kg/day, multiple assay combinations predictive for hepatotoxicity can be seen in 
Table (4-3), including CYP2C6 with VDR and CXCL-9 with ER agonists. VDR involves in 
the metabolic liver damage and its expression correlates inversely with the severity of liver 
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steatosis250 and fibrosis.251 In response to xenobiotics, VDR directly induces the upregulation 
of CYP2C6.252 Hence, it is plausible that compounds that combine activity against CYP2C6 
and upregulation of VDR are more likely to cause hepatotoxicity. Studies have shown links 
between ER agonists and CXCL9, at which estrogen-treated mice have shown a significant 
reduction in the expression of CXCL9,253 a cytokine associated with liver fibrosis.254  
These observations support the importance of conditional associations in studying the 
translatability of in vitro activity into in vivo effects, and using rules we were able to suggest 
which assays are most predictive for hepatotoxicity when used in combination, based on the 
dataset used here. 
4.3.2.6 The case study of troglitazone 
As a case study for the benefit of considering bioactivity combinations in screening 
hepatotoxic compounds, we chose troglitazone, an antidiabetic drug that was withdrawn from 
the market in 2000 due to incidences of hepatotoxicity.255 It was reported that the mechanism 
of troglitazone liver toxicity is initiated through the mitochondrial impairment, cellular stress256 
and triggering immunological responses.257 It was also argued that risk factors including 
genetic and environmental factors, besides biological activity of the compound itself, play a 
contributing role.258,259   
Troglitazone is labelled in our data as toxic at the LEL level of 500mg/mg/day but not at 
15mg/kg/day as extracted from rat studies. This compound matched ten of the rules at the level 
of 500mg/kg/day and two rules at the level of 15mg/kg/day (see Appendix B, Table (B-4) and 
(B-5)). These are described by assays for mitochondrial toxicity, endocrine disruption and 
activity of immunological responses. At level of 500mg/kg/day, troglitazone fulfilled the rules 
describing the combinations of AR with PPAR-g as well as IL-8 with CD40 (see “Combined 
bioactivity readouts”). Additionally, this compound also matched multiple rules in which 
cytotoxicity was combined with specific target activities, for both toxicity levels (see Appendix 
B, Table (B-4) and (B-5)). The average hepatotoxic compound, however, complied with only 
four rules at 500mg/mg/day and two rules at 15mg/kg/day (Appendix B, Figure (B-4)). Also, 
there is significant difference in number of satisfied rules by toxic and non-toxic compounds 
at both thresholds (Appendix B, Figure (B-4)). Given the number of rules satisfied by 
troglitazone, it had more bioactive liabilities compared to the average toxic compound at the 
level 500mg/kg/day and equivalent to the average liability at the level of 15mg/kg/day. 
Therefore, troglitazone’s promiscuity in hepatotoxic rule space predict it to be likely 
hepatotoxic in vivo. 
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4.3.3 Comparison of prioritized bioactivities with commercial hepatotoxic assay 
endpoints 
 
Further, we compared the bioactivities covered by prioritized rules with the in vitro endpoints 
conducted by commercial models for hepatotoxicity. Bale et al., reviewed a series of 
commercially available in vitro platforms for the detection of hepatotoxic compounds260 which 
we will use here. From this review, we selected four in vitro models which screen against 
multiple readouts and endpoint classes, namely Cellciphrâ261, 3D Insightä262 , Hepatopacâ263 
and RegeneMed112, which are summarized in Table (4-4). 
There is an overall large overlap between bioassay endpoints (see Table (4-4)) screened 
within commercial models and assays prioritized by the rules generated in this study. Firstly, 
all models, as well as the rules derived in the current study, involve screening against 
mitochondrial impairment and cell stress, which are known as key signals for hepatotoxicity.107 
Secondly, phenotypic readouts associated with cell growth or morphology are used by 
CellCiphrâ, InSphero 3D Insightä as well as in the rules, examples of which are apoptosis, 
cell loss and changes in nuclear size and mitochondrial mass. Additionally, screening for 
Cytochrome P activity is an endpoint used in InSphero 3D Insightä, Hepatopacâ, RegeneMed. 
3D Insightä and RegeneMed also screen for changes in cytokine levels, which is in agreement 
with the assays identified as important in the current study. Another relevant endpoint is the 
inhibition of the bile acid transporter which is screened in 3D Insightäand Hepatopacâ. 
Although the original ToxCast assay set we used in this analysis did not include the inhibition 
of bile acid transporters, the rules detected activity against FXR and CAR, which directly 
regulate the expression of these transporters.220 Moreover, inhibition of a set of proteins, such 
as albumin, urea, and fibrinogen is conducted by InSphero 3D Insightä, Hepatopacâ and 
RegeneMed. The counterpart assay used in the prioritized rules screen for the decrease in total 
protein level in the cell (“A.21”). 
  In addition to the above endpoints, our analysis also identified other assay readouts with 
association with hepatotoxicity, in particular nuclear receptor activity (Tables (4-2) and (4-3)), 
that at the current stage are less covered in commercial hepatotoxicity assays.  The involvement 
of nuclear receptors in hepatotoxicity is supported by mechanistic studies - for example, Liu et 
al. reported that estrogen and androgen antagonism are related to proliferative lesions.101 
Additionally, Hu et al., demonstrated a significant univariate association of two ToxCast assays 
for androgen receptor activity with human hepatotoxicity.80 Hence, although it is known that 
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estrogen and androgen disruption can cause hepatotoxicity217,219, this endpoint is often not 
currently used in commercial assay setups (Table (4-4)). Therefore, while generally overlap 
between the features identified in our work and commercial assays for hepatotoxicity exists, it 
would be suggested that including endocrine activity among in vitro models can improve the 
coverage, and hence detection, of hepatotoxic compounds beyond the current state of the art. 
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Table (4-4) Comparison of bioactivities used in prioritized rules and assay endpoints adopted by hepatotoxicity in vitro models in four commercial setups. The table shows that 
the endpoints prioritized by rule models represent a combination of endpoint types used in the four commercial in vitro models. Nuclear receptor activity, and in particular 
endocrine disruption, was prioritized by rules in but not included in in vitro models. With reference to Tables (4-2) and (4-3), nuclear receptor activity represents a key 
independent cluster among hepatotoxic compounds. 
In vitro 
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4.3.4 Influence of physicochemical properties in improving in vitro/in vivo associations 
We next analyzed the significance of physicochemical properties in the prioritized rule sets, 
to see to what extent those proxies for exposure 117,118  add value when attempting to anticipate 
the hepatotoxicity of compounds. For this, the deterioration in accuracy after removal of 
physicochemical condition combinations from prioritized rules was quantified with respect to 
the two toxicity thresholds, the results are shown in Appendix B, Figure (B-5). The absolute 
drop in accuracy by removing physicochemical conditions from all bioactivity rules ranged 
from 0% up to almost 20%. The overall drop in accuracy was more pronounced at a toxicity 
threshold of 15mg/kg/day, with an overall error rate usually around 6-11%. The distribution of 
error rate as a result of removing physicochemical conditions from rules at 500mg/kg/day was 
broad, ranging from no effect to up to 9% in most cases. Hence, incorporating physicochemical 
properties improve in vitro-in vivo associations, especially at a lower dose (and hence for the 
more potent toxicants). 
 
Figure (4-6) Percentage change in error rates as a result of removing physicochemical property 
conditions from best performing rules as a function of assay class. The overall deterioration of accuracy 
by removing physicochemical conditions varies with the assay type. The accuracy drop is minimal 
among rules of Cytochrome P activity and at the dose level of 500mg/kg/day, while very significant 
accuracy deterioration is seen in rules described by nuclear receptor activity, especially at a threshold 
of 15mg/kg/day. 
The error rate varied not only by the toxic dose level but also by assay class (Figure (4-6)). 
The error rates of physicochemical conditions were minimal in rules describing Cytochrome P 
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activity, particularly at 500mg/kg/day. Immunological and phenotypic bioactivities had 
moderate accuracy deterioration from discarding physicochemical properties, at around 5%. 
Yet rules describing phenotypic assays showed a significant difference between toxicity 
thresholds, of more than 10% (p<0.05 Wilcoxon rank sum test). Rules related to nuclear 
receptor activity had the largest increase in error upon removing physicochemical conditions, 
especially at a threshold of 15mg/kg/day, reaching values higher than 10%. The peak in 
accuracy drop is for glucocorticoid receptor activity of almost 20%, followed by over 15% for 
androgen receptor activity at the toxicity level of 500mg/kg/day. Estrogen receptor activity 
showed an approximately 13% drop in accuracy at both toxicity thresholds.  
Direct perturbation of nuclear receptors requires compounds to penetrate the nucleus 
membrane with sufficient permeability to be toxic at low doses. Overall, for an improved 
association with in vivo effect, some assay bioactivities, such as phenotypic and nuclear related 
effects, are more dependent on meeting physicochemical conditions, and hence require a proxy 
for exposure. This is more important for anticipating potent toxicants. 
We next analyzed the most frequent physicochemical properties occurring in the rules (Table 
(4-5)). At a threshold of 15mg/kg/day, these were the number of rotatable bonds (which are 
equal to or below 6 in rules describing hepatotoxicity), the number of hydrogen bond donors 
(where hydrogen bond donors are required to be absent) and the number of aliphatic rings 
(which needs to be equal to or smaller than two). The number of rotatable bonds had the highest 
frequency, occurring in over a third of the rules. This physicochemical condition was 
associated with an accuracy deterioration (error rates) equivalent to 8% when it was removed 
from the rules. The number of rotatable bonds was, however, not abundant among rules at the 
level of 500mg/kg/day. Instead, the number of rings (<=3) was the most frequent 
physicochemical property in this case, and was associated with an increase in error rate of 6% 
and a frequency of 29%.  
The above increase in error rates, when removing physicochemical properties from rules, is 
apparently due to a link between the physicochemical properties of compounds and in vivo 
pharmacokinetics parameters, such as bioavailability.118,264 Bioavailability is governed by the 
extent and onset of absorption and distribution, which in turn are linked to some molecular 
properties such as membrane permeability and plasma protein binding. Good bioavailability in 
vivo means that, upon exposure, compounds achieve sufficient concentrations to achieve an 
effect at the site of action. Rotatable bond count, for example affects the magnitude of cell 
membrane permeability of compounds.196 Majority of compounds that contain 6 rotatable 
bonds or fewer show oral bioavailability higher than 20%, irrespective to their molecular 
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weight.196 Additionally, a number of aromatic rings greater than 3 in a compound is linked to 
higher plasma protein binding (PPB) (>90%), irrespective to cLogP.265 Strong PPB may slow 
the rate of compound distribution among body compartments which will consequently affect 
the concentration at the site of action.266,267 Additionally, higher numbers for aromatic rings 
are linked with Cytochrome P inhibition and higher lipophilicity, both of which are associated 
with toxicity.119,265 DeGoey et al. have introduced a simple multiparametric scoring function 
to describe rat oral bioavailability consisting of three properties, namely cLogD, the number of 
rotatable bonds and the number of rings of a compound.195 This score which involves summing 
the values of these properties (with a correction for cLogD). The authors reported a negative 
correlation between this score and bioavailability with correlation coefficient of -0.41, in 
agreement with our findings above.  
Table (4-5) Physicochemical properties frequently present in prioritized hepatotoxicity rules. The most 
frequent physicochemical property in rules for threshold of 15mg/kg/day is number of rotatable bonds. 
Whereas, number of rings is the most frequent physicochemical property in rules at 500mg/kg/day level.  
 15mg/kg/day 
Physicochemical condition Error rate%* Frequency %** 
NumRotatableBonds <= 6 7.8 ± 3.2 35 
NumHBD <= 0 9.2 ± 3.7 10 
NumAliphaticRings <= 2 2.7 ± 0.3 10 
 
 
 
 
 
 
 
 
 
*Error rate % represents the deterioration in rule accuracy as a result of removing each of the 
physicochemical properties presented in the table. 
** Frequency % is the percentage of rules containing the physicochemical property out of all prioritized rule 
set. 
 
An additional observation, however, is that rules used different properties at different potency 
levels, but consistent properties within each potency threshold. Also, different assay types have 
shown variable magnitudes of dependence on physicochemical properties when measurements 
are extrapolated into in vivo effects. Still, it is apparent that also simple proxies for 
bioavailability are able to improve the prediction of hepatotoxic compounds on the dataset 
 500mg/kg/day 
Physicochemical condition Error rate %* Frequency %** 
NumRings <= 3 5.7±3.6 29 
NumHeavyAtoms <= 33 3.9±0.5 11 
NumAromaticCarbocycles > 0 11.5±1.9 9 
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employed here. Hence, given that in vivo exposure parameters (i.e. dose and Cmax) are often 
not available at primary stages of drug development, these simple proxies such as the number 
of rings and rotatable bonds may act as simple alternatives to exposure measures to anticipate 
the hepatotoxicity of compounds at an early stage. 
 
4.4 Conclusion 
 
We propose in this work a novel framework for generating interpretable rules for the 
hepatotoxicity of compounds, which use both in vitro bioactivity measurements and 
physicochemical properties. Rules generated from machine learning algorithms were pruned 
to remove statistically less informative and biologically less meaningful inactive assay 
conditions from rules describing toxicity. The resulting interpretable rules were used first to 
prioritize hepatotoxicity in vitro endpoints, considering 80% overall compound coverage. The 
resulting rules were compared with four commercial in vitro models for hepatotoxicity. Finally, 
the influence of physicochemical properties on the derived in vitro- in vivo associations were 
investigated separately for each assay class. 
Our results suggest that a set of multiple ToxCast assays are needed for a sufficiently high 
coverage of hepatotoxic compounds, as no single assay can discriminate toxic from non-toxic 
compounds. This was also apparent from the information gain derived for single ToxCast 
assays alone. At two toxicity threshold levels of 15mg/kg/day and 500mg/kg/day, the best- 
performing modified rules, which cover 80% of toxic compounds, cluster into three major 
bioactivity classes, namely Cytochrome P activities, immunological responses, and nuclear 
receptor activities. While overall assays selected for predicting hepatotoxicity overlapped with 
endpoints used in in vitro models from commercial sources, nuclear receptor activity, which 
represented an independent mechanistic cluster, is not currently covered in this way.  
 Specific bioactivity combinations were seen in the rules, such as disruption of androgen 
receptors combined with activities against PPARs, Cytochrome P and increase in 
mitochondrial membrane potential. These describe perturbation in multiple biological 
pathways resulting in a greater likelihood of observing toxicity in vivo. Incorporating 
physicochemical properties, in general, also improved the accuracy of rules describing toxicity 
especially for potent toxicants, i.e. those toxic at the toxicity level of 15mg/kg/day. The likely 
explanation is that, for those compounds, bioavailability plays an important role for toxicity to 
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be observed, which to some extent can be anticipated by physicochemical properties. The most 
frequent physicochemical properties used in rules, namely the number of rotatable bonds and 
the number of rings, are linked to bioavailability parameters, such as membrane permeability 
and plasma protein binding, respectively. Hence, the likelihood of a compound to be 
hepatotoxic in vivo increases both if it is active in relevant bioassays as well as showing the 
necessary bioavailability. 
There has been an increasing interest in understanding the molecular mechanisms 
responsible for initiating toxic side effects, in the form of adverse outcome pathways (AOP) 
frameworks. The assay endpoints screened in the ToxCast project can in principle describe key 
events in an AOP,61 since they provide insights to the perturbation in biological processes in 
the cells by the screened compounds. Our proposed rule-based method can be used as a tool to 
generate molecular hypotheses so as to guide the identification of key events of the AOPs. In 
order to be practically successful in this direction, assay coverage in biological space, 
compound coverage in chemical space and a complete data matrix linking both domains are 
crucial. 
Another application to this rule method framework is to optimize in vitro models for toxicity 
screening. For example, in order to improve the compound coverage of hepatotoxicity in vitro 
models, we recommend assays from three major bioactivity classes are incorporated when 
testing for hepatotoxicity, which are Cytochrome P activity, immune responses and endocrine 
disruption. This is in addition to phenotypic readouts such as cell viability, cell stress, 
mitochondrial impairment and changes in cellular organelles. The combination of assays from 
all areas will then allow for the better detection of hepatotoxic compounds. We also 
recommend considering physiochemical properties as simple proxies for in vivo exposure 
measures, such as Cmax, when attempting to anticipate potential hepatotoxicity. While simple, 
those properties are fast to calculate and they are able to improve predictivity of in vivo 
hepatotoxicity, at least on the data based in this study.  
The workflow presented here can finally be generalized to other types of toxicity, considering 
any type of chemical and biological input data, provided coverage in the chemical and 
biological domain for the toxic endpoint of interest is given. 
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5 DISCOVERING COMPLEX MECHANISMS IN 
ACUTE TOXICITY USING MULTISOURCE DATA 
AND EMERGING PATTERNS  
 
5.1 Introduction 
The use of in vitro screening for systemic acute toxicity, that are derived from a mechanistic 
understanding of modes of action, is as yet immature.6  The current state of art for alternative 
approaches include in vitro assay for basal cytotoxicity using neutral red uptake (NRU) to 
identify starting doses in animal testing.125 Some of the key target specific mechanisms 
identified for acute toxicity include the interference with neurotransmission, ion channels, 
energy haemostasis, antioxidant pathways and cellular integrity.6 Several AOPs were proposed 
around these key events (KE) to describe acute mortality127–129, which are published in the AOP 
database. These are represented by the modulation of ionotropic GABA (gamma-Aminobutyric 
acid) receptors129 and ionotropic glutamate receptors128, and the inhibition of 
acetylcholinesterase.130 However, not much is understood on how perturbation of more than 
one biological pathway influences in vivo observations as the result of compounds’ 
polypharmacology. Studying these interactions is especially essential in cases where complex 
mechanisms are involved such as acute toxicity. 
In the case of acute organophosphate poisoning, the key mechanism driving acute toxicity is 
the inhibition of acetylcholine esterase. A study on the pathological pathways associated with 
the potent AChE inhibitor, chlorpyrifos-oxon, on zebra fish had shown multiple downstream 
effects including calcium ion dysregulation, immune and inflammatory responses and 
cytotoxicity, collectively referred as the cholinergic toxidrome.268 Such complex downstream 
effects can be points of perturbation via diverse stressors due to compounds’ 
polypharmacology, or exposure to bioactive compound mixtures. In this context, adverse 
effects should be captured by multiple pathway perturbations attributed to multiple key events.  
One way to extract the complex associations that can discriminate between classes is emerging 
patterns. Emerging patterns are a form of rule models which identify feature sets frequent in 
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one class of the data, but not the others.151 The main implementation of emerging patterns in 
cheminformatics is to derive structural alerts. This was first conducted by Auer and Bajorath269 
who used discretized physicochemical properties were used to describe target bioactivities. 
Sherhod has used emerging patterns67 and jumping emerging patterns76 to discover structural 
alerts for Ames mutagenicity and hERG activity. Emerging patterns were also implemented on 
gene expression profiles to predict toxic compounds270 and identify diagnostic gene groups.271 
Yet, emerging patterns have limited applications in cheminformatics,272 despite their ability to 
extract interpretable insights about patterns in data. 
 In this study, we analyse the complex associations between acute toxicity and potential 
KE/MIE represented as structural alerts and bioactivity properties. To the best our knowledge, 
this is the first attempt to use emerging patterns by combining chemical and bioactivity data to 
describe toxicity. This study uses data collected from Tox21 screening measurements, 
predicted biological targets, known toxicophores and Globally Harmonized System (GHS) 
labels for acute toxicity. In order to generate hypotheses about features’ additive and 
synergistic interactions, we integrate emerging patterns with network analysis and mutual 
information. We illustrate how some features, which on their own show moderate correlations 
with acute toxicity, play vital roles to intensify the liability of other features through synergy. 
The conditional associations derived here provide novel insights into the mechanisms of acute 
toxicity. We believe that these findings can encourage interpreting potential toxicity as an 
assembly of interacting, rather than independent, key events that reflect multiple perturbations 
in the physiological system. 
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5.2  Materials and Methods 
5.2.1 Datasets 
Tox21 data  The Tox21 project involve high throughput screening measurements of almost 
10,000 compounds against phenotypic cytotoxicity and target-specific assays for toxicity 
pathway profiling.53 Tox21 bioactivity data were collected from PubChem273 (accessed 21 Jul 
2017) for 8747 unique compounds labelled with PubChem ID against 110 assays (see 
Appendix Table (C-1)). The activity label used in this study is the percent activity compared 
with a positive reference determined from three replicates at 1µM. The conventional 
binarization procedure in PubChem is determined by a 40% activity threshold, above which a 
compound is considered active, i.e. 1 for active and 0 for inactive. Here we also added three 
thresholds levels, namely 20%, 60% and 80% activities (in addition to 40%). Therefore, each 
compound was described in an assay by four levels of bioactivity labels, resulting in 440 Tox21 
assay descriptors. For example, if a compound has a bioactivity of 66% in a given assay, then 
this compound will show a positive label at levels of 20%, 40% and 60% but not 80%. This 
intervention was introduced so as to consider potency in Tox21 assays when generating the 
toxic describing rules.  
Predicted bioactivities Compounds extracted from the Tox21 data were also annotated with 
their predicted bioactivities using an in-house predictive model “PIDGIN” (Prediction 
IncluDinG INactives) version 2.274 PIDGIN was built using targets annotated against 
compounds in PubChem including 3394 unique targets in a Random Forest model. In this 
study, targets that have shown True Positive Ratio of 0.7 or higher were considered summing 
to 1790 targets. The annotations outcomes are in binary format (1 if active and 0 if inactive). 
Chemical Descriptors Toxicophores were generated using the Online Chemical Modeling 
Environment (OCHEM) ToxAlerts server73 against over 2300 structural alerts collected from 
17 references. The server performs normalization and curation on query compounds after 
which it matches the curated compounds with the SMARTS of predefined toxicophores. The 
results were stored in form of binary matrix which represent the presence or the absence of the 
structural alert in the compound.  
Additionally, substructures observed in at least 2% of the compounds in the dataset were 
generated using MoSS275 node in KNIME.200 The MoSS undergoes a graph based 
fragmentation followed by appropriate curation to avoid redundant detection of substructures. 
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GHS acute toxicity The Globally Harmonized System of Classification and Labelling (GHS)276 
is international standard system agreed by the United Nations to classify chemical compounds 
for their hazardous potential. The system includes a labelling system for toxicities such as acute 
toxicity, mutagenicity and organ specific toxicity. In this study, we used acute toxicity (oral, 
dermal and inhaled) to label compounds in the dataset. Compounds are assigned with a severity 
level from 1 to 5, where 1 is the most potent toxicant whereas, 5 demonstrate the least severity. 
These classes are derived from the LD50 for oral and dermal and equivalent LC50 for inhalation. 
The data were extracted from PubChem273 for the compounds in the Tox21 dataset (Accessed 
26 July 2017). The GHS classifications reported in PubChem are compiled from multiple 
sources, namely the European Chemcials Agency (ECHA), the EU regulation (EC), 
the Chemical Management Center (CMC) of Japan National Institute of Technology and 
Evaluation (NITE) and the Australian Hazardous Chemical Information System (HCIS). The 
GHS grading was discretised into an arbitrary two-class toxicity label, i.e. toxic and non-toxic. 
Compounds were considered toxic if the classification of either oral, dermal or inhalation were 
at levels 1,2 or 3, and non-toxic otherwise. The compounds selected for this study must show 
at least a valid classification for oral acute toxicity. Also, wherever a contradiction in the GHS 
labelling system was observed, the associated compounds were excluded. Compounds with 
valid labels sum up to 3573, 1261 toxic and 2312 are non-toxic.  
Chemical curation Compound structures were extracted in SMILES format using the 
PubChem exchanger service for their corresponding PubChem CIDs. Chemical standardization 
of compounds was conducted in ChemAxon198 considering the following specifications: add 
explicit hydrogens, clean 2D, remove fragments, neutralize, mesomerize and tautomerize 
In order to generate a complete dataset across the different sources, only compounds that 
overlapped between the Tox21 data and GHS classification were used for analysis. Further, the 
compound set was curated in order to exclude compound mixtures and compounds including 
heavy metals. The overall integration of the dataset resulted in 2000 compounds, 993 toxic 
compounds and 1007 non-toxic. Only features which are present in 5 or more compounds were 
used. The total number of features used was 3732 representing 1789 predicted targets, 440 
Tox21 assay activities, 1259 ToxAlert toxicophores and 242 MoSS derived substructures. 
5.2.2 Emerging patterns generation 
Emerging patterns (rules) were generated using CPAR algorithm developed by LUCS-KDD 
(Liverpool University Computer Science – Knowledge Discovery in DATAS). The CPAR 
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algorithm is explained in Chapter 2 section 2.2.2.2. All parameters were set as default (decay 
factor of 2/3 and similarity ratio of 1:0.99) except for the minimum gain by the split which was 
adjusted to 2.5. In order to generate meaningful and biologically interpretable emerging 
patterns, we applied data space pruning. The search within the descriptors space was restricted 
so as to align with causal or correlation links between these features and in vivo toxicity. The 
emerging pattern algorithm CPAR takes the input data in for of transaction, which are lists of 
features (see section 2.2). Hence each binary feature is described using two labels, i.e. the 
presence and the absence of that feature. To constrain the directional association for in vitro 
data, only the presence of an activity (and the presence of substructures) are included in the 
input set to generate toxic describing patterns. Similarly, patterns describing absence of toxicity 
used input data of variables describing absence of in vitro activity, and the presence of the 
substructure. 
The training set used was randomly sampled to create 70% subsets on which the algorithm was 
run with 50 repeats. Emerging patterns performance was calculated as confidence and coverage 
using the all training set. Unique patterns were then selected according to a minimum of 70% 
confidence and minimum Fisher test p-value of 0.01 to exclude insignificant correlations. This 
process resulted in 7381 patterns describing toxicity and 3866 patterns describing absence of 
toxicity. In this study, terms emerging patterns and rules are used exchangeably.  
5.2.3 Rule network analysis 
Rules were visualized as networks. Feature conditions in rules are represented as nodes, 
whereas, edges connecte node features that co-occurred in the same rule at least once. Figure 
(5-1) demonstrates how groups of rules were converted into network representations. First, 
rules were represented as feature lists describing either toxicity or absence of toxicity, labelled 
as 1 or 0 in Figure (5-1), respectively. For each class label, the list representation is converted 
into a binary matrix where each row is equivalent to a rule and columns are the unique feature 
set. Next, the binary matrix was converted into an adjacency matrix to describe feature pairs 
that co-occurred in at least one rule. The numeric value in the adjacency matrix reflected the 
frequency of observing feature pairs in unique rule sets. Finally, this adjacency matrix was 
used to construct a network of features as nodes and adjacency as edges.  
Visualization and analysis were conducted in Cytoscape software.277 Cytoscape allows to 
perform number of analytical measures on networks to extract the topological properties. These 
properties include three key components which are i) network as whole, ii) nodes and iii) edges. 
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Networks can be described by their size, degree of saturation and betweenness (average 
shortest path to go from a node to another in the network through connected edges). Nodes are 
often described by centrality measures such as the degree, which describes the number of 
unique first neighbours. Edges can be directional or undirectional, and can be weighted.   
 
 
Figure (5-1) Workflow for generating rule networks. The generated rules are represented as lists of 
feature conditions describing presence or absence of acute toxicity. The list representation of rules was 
converted into a binary matrix of rule input in rows and feature set in columns, in which (0,1) reflect 
whether the feature is used or not used in a rule, respectively. The binary representation was then 
converted into an adjacency table, where the digits represented how many times feature pairs co-
occurred in a unique set of rules. The adjacency table was used to generate a network of features as 
nodes and adjacency as edges. Networks were then generated for each class, i.e. presence and absence 
of toxicity. 
 
5.2.4 Synergy measures 
One way to analyse rules of multiple conditions is to measure the interactions between these 
conditions. Analysing these interactions is useful to understand how combining multiple 
features at a time would affect the odds for observing the outcome. For example, it is possible 
to detect synergy between features, where their combination acts beyond the additive effect. It 
should be noted, however, that the synergy in this context represents the improvement in 
probability or likelihood of observing toxicity not the increase in toxic intensity.  
We measured synergy between all feature pairs co-occurred in rules. For rules composing of 
more than two features, all possible combination pairs were investigated. For example, in a 
rule of three conditions {a, b and c}, the investigated pairs are a-b, a-c and b-c.  Two measures 
 85 
were used. One is based on the normalized mutual information as described by Fang et al 278 
and the second measure is based on odds ratios as reported by Cortina-Borja.279 In both cases, 
the association statistic is measured for individual features in a rule as well as for feature pairs, 
and relative to the toxicity outcome.  
I) Synergy using mutual information 
For ci ={a,b} pair in Rule i against toxicity label Z, where ci Í Rule i, and a, b are feature 
conditions. Synergy	 = 	MI(ci, Z)	–	[MI(ai, Z) 	+ 	MI(bi, Z)]                [10] Improvement	 = 	MI(ci, Z)	– 		max[MI(ai, Z)	, MI(bi, Z)]                [11] 
Where MI is the normalized mutual information278 calculated for a, b and their combination ci. 
II) Synergy Factor from odd ratios (equivalent to interaction weight in the regression equation) Synergy	Factor	 = 	ORci	/	(ORa		ORb)						              [12] 
Where OR is the odds ratio279 calculated for a, b and their combination ci. The criteria used to 
label a feature pair as synergistic are magnitudes greater than 0.001, using the MI statistic, and 
values greater than 1 for the OR-based synergy scores.  The relationship between the two 
synergy measures is represented in Appendix C, Figure (C-1). 
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5.3 Results and Discussions 
5.3.1 Univariate associations between biological and chemical properties and acute 
toxicity 
First, in order to understand which classes of features are being captured, as single variables, 
the highest associations with acute toxicity, we examined the normalized mutual information 
(NMI) between all feature-toxicity label pairs. The distribution of NMI is visualized in Figure 
(5-2). The maximum possible NMI value for a perfect correlation is 1 (0 in log10 scale) 
 
Figure (5-2) Distribution of the normalized mutual information (NMI) for each feature class against 
acute toxicity in log10 scale. The dashed line represents the median value of the overall NMI (-2.7). The 
majority of cell viability and substructure features show NMI values above median, which mean these 
features, as single variables, have the strongest association with acute toxicity. Except for nuclear 
receptor activity, target specific features, namely enzymes, ion channels and GPCR show average NMI 
values below median. 
 
Features were grouped into 8 classes, namely substructures, cell viability, nuclear receptors, 
enzymes, kinases, ion channels, G protein-coupled receptors (GPCR) and ‘other’ targets, which 
include transporters. The median value of NMI as shown in Figure (5-2) is around -2.7 and a 
maximum of -1.5 in log10 scale. The difference between these values and the maximum 
possible value for NMI means that acute toxicity cannot be captured by a single variable. Figure 
(5-2) also shows that substructural and cell viability features had the top values for log10 NMI 
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of at an average of -2.3 (equivalent to NMI of 0.005). Cell viability had also shown the least 
spread in values compared to all other features. Following in the rank of the association strength 
were activity against nuclear receptors and ion channels, with log10 NMI of -2.6 and -2.9 
respectively. Other features, including enzymes, kinases and GPCR, had an average log10 NMI 
values less than -3 (less than 0.001 NMI). Overall, cell viability and structural properties have 
stronger associations with acute toxicity than target-specific bioactivities.  
5.3.2 Performance and structure of toxic and non-toxic rules 
To unravel complex associations between acute toxicity and chemical and biological 
properties, emerging patterns were generated to capture these associations. Emerging patterns 
follow conventional rule measures of coverage and accuracy, and here the terms rules and 
emerging patterns were used exchangeably.  
The first set of generated rules were filtered according to accuracy and significance in the 
Fischer test (see Methods). The characteristics of selected rules are shown in Table (5-1) with 
regards to counts, performance, average number of conditions in rules describing presence and 
absence of acute toxicity.  
Table (5-1) Characteristics and performance of rules describing toxicity and rules describing non-
toxicity. The average accuracy (confidence) of rules used in the analysis was above 80 % for both labels. 
Non-toxic rules described, in general, had more number of compounds per rule and more number of 
conditions per rule compared to toxic rules. 
     * Number of unique rules between parentheses 
     ** Values represent mean and standard deviation 
     à   Number of conditions in rules excluding single condition rules 
 
The average confidence as in Table (5-1) was above 80%. Overall, non-toxic rules covered 
more number of compounds per rule, i.e. 34 compounds by non-toxic rule compared to 26 
compounds by a toxic rule (Table (5-1)). The complexity of the rules can be estimated from 
the average number of conditions used per rule. The simplest rules consisted of one condition, 
however, these approximately constituted 8% and 4% of overall unique toxic and non-toxic 
 
N# of all 
rules* 
Single 
condition 
rules 
Multiple 
condition 
rules 
Accuracy** 
Compound 
coverage 
per rule 
N# of 
conditions 
per ruleà 
Toxic rules  
9165 
(7381) 
1267 
(566) 
7898 
(6815) 0.85 ± 0.083 26.3 ± 12.8 2.6 ± 0.83 
Non-toxic 
rules 
4613 
(3866) 
410 
(155) 
4203 
(3711) 0.82  ± 0.082 34.1 ± 20.8 3.3 ± 1.3 
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describing rules, respectively (Table (5-1)). Also, the overall number of conditions in rules 
describing non-toxicity was more than 3 which is greater than that observed in toxicity 
describing rules.  
 
Figure (5-3) Percentages of feature classes used in toxic and non-toxic describing rules. Rules for 
toxicity use diverse set of features, whereas, rules capturing non-toxicity are mainly described by cell 
viability and structural features.  
 
Next, we examined the distribution of feature classes in rules for the two toxicity levels 
represented in Figure (5-3).  The unique features used by toxic and non-toxic rules intersect to 
a great extent, i.e. 512, which represent around 50% and 70% of all features used by toxic and 
non-toxic rules, respectively. However, the variability in feature frequency between rules 
resulted in the distribution seen in Figure (5-3). Toxic rules showed 3-fold higher proportions 
of specific effects such as activity against enzymes, kinases and ion channel receptors. Non-
toxic rules, on the other hand, had higher abundance of substructure- and cytotoxicity- 
describing features than toxic rules, which together represented over 70% of features in the 
former compared to less than half in the later. This pattern can be explained by the relatively 
high NMI magnitudes of these two feature classes with acute toxicity. This means they have 
higher generalizability to describe the presence or absence of in vivo acute toxic effects. 
Nuclear receptors and GPCR activity appeared in two rule classes at almost equal fractions. 
Overall, both rule types showed acceptable performance and share large proportions of unique 
features, however, the frequency at which these features were used by each rule class varied 
significantly. 
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5.3.3 Single condition rules capture known features of acute toxicity 
Although the majority of rules had more than one condition, fewer than 10% were represented 
by single conditions (Table (5-1)). Single condition rules were described mainly by 
substructural features and potent cytotoxicity to a combined percentage of 75% (Appendix C, 
Figure (C-2). Examples of single feature rule with confidence higher than 80%, compound 
coverage greater than 15 and frequency equal to or higher than 2 are represented in Table (5-
2). Substructure conditions such as sulfenic acid derivatives and organophosphates, observed 
in Table (5-2), are known structural alerts for potent toxicants.280–282 These features also 
showed strong associations as estimated by log10 NMI at levels less than -2. Halogenated 
ketones, shown in Table (5-2) are examples of Michael acceptors, which is a known mechanism 
for chemical induced toxicity.6,281 Single feature rules, in general, had an overall log10 NMI 
among the highest in comparison to average values of features in all rules (Figure (5-2)). 
Cytotoxicity is also a key endpoint in assessing the potential acute toxicity6,19 which is used to 
estimate the starting dose in animal tests.125 Therefore, we can conclude that features with 
strong univariate associations and features captured in single condition rules represent known 
structural alerts and biological properties of compounds inducing acute toxicity.  
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Table (5-2) Selected examples of single condition rules and the corresponding normalized mutual 
information (NMI). The selection was based on confidence higher than 80%, compound coverage 
greater than 15 and frequency equal to or higher than 2. Majority of single condition features were 
described by potent cytotoxicity or substructure features, which also show relevant high NMI values 
with reference to Figure (5-2). 
 
 
 
Features Chemical Structure NMI  
 
Cytotoxicity (>60%) 
 
- -2.04 
 
Sulfenic acid derivatives 
 
-1.66  
Organophosphorothionate 
esters, Thiophosphoric acid 
esters 
 
-1.76 
 
Vinyl chlorides 
 
 
-2.02 
 
Haloethyl amines (N-
mustard) 
 
-2.03 
 
Allylic halides and alkoxides  
 
-2.07 
b-Haloamines 
 
-2.22 
Dinitroarenes 
 
-2.35 
Monohalogen substituted 
ketones 
 
-2.50 
Nitroso compounds  -2.50 
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5.3.4 Networks of multi-condition rules demonstrate complex feature-toxicity 
associations 
To investigate rules of more than one condition, networks were generated to describe complex 
patterns in each class, i.e. toxic and non-toxic labels. The characteristic elements in the network 
structure are nodes and edges. Nodes in rule networks represent individual features, whereas, 
edges connect feature pairs co-occurred in one rule. Rule networks can help examine complex 
toxicity associations using network measures of connectivity as well as algorithms for detecting 
communities within the network. The aim is to get insights about important features related to 
acute toxicity which are beyond univariate associations.  
Two rule networks were generated describing the presence and absence of toxicity. The 
characteristics of these networks are presented in Table (5-3), including number of nodes and 
edges, and network density. Network density is the proportion of edges counts present in the 
network to the edge counts of a saturated network. Toxic network consisted of 937 unique 
nodes and 8280 edges, and had a density of 0.019 (Table (5-3)). The non-toxic network 
involved 737 nodes connected via 7500 edges with a density of 0.028. The density is slightly 
higher in non- toxic network, reflecting rule complexity (number of conditions per rule) (Table 
(5-1)) and higher cross connections between the nodes (Table (5-3)).  
Table (5-3) Topology characteristics of toxic and non-toxic networks. The first two clusters in both 
network classes had the largest number of unique features. Despite the similarity in size seen in cluster 
1 and 2, the latter has double number of edges, and hence, double network density. Cluster 2 is 
dominated by target specific features in the toxic network and mixed feature classes in the non-toxic 
network. Cluster, 1 on the other hand, is mainly characterized by cell viability and nuclear receptor 
activity in toxic and non-toxic network alike (Figures (5-4) and (5-5)). Hence, target-specific features 
are involved in more complex associations with acute toxicity.  
 Toxic network 
Clusters Overall 1 2 3 
N# nodes 937 376 328 184 
N# edges 8280 1748 3047 476 
N# synergy connections 1460 258 637 104 
Density 0.019 0.025 0.057 0.028 
 Non-toxic network 
Clusters Overall 1 2 3 4 
N# nodes 737 279 230 132 48 
N# edges 7500 1535 2356 269 63 
N# synergy connections 336 64 93 31 4 
Density 0.028 0.04 0.09 0.031 0.056 
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To detect groups characterized by similar features adjacency, community clustering was 
applied, based on Girvan-Newman method.283 The algorithm finds communities of similar 
neighbours by cutting edges between node pairs exhibiting the highest betweenness (shortest 
path between a nodes pair in the network). Figures (5-4) and (5-5) show toxic and non-toxic 
networks, respectively. Clustering of toxic rule network resulted in 3 large clusters, with nodes 
sizes of 376, 328 and 184, and 9 clusters each has less than 20 nodes. Via applying community 
clustering to the non-toxic network, 15 groups were observed, the first 4 clusters involved 279, 
230, 132 and 48 nodes, whereas each of the remaining clusters included less than 10 nodes. In 
further analysis, we will focus on the first three clusters in rule networks as they capture the 
majority of features.  
The distribution of feature types varied between toxic and non-toxic networks. The content of 
clusters in toxic network showed specificity in the distribution of feature classes, whereas non-
toxic clusters are more consistent in feature class distribution. Almost all clusters in both toxic 
and non-toxic networks included structural features. Cluster 1 in the toxic network is dominated 
by nodes describing cytotoxicity in Tox21 assays and nuclear receptor activity. Both cluster 2 
and 3 have high proportions of specific biological targets under the enzyme and kinase classes. 
In addition, cluster 2 and 3 also include nodes describing activity against kinases, ion channels 
and GPCR. We can conclude two key points, firstly, there is a separation in toxicity induced 
by specific mechanisms and non-specific cell stress mechanisms. This aligns with previous 
reports that in vivo toxicity occurs as a result of either unspecific cytotoxicity and cell stress, 
or perturbation of specific pathways.85 Secondly, the unspecific cytotoxic effect can be 
captured by the combination of cell viability assays and nuclear receptor disruption. This 
combination has previously been observed in ToxCast cluster analysis in Chapter 3 and in the 
nuclear disruption cluster of hepatotoxicity in Chapter 4.  
Moreover, cytotoxicity and nuclear receptors occupied central positions in the first three 
clusters of non-toxic network, indicating critical roles in predicting acute toxicity. In other 
words, in order to ensure lack of acute toxicity, absence of cytotoxicity has to be ensured, as 
the absence of target specific perturbation may not be sufficient.  
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Figure (5-4) Toxic rule network clustered via Girvan-Newman algorithm. Nodes represent features and 
edges connect features co-occurred in a single rule. Nodes are coloured by feature class where the node 
size is proportional to the magnitude of mutual information with acute toxicity. Blue edges connect 
synergistic pairs calculated via normalized mutual information (NMI) (see Methods). The majority of 
features are captured in the first three clusters. Substructures occupy conserved spaces in each cluster. 
The dominant bioactivity classes in cluster 1 are cell viability and nuclear receptor activity, whereas, 
cluster 2 and 3 are dominated with target based features including enzymes and kinases. This means 
that the majority of rules capturing cytotoxicity, as predictors for acute toxicity, are independent of rules 
capturing specific target activity. 
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Figure (5-5)    Non-toxic rule network clustered via Girvan-Newman algorithm. Nodes represent 
features and edges connect features co-occurred in a single rule. Nodes are coloured by feature class. 
Fewer synergistic connections (blue edges) are seen in non-toxic network in comparison to toxic 
network (figure (5-4)). Majority of features are captured in the first four clusters. Substructure features 
are scattered in each cluster. The dominant bioactivity classes in cluster 1 are cell viability and nuclear 
receptor activity, cluster 2 show mixed bioactivity types, whereas, clusters 3 and 4 are mainly described 
by substructure features. This means that absence of toxicity is conditional in most cases by absence of 
cytotoxicity. Even when target specific activity is absent, this must be combined with absence of 
cytotoxicity as seen in cluster 2. 
 
In order to examine the complexity of associations between the various feature classes with 
acute toxicity, densities of individual clusters were investigated. The level of edge density 
varied between clusters in both toxic and non-toxic networks (Table (5-3)). This variability, 
however, does not follow the cluster size. For example, cluster 1 had as double the number of 
nodes as cluster 3 in the toxic network. Yet, they had a similar level of density of 0.025 and 
0.028, respectively. Cluster 2, however, which is similar in size to cluster 1 in toxic network 
has shown almost double number of edges and density, as well as, 2.5 folds more of synergistic 
connections. Hence, more dense clusters involve more complex associations between features 
used and in vivo toxicity. Therefore, the complexity in Cluster 2, which is dominated by target-
specific features, indicates the need to address the effect of multiple perturbations for a proper 
extrapolation into in vivo toxicity. In other words, whereas, cytotoxicity and structural features 
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have direct univariate associations with toxicity, target specific features demand understanding 
the compounds’ polypharmacology to predict toxicity.   
Additionally, to investigate how different levels of potency in Tox21 assays behave in the toxic 
network, potency thresholds in assays were plotted against degree connectivity in the toxic 
network. Figure (5-6) shows that the most connected Tox21 assays in the toxic network were 
describing low potency thresholds. As the potency level increases, the number of connected 
nodes decreases. This means that when compounds show high potency in an assay fewer 
number of other conditions is required to translate into in vivo toxicity. However, in order to 
inform whether weak activity in an assay can lead to toxicity, more features are to be combined 
and considered. This observation is important because it indicates the significance of 
polypharmacology analysis for activities at low potency. Whereas the state of art for the study 
of off-target activity utilizes safety margin calculations using maximum plasma concentrations 
(Cmax),48 this approach fails to consider how combining multiple weak activities would 
translate into clinical effects.  
 
Figure (5-6)    Change in degree connectivity in the toxic network as a function of potency cutoff in 
Tox21 assays. As the potency level decreases, the number of associated conditions increases. Hence, to 
translate into in vivo toxicity, low potency in assays require a larger number of other conditions, and 
vice versa.  
 
 
5.3.5 Important features in toxic and non-toxic networks 
We next investigated the most important features deriving the associations in each cluster. 
These are represented by the nodes showing the highest number of unique connections (highest 
degree) as well as the highest mutual information values (Tables (5-4) and (5-5)). The features 
were selected for both structural and bioactivity properties.  
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5.3.5.1 Known mechanisms and key events in acute toxicity  
Some trends in bioactivities in networks clusters reflect known mechanisms of acute toxicity 
such as cytotoxicity in cluster 1 of toxic networks. Cytotoxicity is a classical in vitro test for 
acute toxicity using neutral red dye uptake (NRU) which is conducted to determine the starting 
doses for in vivo oral acute toxicity tests.125  
Other activities that are highly connected in one or both networks include glutamate receptors, 
disruptors of mitochondrial membrane potential and acetylcholinesterase (AChE) (Tables (5-
4) and (5-5)). Glutamate is an excitatory neurotransmitter of which both overactivation and 
inhibition of its receptors are associated with neurotoxicity.284,285 Impairment of mitochondrial 
membrane potential is a known biomarker for cytotoxicity286 as well as in vivo acute toxicity.287 
Acetylcholine (ACh) is a carbamate derivative which is cleaved and deactivated by AChE into 
acetic acid and choline. The toxic effects of inhibiting AChE are initiated by the accumulation 
of ACh in neuromuscular junction leading to initial overstimulation followed by 
desensitization and ultimately muscle paralysis.288 Cholinergic crisis can be a lethal result of 
the exposure to potent AChE inhibitors. It is also a classic mechanism in acute toxicity, mainly 
manifested as respiratory failure.289 The inhibition of ionotropic glutamate receptors, AChE 
and disruption of mitochondrial membrane potential are known molecular initiating events 
(MIE) in acute mortality.6 Therefore, the most connected target-specific activities in networks 
overlap with key events known to associate with acute toxicity. 
5.3.1.1 Substructural features 
The patterns in substructural features in the toxic and non-toxic networks showed generic and 
specific properties. Example of generic properties, in the toxic network, is the dominance of N 
and O atoms, and aromatic amines in cluster 2,  and P and S in cluster 3, evident by their high 
connectivity. A possible explanation for the connectivity of aromatic amines and N and O 
atoms is the association of these features with compound promiscuity. It has been reported that 
compounds with basic centres and aromatic rings are promiscuous.43 Additionally, promiscuity 
is negatively associated with the count of oxygen atoms.42 Interestingly, these features are 
present in the most dense cluster in the toxic network, cluster 2, which describes target-specific 
activites. Additionally, in the non-toxic network, alcohols, unsaturated groups and carbonyl 
functionalities dominated clusters 1,2 and 3, respectively. 
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Specific substructural features were also seen. For example, carbon chain linked to a polar 
group such as oxygen and nitrogen has been observed as highly correlating with acute toxicity 
in cluster 1 in the toxic network as well as clusters 1 and 2 in the non-toxic network (Tables 
(5-4) and (5-5)). It was also seen as highly connected in toxic network in cluster 1. This feature 
resembles the structural backbone of surfactants, which constitute of a hydrophobic carbon 
chain linked to an ionic or non-ionic polarized functional group.290 Surfactants are known to 
exert skin irritability as a function of solubility and level of organization in micellar 
structures.291 Another feature, which had both high association with toxicity as well as 
connectivity to other conditions, was halogen functional groups, in cluster 2 of toxic network 
and cluster 3 of non-toxic network. Haloalkanes are liable to form free radicals292 and hence 
exert toxic effects via binding and interfering with cellular molecules.293 Heterocyclic 
substructural conditions were highly connected in cluster 1 in toxic network and cluster 3 in 
non-toxic network. The toxicity of heterocyclic compounds can vary according to adjacent 
functional groups and biological properties.294 For example, heterocyclic aromatic amines in 
food contaminants can cause DNA damage which can result in apoptosis.295 Nitrogen and 
sulfur mustard in cluster 2 of the toxic network represent a known cytotoxic substructures 
which are associated with gastrointestinal tract and kidney toxicity.296 Michael reaction 
acceptors6 in cluster 1, urethane derivatives and thiophosphoric acid derivatives281 in cluster 3 
in the toxic network represent classical alerts for acute toxicity. Urethane pesticides can induce 
toxicity by inhibiting acetylcholinesterase, a classic mechanism for systemic acute toxicity.297 
Therefore, the most important chemical features in the networks may represent either specific 
structural alerts/molecular initiating events or generic functionalities and compound 
promiscuity. 
5.3.1.1 Modulatory nuclear receptors 
The most connected nodes in both toxic network and non-toxic describing networks do not 
always represent statistically the most associated features with acute toxicity (Tables (5-4) and 
(5-5)). For example, thyroid hormone receptor (TR) signalling pathway, vitamin D receptor 
(VDR) and arylhydrocarbon receptor (AhR), which have significantly high connectivity in rule 
networks, regulate homeostasis and defence against xenobiotic. These nuclear receptors are 
also common in regulating cellular oxidative stress. TR had shown connectivity of  216 in toxic 
network, which is 10 fold higher than the majority of features used in the toxic network. TR is 
involved in energy regulation, metabolism298 and maintaining cardiac function.299 Studies have 
shown that both hyperthyroidism and hypothyroidism are associated with oxidative stress.300  
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Table (5-4) Important substructural and bioactivity features in toxic network clusters selected the by normalized mutual information (NMI) and degree connectivity. Highly 
connected features in the network means that they are used frequently as conditions in the rules. It can be seen that most connected features in the network do not always 
represent features with the strongest associations with acute toxicity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Highlighted features in the table had 150 or higher values for degree centrality in toxic networks. The median value of degree in network is 7. Features with the top mutual 
information had values higher than -2.2 (see figure 2 for overall distributions). 
 
 Structural alerts Bioactivity features 
 Top degree Top NMI Top degree Top NMI 
Custer 1 
- six membered heterocyclic 
compounds 
- C=O 
- C=N 
- halogen derivatives 
- nitrile 
- saturated heterocycles 
- nitrogen linked to saturated 
carbon chain 
- α,β-unsaturated bond linked to 
oxygen atom (Michael reaction 
acceptor) 
- oxygen- linked to 
aliphatic carbon chain 
(variable length) 
- nitrogen linked to 
saturated carbon 
chain (variable 
length) 
 
- TR (antagonist) 
- Nrf2 
- CAR (antagonist) 
- Glutamate receptor (ion channel) 
- Disruptors of mitochondrial 
membrane potential 
- SIR2  
- Cell viability  
- ARE (agonist) 
- CAR (antagonist) 
- ER (antagonist) 
- AR (antagonist) 
- Cell viability 
Custer 2 
- Halogens 
- Aromatic amines 
- N 
- Amines 
- Oxygen group (O,S,SE)  
- Halogenated alkyls 
and allyls 
- N and S mustard 
- O 
- AhR  
- Troponin T cardiac  
- VDR( antagonists) 
- NOS 
- AMPK 
- AChE  
- MAP kinase kinase 
- DAO 
- Neuronal Ach 
- Tyrosine kinase 
TYRO3 
- AChE 
- Serine threonine 
protein kinase 
- NOS 
Custer 3 
- Pnictogen (N group) 
- Carboxylic acid derivatives 
- Tertiary amine 
- P or S 
- Derivatives of urethane 
(carbamates) 
- Thiophsophoric acid 
derivatives 
- P 
- N-substituted anilines 
- Pnictogens (N-group) 
- Benzyl amine  
- Ephrine type A receptor 
- Ca calmodulin protein kinase 
- Cyclic phosphodiesterase 
- AhR (activator) 
- AChE 
- PIPK 
- Cyclic 
phosphodiesterase 
- Carboxic acid ester 
hydrolase 
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Table (5-5)  Important substructural and bioactivity features in non-toxic network clusters selected by the normalized mutual information (NMI) and degree connectivity. It can 
be seen that the most connected structural features in cluster represent distinct functional groups. Also, an overlap in the most important bioactivity features can be observed 
with toxic network. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Highlighted features in the table show 150 or higher values for degree centrality in non-toxic networks. 
 
 
Structural alerts Bioactivity features 
 Top degree Top NMI Top degree Top NMI 
Custer 1 
- Alcohols (aliphatic and 
phenolic) 
- aromatic amines 
- S 
-  
- oxy- linked to aliphatic carbon 
chain 
- keto-linked to aliphatic chain 
- phenyl sulphonyl 
-  
- Cell viability 
- ER (antagonist) 
- P53 (agonist) 
- Nrf2 
- AhR  
- AMPK 
- Neuronal Ach ion 
channel 
- CAR (antagonist) 
- ER (antagonist) 
 
Custer 2 
- O 
- Aromatic compounds 
- Alkyl aryl ethers 
- Arenes 
- Benzoyl 
-   
- oxy- linked to aliphatic carbon 
chain 
- ethyl phenyl ether 
-  
-       
 
- AhR (activators) 
- Troponin T cardiac  
- Disruptors of 
mitochondrial 
membrane potential 
- Glutamate receptor 
- Alpha-adrenergic 
receptor 
- ER (antagonist) 
- ARE (antagonist) 
- Aldo-keto reductase 
- Carboxylic 
esterhydrolase 
- PPAR gamma 
Custer 3 
- Carbonyl compounds 
- Phenyl ketone 
- Amides 
- Five-member ring 
heterocycles 
- oxy- linked to aliphatic carbon 
chain 
- alkyl halide 
- aliphatic amine 
- aliphatic amide 
- TR (antagonist) 
- Cell viability 
- Alpha-adrenergic 
- NLRP3 inflammasome 
- Cyclic 
phosphodiesterase 
- ARE (agonist) 
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While hyperthyroidism activates reactive oxygen species (ROS) production, hypothyroidism 
is linked to the deficiency in antioxidant responses and altered lipid metabolism.300 TRa-
deficient mice have also shown higher apoptosis in pancreatic cells when stress in endoplasmic 
reticulum is induced.301 AhR, which is a nuclear receptor activated by polycyclic hydrocarbons, 
regulates the expression of phase I and phase II metabolizing enzymes. AhR activation can 
either mediate oxidation or activates antioxidant responses, via Nuclear factor (erythroid-
derived 2)-like 2 (Nrf2), depending on cell type or organ.302 VDR is also known to maintain 
oxidative responses by inhibiting superoxide anion generation and regulating mitochondrial 
functions.303 Therefore, the most connected nuclear receptors in both toxic and non-toxic 
network have high modulatory functions regulating oxidative stress. 
Tables (5-4) and (5-5) also show estrogen (ER) and androgen (AR) receptors, which are related 
to chronic effects304 as highly correlating with acute toxicity. These receptors as well as the 
nuclear receptors above, may not explain on their own how acute toxicity is triggered. As will 
be discussed later, nuclear receptors are involved in several synergistic interactions with other 
features leading to acute toxicity. 
5.3.1.2 Antioxidant pathway 
Our results highlighted three bioactivities involved in the antioxidant responsive element 
(ARE) pathway. These are ARE, Nuclear factor erythroid-derived 2 (Nrf2) and PPARg in 
cluster 1 of toxic network and 1-3 clusters on non-toxic network (Tables (5-4) and (5-5)). ARE 
pathway is one of the first defence lines to protect the cell from ROS-induced DNA damage.193 
ROS activate the translocation if Nrf2 to the nucleus so as to bind to the ARE, resulting in the 
expression of detoxifying genes. It was also found that Nrf2 binds in the PPARg promotor 
regions of ARE.305 PPARg regulates glucose metabolism and adepogenesis, and its disruption 
results in oxidative stress via an increase in lipid peroxidation.193 Hence, targets of the 
antioxidant response pathway are key points in capturing the presence or absence of toxicity.  
 
5.3.1.3 Kinase disruption 
Kinase activity, which contributed mainly to cluster 2 and 3 in the toxic networks, as observed 
in Table (5-4), is associated with a number of adverse effects including cardiovascular, dermal 
and hepatotoxicities.306,307 The well-studied drug doxorubicin is known for its severe 
cardiovascular effects which are attributed to the impairment of energy haemostasis, regulated 
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by kinases including AMPK (AMP-activated protein kinase) .308 Doxorubicin was found to 
decrease AMPK levels, AMPK phosphorylation as well as the phosphorylation of its target 
Acetyl-CoA-carboxylase. 308 Another kinase was Ephrin receptor (EPHA2), which had the 
highest connectivity in the toxic network among kinases (187 node degree), is a subfamily of 
tyrosine kinases (Table (5-4)). Upon activation, EPHA2 inhibits neuronal repair after nervous 
system injury.309 Ephrin receptors are overexpressed in a number of cancer cell lines, and 
responsible for cell adhesion and differentiation.310 Chemical modulators of EPHA2 are 
cytotoxic and induce apoptosis in a number of cancer cell lines, attracting attention as a 
potential anticancer target.310,311 The stress-activated protein kinase, JNK(c-Jun N-terminal 
kinase), which is activated by MAPK (mitogen-activated protein kinase), can mediate 
hepatotoxicity through impairing mitochondrial respiratory and increasing ROS release.312 
This, in turn, activates MAPK leading to further activate and sustain JNK pathway, which 
eventually leads to amplifying the toxic effects.313 Inhibitors of tyrosine kinases, which were 
also observed in toxic networks, exert variable cardiovascular effects306 such as ischemic heart 
diseases and vascular toxicity.314 Phosphatidylinositol phosphate kinase (PIPK)  contributed to 
cluster 3 in the toxic network, of which inhibitors are known to induce dermal and liver 
toxicities.307 Calmodulin kinase (CaMK) is a multifunctional serine-threonine kinase which is 
activated when intracellular concentration of Ca ions increases.315,316 The activation of CaMK 
induces myocardial dysfunction such as arrhythmias, which explains the toxic effects of 
cardiac glycosides.317 The inhibition of CaMK is linked to neurotoxicity which was found to 
induce apoptosis in neurons and control neuronal structure and excitability.315 Overall, kinase 
activity disruption plays a key role in describing acute toxicity. 
5.3.1.4 Other targets 
Toxic and non-toxic rule networks have shown significant connectivity of troponins, nitric 
oxide synthase (NOS) and NLRP3 inflammasome. Cardiac troponins are myofilament proteins 
that regulate cardiac muscle contraction and relaxation via binding to calcium ions.318 
Chemical compounds that increase or decrease calcium sensitization of myofilaments, via 
binding to troponins, can lead to changes in cardiac contractility.319,320 Also mutation in cardiac 
troponin T was associated with a number of cardiomyopathies.318,321 NOS is an enzyme that 
produces the vasodilator nitric oxide (NO), which is protective in ischemic events.322  Activity 
against NOS is linked to cardiotoxicity as well as  ROS production.323 NLRP3 is a protein 
complex which activates a highly inflammatory cell death pathway, in response to non-
microbial damage signals.324 NLRP3 activates caspase 1, which is an IL-1b converting 
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enzymes, resulting in the release of a potent pro-inflammatory cytokine. This pathway is 
induced by reactive oxygen species (ROS) and environmental irritants. IL-1b  mediates 
inflammatory responses that induce cardiac cell death linked to atherosclerosis, myocardial 
infarction and cardiac fibrosis.324 
Other significant features in the networks include diamine oxidase (DAO), sirtulin-2 (SIR2) 
and tumor protein (p53). DAO is responsible for the degradation of a number of substances 
mainly histamine. The impaired breakdown of histamine can result in histamine accumulation 
which is itself cause acute toxicity at abnormal levels.325 Symptoms of histamine toxicity 
include rash and hypotension.326 SIR2 is a NAD-dependant deacetylase enzyme, a tumor 
suppressor which regulates DNA repair, apoptosis, neuroprotection and inflammation.327 SIR2 
deficiency is linked to mitotic cell death and gender-specific tumors.328 P53 protein is a known 
biomarker in cancer 329 as it mediates several pathological pathways including doxorubicin-
induced cardiotoxicity.330 These findings, in general, demonstrate the high diversity in 
biological processes associated with acute toxicity. 
Overall, the most important features captured in networks, which either have strong 
associations or high connectivity, may not explain alone the mechanisms initiating acute 
toxicity. Therefore, in order to further understand modes of action in acute toxicity, interactions 
between features should be analysed including the synergistic connections.   
5.3.2 Novel insights into polypharmacology in acute toxicity through synergy 
interactions 
High connectivity of some features discussed above demonstrates the importance of 
understanding toxicity with regards to compound polypharmacology. In order to determine 
which feature combinations are more important in acerbating toxic effects, we examined the 
statistical synergy of features pairs. This was performed using mutual information statistic and 
odds ratios on single features and compared with the pair combined (see Methods). A 
synergistic feature pair implies that the association of that pair with toxicity is significantly 
greater than individual features and their additive effect. 
First, to understand why some feature pairs show synergistic interactions, we examined the 
similarity between connected pairs in terms of chemical profiles and biological functions, 
presented in Figure (5-6). As can be seen in Figure (5-6, A), synergy always occurred between 
features dissimilar in compound profiles, i.e. less than 0.2 and peak at 0.05. In other words, the 
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synergistic features often share small proportions of compounds in which both features are 
present. However, it is critical to note that not all dissimilar features, connected in the network, 
are synergistic (Figure (5-6, A)). Additionally, the similarity between target-based feature pairs 
was tested over KEGG biological pathways in Figure (5-6, B) as well as Gene Ontology (GO) 
molecular functions and GO biological processes (Appendix C, Figure (C-3)). It can be seen 
that the inverse relationship was reproduced, as highly synergistic bioactivity pairs had almost 
zero similarity in biological functions and pathways. This means that synergy resulted from 
combining biologically diverse activities, but not all biologically dissimilar activities are 
synergistic.  
Figure (5-6) Similarity of connected feature pairs (co-occurred in rules) in compound profiles (A), and 
KEGG pathways of targets (B) against their corresponding synergy factor score (see methods). it can 
be seen that synergistic feature pairs (of which the synergy factor scores are higher than 1) are dissimilar 
in chemical profiles and biological function represented by pathways. However, not all dissimilar 
features are synergistic. 
 
Next, we selected and analysed synergistic pairs in toxic networks which were present in two 
or more different rules, and summarized in Table (5-6).  
5.3.2.1 Nuclear receptor disruption 
Our results have shown co-clustering of cell viability assays with the disruption of number of 
nuclear receptors regulating proliferation such as estrogen and androgen receptors, in addition 
to nuclear receptors regulating expression of metabolizing enzymes. Proliferation and cell 
death is regulated, in general, by a network of nuclear receptors331,332, which explain the 
observed co-clustering of these two classes. This combination was reproduced in assays 
predictive of hepatotoxicity, in Chapter 4. Although endocrine disruption is more associated 
with chronic effects such as carcinogenicity304, the centrality of these effects in the network, 
A B 
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besides the relatively strong associations, indicate that compounds trigger acute toxicity are 
likely to produce chronic effects.  
The antagonism of AR and ER were synergistic with the presence of six-member heterocycle 
substructures (Table (5-6)). Heterocycles steroids were reported to have an enhanced activity333 
and in some cases produce neurotoxicity and convulsions.334 Synergy was observed between 
metabolizing enzyme Cytochrome 2C19 (CYP2C19) and a number of xenobiotic-sensing 
nuclear receptors such as VDR, constitutive androstane receptor (CAR) and AhR. In Chapter 
4, rules describing hepatotoxicity combined the activity against CYP enzymes with VDR 
activity, an observation which was reproduced in rules describing acute toxicity. This synergy 
can be attributed to inhibiting clearance of toxic compounds via inhibiting the expression of 
xenobiotic metabolizing enzymes.220,252,335  While AhR activation correlates with acute 
toxicity132, the mechanism of AhR mediated acute toxicity was hypothesized to multiple routes. 
One study has demonstrated that AhR activation mediates the catabolism of vitamin D3 via 
inducing Cytochrome P enzymes which may alter the protective effect of VDR signalling 
pathway.336 This can be supported by the observed synergy between CYP enzymes, VDR and 
AhR in our study. Other studies have linked AhR activation with triggering inflammatory 
responses via inducing multiple cytokines337, and promoting cellular morphological changes 
which correlate with activating JNK.338 While specific synergies were observed for endocrine 
and xenobiotic-sensing receptors, nuclear receptors such as TR and VDR are involved in 
diverse synergistic interactions including neurotransmission and cholinergic toxidrome 
discussed below. 
5.3.1.1 Neurosignalling disruption 
Synergistic interactions were seen for the activity of two neuronal receptors, namely, glutamate 
and GABA receptors. The disruption of these receptors represents known key events in the 
AOP of acute toxicity.128,129 However, when these stressors are combined with other specific 
bioactivities, the likelihood for in vivo toxicity is potentiated. Glutamate is an excitatory 
neurotransmitter and its activity is linked to neuronal damage in excessive excitation as well 
as inhibition.284,285 There were multiple synergistic connections of glutamate receptor activity 
with TR, cytotoxicity and mitochondrial membrane potential. Studies have shown that toxicity 
is observed in chemicals which are characterized by mitochondrial toxicity and glutamate 
receptor activity.339,340  
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Table (5-6) Examples of important synergistic pairs in toxic network which occurred more than once in rules. Some of  synergistic interactions in the table correspond 
to known key events (KE) in adverse outcome pathways (AOPs) of acute mortality, stored in the AOP wiki, namely Acetylcholinesterase (AOP ID 16), glutamate 
receptors (AOP ID 113 and 161) and GABA (AOP ID 10).  
Key Event Significantly associated Key Events  
Odd 
Ratio 
comb 
Synergy 
factor 
N# toxic compounds Comments 
Cell 
viability 
(general) 
Nuclear receptor activity (general) 2.8 ± 
1.4 
(Avr) 
0.94 0 ± .32 
(Avr) 58 ± 28 (Avr) 
Cell proliferation and apoptosis are directly regulated by 
nuclear receptors331,332 
AR  
antagonism 
ER 
antagonism 
Six-member ring heterocycles 6.5 2.9 
3.8 
1.5 
37 
47 
Heterocycles steroids have enhanced activity333 and can 
produce neurotoxicity and convulsions334 
Glutamate 
receptor 
TR antagonism 
Cell viability 
Disruption of mitomembrane potential  
3.7 
3.9 
2.4 
2.2 
2.0 
1.5 
46 
37 
68 
Thyroid hormone (T3) activates glutamic neuronal reuptake. 
Mitochondrial toxicity potential toxicity of glutamate 
disruptors.339,340 
GABA 
receptor 
ARE agonist 
TR antagonism 
Disruption of mitomembrane potential  
HIF2 
VDR  
21.7 
22.8 
23.8 
5.8 
2.4 
6.8 
5.4 
6.1  
2.5 
1.4 
21 
21 
22 
23 
62 
TR and ROS control GABA reuptake.341,342343 Vitamin D3 
via VDR regulate GABA expression.344 
Cyp2C19 CAR antagonism 
VDR antagonism 
AhR activation 
1.4 
1.5 
1.5 
1.0 
1.1 
0.9 
327 
308 
326 
CAR, VDR and AhR regulate the expression of Cytochrome 
P enzymes.220,252,335 
AChE Derivatives of carbamates 
Phophstidyl inositol 5 phosphate kinase 
VDR antagonism 
AhR activation 
Troponin T cardiac 
NLRP3 
17.4 
6.4 
1.8 
1.8 
1.6 
1.7 
4.9 
2.6 
1.2 
1.1 
1.0 
1.0 
17 
37 
164 
141 
243 
233 
Cholinergic toxidrome involve Ca ion dysregulation and 
inflammation.268 Interference  with calcium sensitization of 
troponin319,320 and inflammatory responses of NLRP3324 are 
associated with cardiovascular effects. 
Depletion of PIP2 mediated the inhibition of ACh K+ ion 
channels345 via PI5P4K inhibition. 
NOS Retinal dehydrogenase 
VDR  
Alkyl halides 
2.1 
2.0 
3.2 
1.3 
1.2 
1.2 
99 
160 
61 
VDR346  and retinal dehydrogenase347  activities can induce 
NOS expression. 
a-
adrenergic 
 
Cell viability 
Aromatic primary and secondary amine 
Protein kinase C (Tyrosine kinase) 
AhR activator 
9.2 
4.3 
4.1 
2.8 
3.8 
3.2 
2.7 
1.4 
18 
25 
16 
40 
PKC contribute in the a-adrenergic mediated contraction of 
vascular smooth muscles.348,349 
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Additionally, thyroid hormone (T3) activates glutamate neuronal reuptake which results in 
protecting against toxicity triggered by glutamate excessive stimulation.350 Therefore, we can 
conclude that glutamate receptor-mediated toxicity should not only be tested via activity 
against this receptor, but also combined with mitochondrial disruption, cytotoxicity as well as 
thyroid receptor disruption.  
The excitatory neurotransmitter Glutamate is a precursor of the inhibitory transmitter 
GABA.351 The activity against GABA had multiple synergistic links in the toxic network 
including TR antagonism, ARE, VDR and hypoxia-inducible factor-2 (HIF2). Similar to 
glutamate, TR regulates the synthesis, degradation, release and expression of GABA.343  
There is clinical evidence that GABA related nervous disorders are linked to thyroid 
dysfunction.343,352,353 Therefore, TR is highly connected because it regulates neurosignalling, 
including serotonergic, dopaminergic, glutamatergic and GABAergic networks,350 in addition 
to oxidative stress and inflammatory processes.300 Cellular oxidative stress,  which induces the 
antioxidant response element pathway, reduces GABA reuptake and hence increases its 
levels,341,342 which consequently interfere with normal neurotransmitter signalling. This 
explains the synergy between GABA modulators and activators of ARE. It was also reported 
that mitochondrial-derived ROS regulate postsynaptic GABA receptors in cerebral stellar 
cells.354 Additionally, the deficiency of vitamin D3, the endogenous ligand of VDR, lowers the 
expression of genes regulating GABA neurotransmission,344 and hence, explains the detected 
synergy between VDR and GABA activities. Hypoxia inducible factors (HIF-1 and HIF-2) are 
transcription factors that regulate haemostasis in response to low oxygen levels.355 A possible 
association between HIF and GABA can be explained by the induction of GABA catabolism 
(GABA shunt) in hypoxic environment, which is an anaerobic route for energy production 
when the Krebs cycle is compensated.356 The activation of the GABA catabolism produces 
succinate as a metabolite which activates HIF-1 and induces the inflammatory cytokine IL-
1b.357  HIFs also regulates glutamate signalling via upregulating glutamate transporters.358 
Overall, in order to capture neurotoxicity, a network of biological effects should be considered.  
5.3.1.2 Cholinergic toxidrome 
Cholinergic toxidrome represents a set of effects associated with AChE inhibition and linked 
with Ca ions dysregulation, immune and inflammatory responses and cytotoxicity.268 The 
current analysis has shown that AChE involved in a diverse set of synergies (Table (5-6)) and 
was also ranked as one of the most connected nodes in toxic networks (Table (5-4)). AChE 
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have shown synergies with cardiac troponin, NLRP3 inflammasome and VDR, which are all 
involved in cardiovascular functions. AChE inhibitors also increase serum troponin359,360, 
which is the most sensitive biomarker for myocardial infarction.361 Although, levels of serum 
troponin may not be an indication for direct bioactivity against the protein362,363, our study has 
shown synergy between AChE and troponin bioactivities. These findings support the possible 
cardiotoxic effect having these properties combined in compounds. Another bioactivity that 
synergistically connected to AChE and troponin was NLRP3 inflammasome (NACHT, LRR 
and PYD domains-containing protein 3). Inhibition of NLRP3 in models of ischemic injury 
reduces myocardial infarction and serum troponin.364 The severity of toxification by 
organophosphates, which are potent AChE inhibitors, correlated with electrocardiogram 
(ECG) grading and cardiovascular effects such as ischemic changes and arrhythmias.365 
Therefore, combining activities against cardiac troponin, AChE and NLRP3 can induce 
cardiotoxic effects as well as potentiate the signs of cholinergic toxidrome. Another synergy 
interactions was observed between AChE activity and carbamate derivatives. The data has 
shown that around 50% of compounds possessing the carbamate substructure are toxic. 
Whereas, over 90% of carbamate derivatives in the dataset, and also are predicted to be AChE 
inhibitors, are toxic. Moreover, AChE has shown synergy with phosphatidylinositol-5-
phosphate-4-kinase (PI5P4K), which participate in the synthesis of the second messenger 
phosphatidylinositol-4,5-diphosphate (PIP2).366 It was reported that the depletion of PIP2 
inhibits ACh K+ ion channels.345 Therefore, the observed synergy can result from the 
aggregated sensitization by ACh accumulation and PIP2 depletion leading to rapid onset of 
muscle paralysis and respiratory failure. Additionally, this study has shown synergy between 
AhR and AChE. A study has shown that 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) a potent 
AhR activator suppresses the activity of AChE through transcriptional down-regulation.367 
Overall, AChE is a key event in acute toxicity, which when present relevant bioactivity profiles 
should be screened so as to evaluate the possible in vivo effects. 
5.3.1.3 Nitric oxide synthase activity 
The rules have picked multiple isoforms of this enzyme, most notably the inducible and 
endothelial isoforms, iNOS and eNOS, respectively. NOS bioactivity was frequently and 
synergistically connected with VDR antagonism in rules for acute toxicity. VDR induces the 
expression of  NOS via Vitamin D3.346 This is supported by a study on VDR mutant mice, 
which had shown low levels of NO, reduced NOS expression, and associated with atrial 
stiffness and impaired heart function.368 Our study has shown that VDR antagonism on its own 
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does not exert high mutual information with acute toxicity, however, it was one of the top 
bioactivities linked synergistically with diverse biological properties. This is likely due to the 
high regulatory function of VDR in haemostasis and cardiovascular function.369 Moreover, 
NOS has shown synergy with alkyl halides and retinal dehydrogenase. Studies have reported 
that organochlorides induce the expression of NOS as well as ROS production in endothelial 
cells while decreasing NO levels.370 Retinal dehydrogenase-1 (ALDH1)  is an enzyme that 
oxidizes retinal into retinoic acid, and hence, regulating the metabolism of vitamin A.371 
ALDH1 metabolite, retinoic acid, increases the expression of NOS and suppresses T 
lymphocytes proliferation in liver dendritic cells to revert pathological activation of immune 
responses.347 Also, ALDH1 is involved in the defence against oxidative stress.372 Therefore, 
inhibiting ALDH1 may interfere with NOS-mediated immunological response. 
5.3.1.4 a-Adrenergic receptor activity 
Inhibition of a-adrenergic receptors can cause hypotension via decreasing constriction of 
vascular smooth muscles.373 Synergy was observed between a-adrenergic receptors and protein 
kinase C (PKC), AhR and cytotoxicity (Table (5-6)). PKC contribute in the a-adrenergic 
mediated contraction of vascular smooth muscles.348,349 a-adrenergic receptors also control the 
expression of PKC via the accumulation of downstream second messenger diacylglycerol 
(DAG).374 Blocking PKC activity via gene deletion results in hypotension and decreased 
vascular contractility.375 Therefore, the simultaneous blocking of a-adrenergic receptors and 
PKC can manifest in severe hypotension. Additionally, studies in AhR (-,-) mice have shown 
a higher expression of a1D-adrenergic receptors and an increase in the maximal effect in aorta 
contraction by a-receptors agonists; noradrenaline and phenylephrine.133 Therefore, it is 
possible that AhR modulator would modulate basal a-adrenergic effects, which may explain 
the synergy between Ahr and a-receptors. Cytotoxicity also has shown synergy with a-
adrenergic receptors, which may be a direct or an independent phenotype. The stimulation of 
a1A-receptors is associated with proliferative as well as antiproliferative effects.376 
Additionally, the analysis has demonstrated synergy between the presence of an aromatic 
amine substructure and a-adrenergic activity. 
For the mechanistic interpretation of acute toxicity, our results indicate the importance of 
considering multiple bioactivities at a time. Single features on their own may not be strong 
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alerts for toxicity. Given the pairwise analysis conducted, the interpretation here may miss 
important interactions resulted from more than two properties at a time. 
 
5.4 Conclusions  
In this study, we investigated mechanistic interactions in acute toxicity from a feature space 
collected from structural properties, Tox21 assays and predicted targets. In order to understand 
complex interactions, we used emerging patterns which are generated for both the presence 
and absence of in vivo toxicity.  
Rule patterns held associations of variable complexities as captured by single and multiple 
conditions, respectively. Chemical features had simpler and less complex interactions with 
acute toxicity. In contrast, target specific features involved complex and diverse connected 
conditions. The implications of complex bioactivity associations, observed in this study, may 
translate into complex predictive models for toxicity using bioactivity data. Hence, we 
anticipate that this complexity can explain the  low performance of bioactivity-based models 
reported in the literature.98,99,146 Also, understanding possible interactions, and hence 
significant polypharmacology is particularly important for weak assay activities. 
Via rules, we gained novel insights into how specific polypharmacology profiles have higher 
odds of acute toxicity. For example, disruption of neurosignalling by GABA and glutamine 
receptors are more likely to trigger neurotoxicity when combined with thyroid receptor 
disruption. Another example is the cholinergic toxidrome which is characterized by inhibiting 
acetylcholinesterase AChE, and downstream effects including inflammation and Ca ion 
dysregulation. 268 we demonstrated that the likelihood of acute toxicity incidences is 
significantly greater when compounds inhibit with AChE also interfere with the calcium 
sensitization of troponin319,320 and inflammatory responses of NLRP3324, which are associated 
with cardiovascular effects. 
In conclusion, the framework described in this study can be used to generate hypotheses about 
interacting key events in the adverse outcome pathway.
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6      UNDERSTANDING PROMISCUITY BIAS OF IN 
SILICO MODELS PREDICTING ACUTE TOXICITY  
6.1 Introduction 
As discussed in earlier chapters, understanding the confounders and biases in in vitro data is 
essential for interpreting in vitro measurements. For example, overly activated pathways as a 
result of the cytotoxicity burst phenomenon can result in compounds inaccurately flagged as 
positives, i.e. false positives.85 Consequently in these cases, and without consideration of 
factors deriving compounds’ promiscuity, rationalization of in vitro measurements can be 
inaccurate.  Additionally, it is likely that such confounders can result in spurious associations 
derived by statistical predictive models. It has been debated whether incorporating in vitro 
assay measurements as descriptors to predict toxicity is beneficial.100 Mixed outcomes were 
observed as such leading to improving performance in some cases146 and deteriorating in 
others.99 This mean care should be taken when using bioactivity data to train statistical models 
for toxicity. 
The aim of this study is to examine biases in predictive models that occur as a result of using 
bioactivity data. In a conformal prediction framework (see section 2.3), the predictivity of rule 
models, described in Chapter 5, will be investigated against Random Forest models trained on 
chemical descriptors (without bioactivity data). The distribution of predictions made by the 
models in the chemical space are compared with experimental toxicity labels to explore 
possible biases. 
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6.2 Materials and Methods 
 
6.2.1 Datasets 
 
The dataset used in this chapter was adapted from Chapter 5, including Tox21 assays, predicted 
targets, substructures and GHS acute toxicity labels (see section 5.1.1). The data represents 
2000 compounds, 993 toxic compounds and 1007 non-toxic, against 3732 features. These 
represent 1789 predicted targets, 440 Tox21 assay activities, 1259 ToxAlert toxicophores and 
242 MoSS derived substructures. Additionally, using the chemical structures of the 2000 
compounds, chemical descriptors were calculated using RDKit199 node in KNIME200 to 
generate 117 physicochemical properties as well as circular fingerprints with a radius of 2 and 
2048-bit length.  
6.2.2 Emerging patterns generation  
Emerging patterns were generated using CPAR algorithms following the data and specification 
described in Chapter 5 (see section 5.1.2).  
6.2.3 Random Forest models 
Classification models were built based on Random Forest algorithm, which was trained on 
chemical descriptors (physicochemical properties and circular fingerprints) for 2000 
compounds. The model was generated in R (version 3.3.3) using the package ‘RandomForest’ 
setting the number of trees to 500, while all other parameters are set to default. 
 
6.2.4 Conformal prediction 
A conformal prediction framework (Chapter 2, section 2.3) was applied to evaluate the 
reliability of predictions made by rules and represented in Figure (6-1). In the conformal 
prediction framework, the data are split into proper training and test sets in a 4: 1 ratio (see 
Figure (6-1)). The proper training set is then split into training and calibration sets at a 4:1 ratio. 
The training set is used to train the models, whereas predictions are made for calibration and 
test sets. A key component of the conformal framework is the non-conformity measure (a), 
which is used to estimate how a test set compares to an independent set, i.e. the calibration set. 
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With regards to emerging patterns, each test (or calibration) compound can satisfy i number of 
toxic describing emerging patterns, where i Î{0, 1, 2, 3 ,…. , m}, and m is the total number of 
toxic describing patterns. Similarly, compounds can satisfy j number of non-toxic describing 
emerging patterns, where j Î{0, 1, 2, 3 ,…. , n}, and n is the total number of non-toxic 
describing patterns. The non-conformity score is the difference in compound promiscuity over 
emerging patterns describing toxicity and non- toxicity, called the rule promiscuity score (see 
equation below). Rule	promiscuity	score	= 	N#	satisfied	toxicity	describing	patterns	– 	N#	satisfied	non_toxicity	describing	patterns	 
     = ; − =                        [13] 
 
In order to examine if promiscuity over rules outperform promiscuity over important features, 
we also used promiscuity over significant features as a non conformity score. Significant 
features were determined through univariate associations with acute toxicity (Fischer test p-
value < 0.01 on features used to train rule models). 
As for Random Forest models, the probability values were used as the non-conformity score 
(see Figure (6-1)). The non-conformity score is calculated for the calibration set and test sets. 
Then the rank of the test set among the calibration set determines the significance (p-value). In 
a Mondrian conformal models, non-conformity scores are calculated for both labels (atoxic and 
bnon-toxic), and hence, two independent ranks are produced for each test set in a two-class label 
setup. The non-conformity scores for the non-toxic label were obtained as follows for the 
emerging patterns models: 
b	>?>_@?A;B = 	−[DEFG	HI?J;KBE;@L	KB?IG] = 	−[a]           [14] 
And for the Random forest model: 
b	>?>_@?A;B = 	1 − [O] = 	1 − [a]           [15] 
According to the p-values obtained from non-conformity score rankings and a predefined 
confidence levels, four labels can be assigned by the conformal models, namely, ‘Toxic’, ‘Non-
toxic’, Both’ or ‘None’. The process to derive these predictions is explained in section 2.3.  
Conformal models generation and predictions were conducted in R176 environment (version 
3.3.2). 
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6.2.5 Model validation  
We applied 5-fold cross-validation for both models (see data split in Figure (6-1). Within each 
fold, another 5-fold cross conformal was applied on the training set as described by Sun et 
al.377 The training data were split randomly into proper training and calibration sets in a 4:1 
ratio 5 times against one test set. Therefore, each test instance had 5 P-value scores, which 
were then averaged. The averaged P-value was used to make predictions with respect to the 
confidence level used. 
6.2.6 Chemical space analysis 
In order to compare the distribution of experimental toxicity labels against predicted labels, the 
compounds were visualized in chemical space and labelled accordingly. Circular fingerprints 
of compounds were and plotted into two dimensions using multidimensional scaling analysis 
(MDS). MDS was conducted in R using ‘cmdscale’ function on the Euclidean distances of 
fingerprint matrix. The generated weights (eigenvalues) for each compound against the two 
compressed dimensions represented the scales in the 2D plot. 
6.2.7 Cluster analysis 
To detect which chemical and biological properties were driving the coefficients in the MDS 
2D plot, hierarchical clustering was applied to these coefficients against physicochemical 
properties and compounds promiscuity. The similarity was calculated using the Pearson 
correlation statistic and the similarity matrix was visualized in heatmaps using ‘heatmap.2’ 
function  of ‘ggplot2’205 package in R176 environment (version 3.3.3) at default settings.
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Figure (6-1) Cross-conformal workflow for chemical fingerprint (FP) models and emerging patterns 
(EP) model. FP model used circular descriptors and physicochemical properties as input, whereas, rule 
models use bioactivities from Tox21 measurements, predicted targets in addition to chemical 
substructures. The toxicity label was generated from GHS classification grading for acute toxicity. The 
data split involved 5-fold cross-validation of training and test set. At each fold, the training data were 
partitioned into calibration and proper training sets in 5 random repeats of 1:4 splits. The proper training 
was used to build the predicted models via random forest in the FP model and CPAR-based emerging 
patterns for EP model. The nonconformity scores (NMC) used to rank compounds were label 
probability and rule promiscuity score for FP and EP models, respectively (see Methods). According to 
the descending ranks of test data points in the calibration sets for each label class, the significant level 
(p-value) is computed of which confidence is estimated. 
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6.3 Results and Discussions 
6.3.1 Conformal Predictions 
Three measures were used to examine the performance of the conformal model, namely, 
validity and efficiency (see Section 2.3) and correct classification rate. Firstly, the validity was 
tested across multiple confidence thresholds. We compared three sets of models generated from 
i) conventional Random Forest model using calculated circular fingerprints and 
physiochemical properties, ii) emerging patterns model and iii) model using the promiscuity 
over statistically significant features. Figures (6-2) shows that the error rates align with the 
corresponding confidence levels for all models. This means that the models were capable of 
producing valid predictions (‘Toxic’, ‘Non-toxic’ and ‘Both’). While the overall validity trends 
aligned well with the identity line, a slight fluctuation can be seen for the validity of individual 
class labels due to statistical noise.378 
 
 
Figure (6-2) Validity of conformal models. The validity (conformal accuracy) reflects the percentage 
of valid predictions (‘toxic’, ‘non-toxic’ and ‘both’) to all predictions. A correct prediction in the 
conformal model setting is given to classes where the label is classified correctly as well as points 
predicted to satisfy both classes. The plots show that all models generated valid predictions at the given 
confidence levels (percentage of valid predictions is equal to the predefined confidence level). 
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The second step in assessing the performance of conformal models is to examine the 
percentages of single predictions made by each model in a given confidence level, which 
reflects the models’ efficiency. Table (6-1) represents the percentages of single predictions 
made by each model at three confidence thresholds, namely 90%, 80% and 70%. As a general 
trend, the percentage of single predictions increased as the confidence level decreased. This 
means that the model was allowed to assign more single labels to new instances when the 
expected error rate was higher. In other words, at higher degrees of confidence, the model can 
only assign single labels to fewer instances. The higher the number of single predictions, the 
more efficient the model. Chemical descriptors and rule promiscuity models had shown the 
highest efficiency up to around 90% and 82% at 70% compared to significant feature 
promiscuity with 64% efficiency at the same level. At the higher levels of confidence, namely 
80% and 90%, the difference in efficiency by chemical descriptors was about 2 folds higher 
compared to feature promiscuity (absolute differences of 24% and 21%, respectively) , whereas 
rule promiscuity is 50% higher than feature promiscuity (absolute differences of 7% and 11%, 
respectively).  
Table (6-1) Percentages of single class predictions, namely ‘toxic’ and ‘non-toxic’ labels. 
 
 
Confidence level 
90% 80% 70% 
Calculated Descriptors 42.75 67.1 90.4 
Rule Promiscuity 31.55 60.35 81.85 
Feature Promiscuity 21.5 43.3 64.3 
 
Next, the distribution of predicted labels generated by the models across the three confidence 
levels are presented in Figure (6-3). It can be observed that feature promiscuity-based models 
produced the highest proportion of instances predicted as ‘Both’. This means that the latter had 
the least ability to discriminate between classes as compared to the other two. Moreover, 
chemical descriptors and rule promiscuity models were almost similar in the percentages of 
Toxic class predictions especially at 80 and 70% confidence, which was equivalent to above 
30% and 40%, respectively, of all predictions. Given that rule and feature promiscuity-based 
models arise from similar concepts, the former significantly outperformed the latter in 
efficiency.  
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Figure (6-3) The percentage of predicted/assigned class labels at confidence levels of 90%, 80% and 
70%. At the level of 90% confidence, the majority of predictions were classified as ‘both’. As the 
threshold for confidence decreases, the models produce more single prediction labels, namely ‘toxic’ 
and ‘non-toxic’. In general, chemical descriptor models (FP) always generated higher numbers of single 
label predictions, whereas models based on feature promiscuity had the least number of single class 
predictions across the confidence levels. 
 
The third step in performance is measuring the correct classification rate of the single 
predictions, which are reported in Table (6-2). The table shows that both chemical descriptors 
and rule promiscuity, at 90% confidence had an overall accuracy higher than 70%.  However, 
the correct classification rate of feature promiscuity models was almost random. This means 
that using the absolute promiscuity over significant features was less useful in discriminating 
between toxic and non-toxic compounds. Overall, the accuracy deteriorated as the confidence 
level decreases, where higher error rates are expected. This decrease was steeper for chemical 
descriptors models and rule-based models. The accuracy was also higher in predicting the toxic 
compounds across all models, especially at higher confidence. For example, at 90% 
confidence, the accuracies of the toxic class predictions by chemical descriptors and rule 
models were around 80% and 73%, respectively. Lower accuracy can be seen for classifying 
non-toxic compounds at the same threshold to around 75% and 69% for chemical descriptor 
and rule-based models, respectively. The class-wise variability in performance diminished as 
the confidence decrease, so that the accuracy of predicting both classes is almost the same at 
70% confidence for chemical descriptor models and in favour of non-toxic compounds using 
rule models. In average and across all threshold levels, rule models are only 5% less accurate 
than chemical descriptor models. In further analysis, only rule and Random Forest models are 
examined due to the low performance of feature promiscuity models. 
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Table (6-2) Correct classification rate of single predictions (FP: chemical descriptors, EP: emerging 
patterns/ rule models, SP: promiscuity over significant features). As the confidence level decreases, the 
accuracy of single class predictions decreases. Overall, FP models had shown the highest accuracies. 
The difference between the EP model and FP model accuracies was consistent around 5%. Using target 
promiscuity as a nonconformity sore in the models had almost random performance. 
 
6.3.2 Distribution of model predictions across chemical space 
 
In order to visualize predictions made by Random Forest (FP) and rule models in chemical 
space, 2D multidimensional scaling analysis (MDS) plots were generated using circular 
fingerprint descriptors. As a reference, the toxicity labels from the GHS classification were 
also visualized in Figure (6-4). As can be observed in Figure (6-4, a), the distribution of toxic 
and non-toxic labels, from GHS data, in the chemical space is almost random especially across 
the second dimension in the MDS plot (D2). At the negative scale of the horizontal D1 axis, 
the ratio of two labels is in favour of toxic compounds, which is also captured in the 
corresponding density plot. With regards to predictive models (Figure (6-4, b and c)), a clear 
pattern can be seen in the distribution of predicted toxic and non-toxic classes in the chemical 
space. For example, across the negative scale of D1, the imbalance between the two labels is 
greater than GHS toxicity labels. Also, along D2, there is higher density of toxic compounds 
at the positive scale (precisely at ranges higher than 0.5). The majority of compounds at the 
negative scale of D2 were predicted as non-toxic. The imbalance in distribution and segregation 
in predicted labels across D2 is more pronounced in rule models (Figure (6-4, c)). Therefore, 
models tend to amplify trends observed in the original data at variable extremes and depending 
on the accuracy of the model. 
 
 Confidence level 
 90%  80%  70% 
 FP EP SP  FP EP SP  FP EP SP 
Overall 77.07 70.99 54.65  71.31 66.86 53.46  68.03 63.89 53.26 
Toxic 79.64 72.92 56.62  72.76 67.34 53.96  68.05 62.79 55.13 
Non toxic 74.84 68.95 51.93  69.97 66.31 52.94  68.01 65.09 51.51 
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Figure (6-4) Visualization of the chemical space labelled by toxicity classes (a), chemical descriptors 
(FP) model predictions (b) and emerging patterns (EP) model predictions (c) in multidimensional 
scaling (MDS) plot using circular fingerprints. Toxicity labels are red and non-toxicity labels are blue. 
Compounds predicted to be either ‘both’ or ‘none’ are labelled black. The density plot at each axis 
shows the distribution of toxic and non-toxic label with regards to dimension 1 in the x-axis of the MDS 
and dimension 2 in the y-axis. Toxicity labels in the data had random distribution in the chemical space 
(a), however, both models, FP and EP, had unbalance distributions of the predicted labels, especially 
across the y-axis (D2) in b and c. Compounds predicted as toxic populated more at the positive scale of 
the y-axis whereas non-toxic predictions were denser at scales <0.5 in the y-axis. This is also reflected 
in the density plots of the y-axes, as the distributions of predicted classes are more separated than the 
actual toxicity labels. Abbreviations: MDS D1, dimension 1 in chemical space plot; MDS D2, 
dimension 2 in chemical space plot.  
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In order to interpret the features deriving the bias in the model, we investigated how the 
coefficients of D1 and D2 correlate with physicochemical properties as well as promiscuity 
over bioactivity and structural features. The pairwise Pearson correlations were calculated and 
visualized as a square hierarchical clustering heatmap in Figure (6-5). D1 in chemical space is 
highly correlated with the number of aromatic rings (0.75 Pearson coefficient). The majority 
of compounds clustered at the negative range of D1 have no rings (results not shown). D2, on 
the other hand, had shown correlations with promiscuity over significant bioactivity features 
at 0.65 Pearson coefficient. Also, D2 had negative correlations with the number of atoms and 
promiscuity over structural features at -0.67 and -0.6 correlation magnitudes, respectively. This 
means that compounds of high D2 coefficients are associated with high promiscuity over 
targets whereas low D2 coefficients indicate that compounds have a higher number of atoms 
as well as high diversity over structural alerts. SLogP lipophilicity is a property frequently 
linked with promiscuity over targets. However, this was not observed in our study, nor with 
D2 coefficients. One interpretation for this is that the bioactivity in our dataset was derived 
from cell-based assays and hence permeability can be a key condition for intracellular activity. 
We found that SLogP values of the most promiscuous compound peaked around 3 (results not 
shown), which was reported for good permeability.195  
D2 coefficients, as well as promiscuity over bioactivities, also negatively correlated with the 
number of saturated carbons and number of oxygen atoms (-0.69 and -0.62, respectively). The 
trends seen here aligns with previous studies that reported an association between compound 
promiscuity and the fraction of sp3 hybridised carbons to the total number of carbons.379 
Promiscuity also negatively correlated with the number of oxygen atoms.42 Although the 
presence of aromatic amines in the chemical structure is associated with promiscuity43, the 
number of rings and number of nitrogen atoms, on their own, did not show here significant 
correlations with promiscuity here. Promiscuity over significant bioactivities had shown a 
negative correlation with molecular weight and promiscuity over alerts at –0.51 and –0.37 
Pearson coefficients, respectively. The low promiscuity of structurally complex compounds 
was previously reported380 and  can be attributed to the higher specificity in interactions with 
biological targets.381 Overall, we can conclude that the observed bias in the predicted labels 
across chemical space (in Figure (6-4)) is greatly associated with compounds promiscuity over 
bioactivities as well as chemical features driving this promiscuity. 
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Figure (6-5) Heatmap plot for the cluster analysis of the MDS weights from Figure (6-4) against 
compounds promiscuity and physicochemical properties. Pairwise Pearson correlation was calculated 
between variables, and used as distances to perform hierarchical clustering.  The second dimension D2 
positively correlated with promiscuity over bioactivities but negatively correlated with the count of 
unique substructures. Promiscuity over bioactivity features negatively correlated with the number of 
saturated carbons and number of atoms, reproducing findings in literature.379  Abbreviations: 
D1_Chemical_Space, dimension 1 in chemical space plot; D2_Chemical_Space, dimension 2 in 
chemical space plot; FP_density, Count of present bits in chemical fingerprint; Mwt, molecular weight; 
Num_N_atoms, number of nitrogen atoms; Num_O_atoms, number of oxygen atoms; 
Num_saturated_carbons, number of saturated carbons; NumAromaticRings, number of aromatic rings; 
NumAtoms,total  number of atoms; NumHBA, number of hydrogen bond acceptors; NumHBD, number 
of hydrogen bond donors; NumRings, number of rings; NumRotatableBonds, number of rotatable 
bonds; NumSaturatedRings, number of saturated rings; Promiscuity_Alerts, total number of 
substructural features; Promiscuity_Bioactivity, total number of positive activities in Tox21 assays and 
predicted targets; Promiscuity_significant_Alerts, total number of significant substructural features 
(Fischer < 0.05 with acute toxicity label); Promiscuity_significant_bioactivity,  total number of positive 
activities in significant Tox21 assays and predicted targets (Fischer < 0.05 with acute toxicity label); 
Promiscuity_targets total number of positive activities in predicted targets. 
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6.3.3 Promiscuity biased predictions 
The models’ bias over promiscuity was assessed by measuring the performance (the number 
of single predictions and accuracy) across three promiscuity intervals, namely high, moderate 
and low. The boundaries of these intervals were determined by discretising the ranked 
promiscuity values into equal sized groups. Figure (6-6) compares the number of single label 
predictions with the distribution of GHS toxicity classes across promiscuity intervals. Both 
Random Forest (FP) and rule-based models produced significantly higher fractions of toxic 
predictions compared to non-toxic predictions for highly promiscuous compounds. The 
differences in prediction labels were 7 fold and 2 fold difference for rule and FP models 
respectively. Yet, only 15% difference in the distribution was observed for GHS toxicity labels 
at the high promiscuity level. In contrast, at low promiscuity, there were significantly larger 
numbers of non-toxic predictions produced by rule and FP models to almost 6 and 2 folds, 
respectively, compared to toxic label predictions. This means that both models over-predicted 
high promiscuous compounds as toxic and low promiscuous compounds as non-toxic, although 
the maximum variability in class proportions is not exceeding 30%, at any promiscuity level. 
At the moderate promiscuity level, both models produced balanced counts of predicted toxic 
and non-toxic labels. FP models, however, generated around 55 more single predictions for 
each class than rule models at the same promiscuity level. 
 
Figure (6-6) The distribution of toxicity labels (a) and single class predictions by FP model (b) and EP 
model (c) against three levels of promiscuity. The variability in toxicity label proportions in the data 
did not exceed 30% at any promiscuity level. With regards to predictions, the imbalance in class labels 
was in favour of non-toxic at low promiscuity levels and toxic at high promiscuity levels. EP models 
showed the highest bias to the level of compound promiscuity, as this model used predicted targets as 
input data and promiscuity score as the predicting function. 
Next, we quantified the ability of the models to generate correct predictions for toxic and 
nontoxic labels across promiscuity levels, which is presented in Figure (6-7).  We found that 
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the promiscuity level has also reflected on the true positives rates (TPR) and true negatives 
rates (TNR). For low promiscuity compounds, FP model gave the most accurate single labels 
predictions at an average of 75%. Rules also correctly assigned 77% of predicted toxic labels 
for low promiscuity compounds, and below 65% correct predictions of single non-toxic labels. 
Whereas, for high promiscuity compounds, FP model had over 70% TPR but less than 65% 
TNR. Rules had shown higher TNR for high promiscuous compounds than FP models, 
exceeding 70%. At moderate promiscuity levels, both models had similar rates of correct 
classification of almost 70% for both classes wherever a single class prediction was made.  
 
 
 
Figure (6-7) Accuracy of single class predictions across different levels of D2 in chemical space and 
promiscuity, measured as the true positive rate (TPR), true negative rate (TNR) and correct 
classification rate (CCR). FP model generated the most accurate single class prediction for low 
promiscuous compounds. The accuracy of single class predictions of both models was almost similar 
for compounds of moderate promiscuity ranging between 65% and 70%. However, whenever a non-
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toxic label was generated by EP model for a high promiscuous compound, there are greater chances of 
correct predictions compared to FP models, with a difference of TNR of about 6%.  
The factors deriving this promiscuity based biased can be attributed to the nature of the model 
and data used. Rule models used predicted target annotations, and hence, the bioactivity 
profiles of compounds may not be 100% accurate. Also, rules models predicted toxicity labels 
as a function of promiscuity over rules. For example, compounds that satisfy a higher number 
of rules describing toxicity are likely to be predicted as toxic. Hence, it is likely that 
promiscuous compounds will satisfy a greater number of rules even if they were non-toxic. 
Another factor that can affect performance is the lack of physicochemical properties in the data 
used to generate the rules. While perturbing multiple pathways has a greater likelihood of 
observing in vivo toxicity compared to no perturbation, rapid onset is also a key factor. Cell 
permeability and bioavailability, which are governed by physicochemical properties, 
contribute to whether an acute effect will be observed.  
FP models, on the other hand, did not use target-based features but still showed bias over 
promiscuity. Chemical features can be associated with compound promiscuity over targets if 
the features represent a pharmacophore for target binding. Hence the chemical feature, in this 
case, substituted target activity. Additionally, the bias of FP models was greater over specific 
chemical features (captured by D2 in chemical space) than target promiscuity. The FP models 
performed overall better for compounds with low (negative) coefficients in D2 of chemical 
space (Figure (6-7)). D2 in chemical space also strongly correlated with fingerprint density, 
i.e. 0.7 Pearson coefficient (see Figure (6-5)). Since the model learning is affected by data 
sparsity, complex compounds are denser in the fingerprint space allowing for better 
predictivity.  
6.4 Conclusions 
Conformal prediction models provide an assessment of confidence for a given prediction. We 
used the conformal prediction framework to evaluate the performance of rules used in Chapter 
5, given their interpretability. For a reference, we compared the performance of these rules with 
two models i) Random Forest algorithm on circular fingerprints and physicochemical 
properties, and ii) models based on promiscuity over statistically significant features.  The 
overall performance of rule models outperformed promiscuity over features and showed an 
average accuracy 5% lower than the benchmark Random Forest model. Given the 
interpretability of rule models in comparison to Random Forest, rules can aid data-based 
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decision making by providing mechanistic insights about predicted toxicity. The results also 
show that the mere application of promiscuity in toxicity assessment should be interpreted with 
caution, aligning with previous reports.382 Specific feature combinations capturing synergistic 
interactions, as shown in Chapter 5, explain why promiscuity over rules outperforms 
promiscuity over significant features. 
Upon investigating the models’ performances with regards to the chemical space, we found a 
clear bias in performance and in association with compound promiscuity. Rule models 
displayed larger biases due to two key factors. First, the promiscuity is part of the prediction 
formula, and hence the higher the promiscuity, the higher the likelihood that a compound will 
be classified as toxic. Second, unlike chemical descriptor models, physicochemical properties 
were not used, resulting in missing kinetics-based factors. Nonetheless, the Random Forest 
model on chemical descriptors has also shown the promiscuity bias trend. We anticipate that 
the promiscuity bias, in this case, is indirect and captured by the structural complexity, a 
property directly linked to promiscuity. Overall, in order to improve the predictive performance 
of rules, it is recommended to incorporate physicochemical properties, and also to optimize the 
prediction algorithm. For example, as an alternative for rule promiscuity, predictions can be 
made using the best rule or averaging the performances of the best k-number of rules for each 
class label. 
Variability was seen between the true positive rates and true negative at the same space of 
chemistry or promiscuity.  Therefore, assigning a correct prediction within a given chemical 
space is influenced by the class type. We, hence, recommend that measures of confidence and 
applicability domain should be class specific. 
The results here report compounds promiscuity as a confounding factor for classifying in vivo 
toxicity. Irrespective to data type used, models often predict promiscuous compounds as toxic. 
This promiscuity is governed by the chemical structure and physicochemical properties, such 
as number of oxygen atoms and number of saturated carbons. Therefore, we recommend that 
compounds’ intrinsic promiscuity should be considered when rationalizing outcomes from 
statistical models as well as from in vitro assays. 
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CONCLUSION 
 
Toxicity mode of action analysis is a key component of the integrated approaches in testing 
and assessment (IATA). Repositories of in vitro bioactivity measurements such as Tox2153 and 
ToxCast52 , combined with advancement in computational power allowed for the generation of  
statistical models for in vivo toxicity52,53, as well as the derivation of hypotheses on possible 
modes of action. However, perturbation mechanisms at the molecular level can be highly 
complex due to multiple routes for downstream effects as a result of interfering with a single 
pathway. Additionally, compounds rarely have a single biological action and are rather 
characterized by polypharmacology profiles rendering the task even harder. The adverse 
outcome pathway (AOP) framework describes adverse events as directional series of key 
events across the biological systems. This directional association is widely held when 
interpreting mechanisms of toxicity, however,  its application in modeling toxicological data 
is rare.144 To tackle this, we used rule-based models which allow mining associations between 
bioactivity and chemical conditions against toxicity. In order to improve the interpretability of 
rules, we applied constraints on the direction of the expected associations between in vitro 
activity and in vivo toxicity. First, rules were used to prioritize assays for hepatotoxicity in vitro 
models using ToxCast and data from animal studies (Chapter 4). We detected known endpoints 
such as activity against Cytochrome P, immunological responses and mitochondrial toxicity. 
Further, we found that endocrine disruption, such as modulation of estrogen and androgen 
receptors, are key bioactivities in hepatotoxicity. These were missed from four commercial in 
vitro models for hepatotoxicity. Second, we explored the role of chemical properties in the 
improving the translatability of in vitro readouts into in vivo hepatotoxicity. A specific set of 
physicochemical properties, such as number of rotatable bonds showed improved odds of 
hepatotoxicity when combined with in vitro endocrine disruption (Chapter 4). These 
physicochemical conditions are related to kinetic parameters such permeability,196 and hence 
can act as proxies for in vivo exposure measures. Despite endocrine disruption being commonly 
associated with chronic effects such as reproductive toxicity, we showed that endocrine 
disrupting compounds bearing a heterocycle ring can trigger acute toxicity (Chapter 5). Third, 
rules also facilitate gaining novel insights into the influence of polypharmacology on toxicity. 
We found that not mere promiscuity is triggering toxicity, but specific combinations of 
activities which can be synergistic and lead to toxicity. For example, thyroid hormone receptor 
modulation, when combined with the disruption of ionotropic GABA and glutamate receptors, 
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increases the odds of acute toxicity significantly (Chapter 5). Also, we provided novel insights 
into the cholinergic toxidrome which is characterized by inhibiting acetylcholinesterase AChE, 
and downstream effects including inflammation and calcium ion dysregulation. 268 The 
probability of acute toxicity is significantly higher when AChE inhibitors also interfere with 
the calcium sensitization of troponin319,320 and inflammatory responses of NLRP3324, resulting 
in cardiovascular effects. 
Finally, we tested the predictive power of rules for acute toxicity, in a conformal prediction 
framework, against Random Forest as a benchmark model using chemical descriptors (Chapter 
6). The performance of rule models was comparable with Random Forest at 80% confidence 
with an overall accuracy of 66.86% and 71.31%, respectively for. Additionally, we observed 
that both models exerted a bias over compound promiscuity. Despite the even distribution of 
toxicity classes across different levels of compound promiscuity, promiscuous compounds 
were frequently predicted as toxic, whereas low promiscuous compounds were often predicted 
as non-toxic.  
Overall, our findings provide novel insights into the molecular mechanisms of toxicity and 
polypharmacology. The workflows proposed in this work can be generally used to improve the 
utility and design of alternative methods for toxicity. For example, assays predictive of toxicity 
can be prioritized so as to sufficiently cover the biological space of toxic compounds. Also, via 
understanding the synergistic interactions between key events, cost and time effective iterative 
screening protocols can be developed. In this way, initial screening of major bioactivity classes 
is followed up by screening relevant endpoints where interactions are expected to trigger 
toxicity. 
  Nonetheless, in order to accelerate regulatory acceptance of alternative methods for toxicity, 
interpretable and robust models should be developed which consider a number of factors 
including chemical reactivity, polypharmacology, bioavailability and exposure. Further 
analysis is to be conducted to understand complex mechanisms of toxicity and how 
perturbation of a pathway can progress into in vivo effect. Uncertainty of prediction should be 
assessed with care, and with regards to chemical space and compound promiscuity. Above all, 
collaboration and harmonization across the academic, governmental and private sectors is 
needed to accelerate the acceptance of alternative methods in regulatory toxicology. 
 128 
REFERENCES   
 
(1)  Cruelty Free International (2018) Facts and figures on animal testing, 
http://www.crueltyfreeinternational.org/why-we-do- (accessed 2018-10-18). 
(2) Pauwels, M., and Rogiers, V. (2010) Human health safety evaluation of cosmetics in the EU: a 
legally imposed challenge to science. Toxicol. Appl. Pharmacol. 243, 260–274. 
(3) Ahuja, V., Bokan, S., and Sharma, S. (2017) Predicting toxicities in humans by nonclinical safety 
testing: an update with particular reference to anticancer compounds. Drug Discov. Today 22, 127–
132. 
(4) Shanks, N., Greek, R., and Greek, J. (2009) Are animal models predictive for humans? Philos. 
Ethics, Humanit. Med. 4, 1–20. 
(5) Waring, M. J., Arrowsmith, J., Leach, A. R., Leeson, P. D., Mandrell, S., Owen, R. M., 
Pairaudeau, G., Pennie, W. D., Pickett, S. D., Wang, J., Wallace, O., and Weir, A. (2015) An analysis 
of the attrition of drug candidates from four major pharmaceutical companies. Nat. Rev. Drug Discov. 
14, 475–486. 
(6) Hamm, J., Sullivan, K., Clippinger, A. J., Strickland, J., Bell, S., Bhhatarai, B., Blaauboer, B., 
Casey, W., Dorman, D., Forsby, A., Garcia-Reyero, N., Gehen, S., Graepel, R., Hotchkiss, J., Lowit, 
A., Matheson, J., Reaves, E., Scarano, L., Sprankle, C., Tunkel, J., Wilson, D., Xia, M., Zhu, H., and 
Allen, D. (2017) Alternative approaches for identifying acute systemic toxicity: Moving from 
research to regulatory testing. Toxicol. In Vitro 41, 245–259. 
(7)  Basic Information | Risk Assessment Portal | US EPA. https://www.epa.gov/risk/about-risk-
assessment#whatisrisk (accesed 2015-09-14). 
(8)  OECD Guidelines for the Testing of Chemicals, Section 4:Health Effects. 
(9)  OECD Guidelines for the Testing of Chemicals, Section 4, Test No. 421: 
Reproduction/Developmental Toxicity Screening Test. 
(10)  OECD Guidelines for the Testing of Chemicals, Section 4, Test No. 451: Carcinogenicity 
Studies. 
(11)  OECD Guidelines for the Testing of Chemicals, Section 4, Test No. 452: Chronic Toxicity 
Studies. 
(12) Andrade, E. L., Bento, A. F., Cavalli, J., Oliveira, S. K., Schwanke, R. C., Siqueira, J. M., 
Freitas, C. S., Marcon, R., and Calixto, J. B. (2016) Non-clinical studies in the process of new drug 
development - Part II: Good laboratory practice, metabolism, pharmacokinetics, safety and dose 
translation to clinical studies. Brazilian J. Med. Biol. Res. 49, e5646. 
(13) EC. (2008) Council Regulation (EC) No. 440/2008 of 30 May 2008 Laying Down Test Methods 
Pursuant to Regulation (EC) No. 1907/2006 of the European Parliament and of the Council on the 
Registration, Evaluation, Authorization, and Restriction of Chemicals (REACH). Off. J. Eur. Union. 
(14) Mayr, L. M., and Bojanic, D. (2009) Novel trends in high-throughput screening. Curr. Opin. 
Pharmacol. 9, 580–8. 
(15) Judson, R. S., Houck, K. A., Kavlock, R. J., Knudsen, T. B., Martin, M. T., Mortensen, H. M., 
Reif, D. M., Rotroff, D. M., Shah, I., Richard, A. M., and Dix, D. J. (2010) In vitro screening of 
environmental chemicals for targeted testing prioritization: the ToxCast project. Environ. Health 
 129 
Perspect. 118, 485–492. 
(16) Rang, H. P., and Vasella, D. (2006) Drug Discovery and Development: Technology in Transition 
(Hill, R., Ed.). Elsevier. 
(17) Russell, W. M. S., and Burch, R. L. (1959) The principles of humane experimental technique. 
Methuen & Co. Ltd., London. 
(18) Törnqvist, E., Annas, A., Granath, B., Jalkesten, E., Cotgreave, I., and Öberg, M. (2014) 
Strategic focus on 3R principles reveals major reductions in the use of animals in pharmaceutical 
toxicity testing. PLoS One 9, 101638. 
(19) Strickland, J., Clippinger, A. J., Brown, J., Allen, D., Jacobs, A., Matheson, J., Lowit, A., 
Reinke, E. N., Johnson, M. S., Quinn, M. J., Mattie, D., Fitzpatrick, S. C., Ahir, S., Kleinstreuer, N., 
and Casey, W. (2018) Status of acute systemic toxicity testing requirements and data uses by U.S. 
regulatory agencies. Regul. Toxicol. Pharmacol. 94, 183–196. 
(20) Burden, N., Mahony, C., Müller, B. P., Terry, C., Westmoreland, C., and Kimber, I. (2015) 
Aligning the 3Rs with new paradigms in the safety assessment of chemicals. Toxicology 330, 62–66. 
(21) OECD. (2015) Guidance Document on Revisions to OECD Genetic Toxicology Test Guidelines. 
Genetic Toxicology Guidance Document: Second Commenting Round. 
(22) OECD. (2009) Table 1 . Adopted OECD Test Guidelines on Short , and Long-Term Toxicity 
Testing with 3R Relevance. 1–4. 
(23) OECD. (2015) Performance-Based Test Guideline for Human Recombinant Estrogen Receptor 
(hrER) In Vitro Assays to Detect Chemicals with ER Binding Affinity, OECD Guidelines for Testing 
Chemicals; 493 1–64. 
(24) OECD. (2011) H295R Steroidogenesis Assay, OECD Guidelines for Testing Chemicals; 456. 
(25) Rouquié, D., Heneweer, M., Botham, J., Ketelslegers, H., Markell, L., Pfister, T., Steiling, W., 
Strauss, V., and Hennes, C. (2015) Contribution of new technologies to characterization and 
prediction of adverse effects. Crit. Rev. Toxicol. 45, 172–183. 
(26) Worth, A. P., and Patlewicz, G. (2016) Integrated approaches to testing and assessment, in 
Validation of alternative methods for toxicity testing (Eskes, C., and Whelan, M., Eds.), pp 317–342. 
Springer International Publishing. 
(27) Bernauer, U., Oberemm, A., Madie, S., and Gundert-Remy, U. (2005) The use of in vitro data in 
risk assessment. Basic Clin. Pharmacol. Toxicol. 96, 176–181. 
(28) Jennings, P. (2015) The future of in vitro toxicology. Toxicol. In Vitro 29, 1217–1221. 
(29) Hertzberg, R. P., and Pope, A. J. (2000) High-throughput screening: new technology for the 21st 
century. Curr. Opin. Chem. Biol. 4, 445–451. 
(30) Sittampalam, G. S., Kahl, S. D., and Janzen, W. P. (1997) High-throughput screening: advances 
in assay technologies. Curr. Opin. Chem. Biol. 1, 384–391. 
(31) Broach, J. R., and Thorner, J. (1996) High-throughput screening for drug discovery. Nature 384, 
14–6. 
(32) Inglese, J., Johnson, R. L., Simeonov, A., Xia, M., Zheng, W., Austin, C. P., and Auld, D. S. 
(2007) High-throughput screening assays for the identification of chemical probes. Nat. Chem. Biol. 
3, 466–79. 
 130 
(33) Bleicher, K. H., Böhm, H.-J., Müller, K., and Alanine, A. I. (2003) Hit and lead generation: 
beyond high-throughput screening. Nat. Rev. Drug Discov. 2, 369–78. 
(34) Scheiber, J., Chen, B., Milik, M., Sukuru, S. C. K., Bender, A., Mikhailov, D., Whitebread, S., 
Hamon, J., Azzaoui, K., Urban, L., Glick, M., Davies, J. W., and Jenkins, J. L. (2009) Gaining insight 
into off-target mediated effects of drug candidates with a comprehensive systems chemical biology 
analysis. J. Chem. Inf. Model. 49, 308–17. 
(35) Kim, S., Thiessen, P. A., Bolton, E. E., Chen, J., Fu, G., Gindulyte, A., Han, L., He, J., He, S., 
Shoemaker, B. A., Wang, J., Yu, B., Zhang, J., and Bryant, S. H. (2016) PubChem substance and 
compound databases. Nucleic Acids Res. 44, D1202–D1213. 
(36) Gaulton, A., Bellis, L. J., Bento, A. P., Chambers, J., Davies, M., Hersey, A., Light, Y., 
McGlinchey, S., Michalovich, D., Al-Lazikani, B., and Overington, J. P. (2012) ChEMBL: a large-
scale bioactivity database for drug discovery. Nucleic Acids Res. 40, D1100–D1107. 
(37) Wishart, D. S., Knox, C., Guo, A. C., Shrivastava, S., Hassanali, M., Stothard, P., Chang, Z., and 
Woolsey, J. (2006) DrugBank: a comprehensive resource for in silico drug discovery and exploration. 
Nucleic Acids Res. 34, D668–D672. 
(38) Seiler, K. P., George, G. A., Happ, M. P., Bodycombe, N. E., Carrinski, H. A., Norton, S., Brudz, 
S., Sullivan, J. P., Muhlich, J., Serrano, M., Ferraiolo, P., Tolliday, N. J., Schreiber, S. L., and 
Clemons, P. A. (2007) ChemBank: a small-molecule screening and cheminformatics resource 
database. Nucleic Acids Res. 36, D351–D359. 
(39) Whitebread, S., Hamon, J., Bojanic, D., and Urban, L. (2005) Keynote review: in vitro safety 
pharmacology profiling: an essential tool for successful drug development. Drug Discov. Today 10, 
1421–33. 
(40) Whitebread, S., Dumotier, B., Armstrong, D., Fekete, A., Chen, S., Hartmann, A., Muller, P. Y., 
and Urban, L. (2016) Secondary pharmacology: screening and interpretation of off-target activities – 
focus on translation. Drug Discov. Today 21, 1232–1242. 
(41) Bowes, J., Brown, A. J., Hamon, J., Jarolimek, W., Sridhar, A., Waldron, G., and Whitebread, S. 
(2012) Reducing safety-related drug attrition: the use of in vitro pharmacological profiling. Nat. Rev. 
Drug Discov. 11, 909–22. 
(42) Azzaoui, K., Hamon, J., Faller, B., Whitebread, S., Jacoby, E., Bender, A., Jenkins, J. L., and 
Urban, L. (2007) Modeling promiscuity based on in vitro safety pharmacology profiling data. 
ChemMedChem 2, 874–880. 
(43) Peters, J. U., Hert, J., Bissantz, C., Hillebrecht, A., Gerebtzoff, G., Bendels, S., Tillier, F., 
Migeon, J., Fischer, H., Guba, W., and Kansy, M. (2012) Can we discover pharmacological 
promiscuity early in the drug discovery process? Drug Discov. Today 17, 325–335. 
(44) Wang, X., and Greene, N. (2012) Comparing measures of promiscuity and exploring their 
relationship to toxicity. Mol. Inform. 31, 145–159. 
(45) Mencher, S. K., and Wang, L. G. (2005) Promiscuous drugs compared to selective drugs 
(promiscuity can be a virtue). BMC Clin. Pharmacol. 5, 1:7. 
(46) Muthas, D., Boyer, S., and Hasselgren, C. (2013) A critical assessment of modeling safety-
related drug attrition. Medchemcomm 4, 1058–1065. 
(47) Papoian, T., Chiu, H.-J., Elayan, I., Jagadeesh, G., Khan, I., Laniyonu, A. A., Xinguang Li, C., 
Saulnier, M., Simpson, N., Yang, B., Li, C. X., Saulnier, M., Simpson, N., and Yang, B. (2015) 
Secondary pharmacology data to assess potential off-target activity of new drugs: a regulatory 
perspective. Nat. Rev. Drug Discov. 14, 294. 
 131 
(48) Muller, P. Y., and Milton, M. N. (2012) The determination and interpretation of the therapeutic 
index in drug development. Nat. Rev. Drug Discov. 11, 751–761. 
(49) Kavlock, R., Chandler, K., Houck, K., Hunter, S., Judson, R., Kleinstreuer, N., Knudsen, T., 
Martin, M., Padilla, S., Reif, D., Richard, A., Rotroff, D., Sipes, N., and Dix, D. (2012) Update on 
EPA’s ToxCast program: Providing high throughput decision support tools for chemical risk 
management. Chem. Res. Toxicol. 25, 1287–1302. 
(50) Dix, D. J., Houck, K. A., Martin, M. T., Richard, A. M., Setzer, R. W., and Kavlock, R. J. (2007) 
The ToxCast program for prioritizing toxicity testing of environmental chemicals. Toxicol. Sci. 95, 5–
12. 
(51) Krewski, D., Acosta, D., Andersen, M., Anderson, H., Bailar, J. C., Boekelheide, K., Brent, R., 
Charnley, G., Cheung, V. G., Green, S., Kelsey, K. T., Kerkvliet, N. I., Li, A. A., McCray, L., Meyer, 
O., Patterson, R. D., Pennie, W., Scala, R. A., Solomon, G. M., Stephens, M., Yager, J., and Zeise, L. 
(2010) Toxicity testing in the 21st century: a vision and a strategy. J. Toxicol. Environ. Health. B. 
Crit. Rev. 13, 51–138. 
(52) Richard, A. M., Judson, R. S., Houck, K. A., Grulke, C. M., Volarath, P., Thillainadarajah, I., 
Yang, C., Rathman, J., Martin, M. T., Wambaugh, J. F., Knudsen, T. B., Kancherla, J., Mansouri, K., 
Patlewicz, G., Williams, A. J., Little, S. B., Crofton, K. M., and Thomas, R. S. (2016) ToxCast 
Chemical Landscape: Paving the Road to 21st Century Toxicology. Chem. Res. Toxicol. 29, 1225–
1251. 
(53) Tice, R. R., Austin, C. P., Kavlock, R. J., and Bucher, J. R. (2013) Improving the human hazard 
characterization of chemicals: a Tox21 update. Environ. Health Perspect. 121, 756–65. 
(54) OECD. (2017) Guidance Document for the Use of Adverse Outcome Pathways in Developing 
Integrated Approaches to Testing and Assessment (IATA), OECD Guidelines for the Testing of 
Chemicals 1–31. 
(55) Sewell, F., Doe, J., Gellatly, N., Ragan, I., and Burden, N. (2017) Steps towards the international 
regulatory acceptance of non-animal methodology in safety assessment. Regul. Toxicol. Pharmacol. 
89, 50–56. 
(56) Blaauboer, B. J., Barratt, M. D., and Houston, J. B. (1999) The Integrated Use of Alternative 
Methods in Toxicological Risk Evaluation - ECVAM Integrated Testing Strategies Task Force Report 
1. Altern. Lab. Anim. 27, 229–37. 
(57) Borgert, C. J., Quill, T. F., McCarty, L. S., and Mason, A. M. (2004) Can mode of action predict 
mixture toxicity for risk assessment? Toxicol. Appl. Pharmacol. 201, 85–96. 
(58) Ankley, G. T., Bennett, R. S., Erickson, R. J., Hoff, D. J., Hornung, M. W., Johnson, R. D., 
Mount, D. R., Nichols, J. W., Russom, C. L., Schmieder, P. K., Serrrano, J. A., Tietge, J. E., and 
Villeneuve, D. L. (2010) Adverse outcome pathways: A conceptual framework to support 
ecotoxicology research and risk assessment. Environ. Toxicol. Chem. 29, 730–741. 
(59) Villeneuve, D. L., Crump, D., Garcia-Reyero, N., Hecker, M., Hutchinson, T. H., LaLone, C. A., 
Landesmann, B., Lettieri, T., Munn, S., Nepelska, M., Ottinger, M. A., Vergauwen, L., and Whelan, 
M. (2014) Adverse outcome pathway (AOP) development I: Strategies and principles. Toxicol. Sci. 
142, 312–320. 
(60) Villeneuve, D. L., Crump, D., Garcia-Reyero, N., Hecker, M., Hutchinson, T. H., LaLone, C. A., 
Landesmann, B., Lettieri, T., Munn, S., Nepelska, M., Ottinger, M. A., Vergauwen, L., and Whelan, 
M. (2014) Adverse Outcome Pathway Development II: Best Practices. Toxicol. Sci. 142, 321–330. 
(61) Wittwehr, C., Aladjov, H., Ankley, G., Byrne, H. J., de Knecht, J., Heinzle, E., Klambauer, G., 
 132 
Landesmann, B., Luijten, M., MacKay, C., Maxwell, G., Meek, M. E. B., Paini, A., Perkins, E., 
Sobanski, T., Villeneuve, D., Waters, K. M., and Whelan, M. (2017) How adverse outcome pathways 
can aid the development and use of computational prediction models for regulatory toxicology. 
Toxicol. Sci. 155, 326–336. 
(62) Patlewicz, G., Simon, T. W., Rowlands, J. C., Budinsky, R. A., and Becker, R. A. (2015) 
Proposing a scientific confidence framework to help support the application of adverse outcome 
pathways for regulatory purposes. Regul. Toxicol. Pharmacol. 71, 463–477. 
(63) OECD. (2013) Guidance document on developing and assessing Adverse Outcome Pathways. 
Series on Testing and Assessment, OECD Publications 184, 1–32. 
(64) Ashby, J. (1985) Fundamental structural alerts to potential carcinogenicity or noncarcinogenicity. 
Environ. Mutagen. 7, 919–921. 
(65) Dehaspe, L., Toivonen, H., and King, R. D. (1998) Finding frequent substructures in chemical 
compounds, in Proceedings of the Fourth International Conference on Knowledge Discovery and 
Data Mining, pp 30–36. AAAI Press. 
(66) Alves, V. M., Muratov, E. N., Capuzzi, S. J., Politi, R., Low, Y., Braga, R. C., Zakharov, A. V., 
Sedykh, A., Mokshyna, E., Farag, S., Andrade, C. H., Kuz’min, V. E., Fourches, D., Tropsha, A., 
Luechtefeld, T., Maertens, A., Marty, S., Naciff, J. M. J. M., Palmer, J., Pamies, D., Penman, M., 
Richarz, A.-N. A.-N., Russo, D. P. D. P., Stuard, S. B. S. B., Patlewicz, G., Ravenzwaay, B. Van, Wu, 
S., Zhu, H., and Hartung, T. (2016) Alarms about structural alerts. Green Chem. 18, 4348–4360. 
(67) Sherhod, R., Judson, P., Hanser, T., Vessey, J., Webb, S. J., and Gillet, V. (2014) Emerging 
Pattern Mining to Aid Toxicological Knowledge Discovery Emerging Pattern Mining to Aid 
Toxicological Knowledge Discovery. J. Chem. Inf. Model 54, 1864–1879. 
(68) Liu, R., Yu, X., and Wallqvist, A. (2015) Data-driven identification of structural alerts for 
mitigating the risk of drug-induced human liver injuries. J. Cheminform. 7, 4. 
(69) Lepailleur, A., Poezevara, G., and Bureau, R. (2013) Automated detection of structural alerts 
(chemical fragments) in (eco)toxicology. Comput. Struct. Biotechnol. J. 5, e201302013. 
(70) Barber, C., Hanser, T., Judson, P., and Williams, R. (2017) Distinguishing between expert and 
statistical systems for application under ICH M7. Regul. Toxicol. Pharmacol. 84, 124–130. 
(71) Marchant, C. A., Briggs, K. A., and Long, A. (2008) In Silico Tools for Sharing Data and 
Knowledge on Toxicity and Metabolism: Derek for Windows, Meteor, and Vitic. Toxicol. Mech. 
Methods 18, 177–187. 
(72) Patlewicz, G., Jeliazkova, N., Safford, R. J., Worth, A. P., and Aleksiev, B. (2008) An evaluation 
of the implementation of the Cramer classification scheme in the Toxtree software. SAR QSAR 
Environ. Res. 19, 495–524. 
(73) Sushko, I., Salmina, E., Potemkin, V. A., Poda, G., and Tetko, I. V. (2012) ToxAlerts: A web 
server of structural alerts for toxic chemicals and compounds with potential adverse reactions. J. 
Chem. Inf. Model. 52, 2310–2316. 
(74) Cortes-Ciriano, I. (2016) Bioalerts: a python library for the derivation of structural alerts from 
bioactivity and toxicity data sets. J. Cheminform. 8, 13. 
(75) Métivier, J. P., Lepailleur, A., Buzmakov, A., Poezevara, G., Crémilleux, B., Kuznetsov, S. O., 
Goff, J. Le, Napoli, A., Bureau, R., and Cuissart, B. (2015) Discovering structural alerts for 
mutagenicity using stable emerging molecular patterns. J. Chem. Inf. Model. 55, 925–940. 
(76) Sherhod, R., Gillet, V. J., Judson, P. N., and Vessey, J. D. (2012) Automating Knowledge 
 133 
Discovery for Toxicity Prediction Using Jumping Emerging Pattern Mining. J. Chem. Inf. Model. 52, 
3074–3087. 
(77) Garcia-Serna, R., Vidal, D., Remez, N., and Mestres, J. (2015) Large-Scale Predictive Drug 
Safety: From Structural Alerts to Biological Mechanisms. Chem. Res. Toxicol. 28, 1875–1887. 
(78) Plunkett, L. M., Kaplan, A. M., and Becker, R. A. (2015) Challenges in using the ToxRefDB as a 
resource for toxicity prediction modeling. Regul. Toxicol. Pharmacol. 72, 610–614. 
(79) Martin, M. T., Dix, D. J., Judson, R. S., Kavlock, R. J., Reif, D. M., Richard, A. M., Rotroff, D. 
M., Romanov, S., Medvedev, A., Poltoratskaya, N., Gambarian, M., Moeser, M., Makarov, S. S., and 
Houck, K. A. (2010) Impact of environmental chemicals on key transcription regulators and 
correlation to toxicity end points within EPA’s ToxCast program. Chem. Res. Toxicol. 23, 578–90. 
(80) Hu, B., Gifford, E., Wang, H., Bailey, W., and Johnson, T. (2015) Analysis of the ToxCast 
Chemical-Assay Space using the Comparative Toxicogenomics Database. Chem. Res. Toxicol. 28, 
2210–2223. 
(81) Svensson, F., Zoufir, A., Mahmoud, S., Afzal, A. M., Smit, I., Giblin, K. A., Clements, P. J., 
Mettetal, J. T., Pointon, A., Harvey, J. S., Greene, N., Williams, R. V, and Bender, A. (2018) 
Information-Derived Mechanistic Hypotheses for Structural Cardiotoxicity. Chem. Res. Toxicol. 31, 
1119–1127. 
(82) Piersma, A. H., Hessel, E. V., and Staal, Y. C. (2017) Retinoic acid in developmental toxicology: 
Teratogen, morphogen and biomarker. Reprod. Toxicol. 72, 53–61. 
(83) Baker, N., Hunter, S., Franzosa, J., Richard, A., Judson, R., and Knudsen, T. (2016) Toxcast 
Chemical and Bioactivity Profiles for In Vitro Targets in the Retinoid Signaling System, in SOT 2016 
Annual Meeting, p 2680. 
(84) Fay, K. A., Villeneuve, D. L., Swintek, J., Edwards, S. W., Nelms, M. D., Blackwell, B. R., and 
Ankley, G. T. (2018) Differentiating Pathway-Specific From Nonspecific Effects in High-Throughput 
Toxicity Data: A Foundation for Prioritizing Adverse Outcome Pathway Development. Toxicol. Sci. 
163, 500–515. 
(85) Judson, R., Houck, K., Martin, M., Richard, A. M., Knudsen, T. B., Shah, I., Little, S., 
Wambaugh, J., Woodrow Setzer, R., Kothya, P., Phuong, J., Filer, D., Smith, D., Reif, D., Rotroff, D., 
Kleinstreuer, N., Sipes, N., Xia, M., Huang, R., Crofton, K., and Thomas, R. S. (2016) Analysis of the 
Effects of Cell Stress and Cytotoxicity on In Vitro Assay Activity Across a Diverse Chemical and 
Assay Space. Toxicol. Sci. 152, 323–339. 
(86) Wambaugh, J. F., Hughes, M. F., Ring, C. L., MacMillan, D. K., Ford, J., Fennell, T. R., Black, 
S. R., Snyder, R. W., Sipes, N. S., Wetmore, B. A., Westerhout, J., Setzer, R. W., Pearce, R. G., 
Simmons, J. E., and Thomas, R. S. (2018) Evaluating in vitro-in vivo extrapolation of toxicokinetics. 
Toxicol. Sci. 163, 152–169. 
(87) Wambaugh, J. F., Wetmore, B. A., Pearce, R., Strope, C., Goldsmith, R., Sluka, J. P., Sedykh, 
A., Tropsha, A., Bosgra, S., Shah, I., Judson, R., Thomas, R. S., and Woodrow Setzer, R. (2015) 
Toxicokinetic Triage for Environmental Chemicals. Toxicol. Sci. 147, 55–67. 
(88) Yoon, M., Campbell, J. L., Andersen, M. E., and Clewell, H. J. (2012) Quantitative in vitro to in 
vivo extrapolation of cell-based toxicity assay results. Crit. Rev. Toxicol. 42, 633–652. 
(89) Wetmore, B. A. (2015) Quantitative in vitro-to-in vivo extrapolation in a high-throughput 
environment. Toxicology 332, 94–101. 
(90) Wetmore, B. A., Wambaugh, J. F., Ferguson, S. S., Sochaski, M. A., Rotroff, D. M., Freeman, 
K., Clewell, H. J., Dix, D. J., Andersen, M. E., Houck, K. A., Allen, B., Judson, R. S., Singh, R., 
 134 
Kavlock, R. J., Richard, A. M., and Thomas, R. S. (2012) Integration of Dosimetry, Exposure, and 
High-Throughput Screening Data in Chemical Toxicity Assessment. Toxicol. Sci. 125, 157–174. 
(91) Punt, A. (2018) Toxicokinetics in Risk Evaluations. Chem. Res. Toxicol. 31, 285–286. 
(92) MacDonald, M. L., Lamerdin, J., Owens, S., Keon, B. H., Bilter, G. K., Shang, Z., Huang, Z., 
Yu, H., Dias, J., Minami, T., Michnick, S. W., and Westwick, J. K. (2006) Identifying off-target 
effects and hidden phenotypes of drugs in human cells. Nat. Chem. Biol. 2, 329–37. 
(93) Sipes, N. S., Martin, M. T., Kothiya, P., Reif, D. M., Judson, R. S., Richard, A. M., Houck, K. 
A., Dix, D. J., Kavlock, R. J., and Knudsen, T. B. (2013) Profiling 976 ToxCast chemicals across 331 
enzymatic and receptor signaling assays. Chem. Res. Toxicol. 26, 878–95. 
(94) Houck, K. A., Dix, D. J., Judson, R. S., Kavlock, R. J., Yang, J., and Berg, E. L. (2009) Profiling 
bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J. Biomol. 
Screen. 14, 1054–66. 
(95) Kleinstreuer, N. C., Yang, J., Berg, E. L., Knudsen, T. B., Richard, A. M., Martin, M. T., Reif, D. 
M., Judson, R. S., Polokoff, M., Dix, D. J., Kavlock, R. J., and Houck, K. A. (2014) Phenotypic 
screening of the ToxCast chemical library to classify toxic and therapeutic mechanisms. Nat. 
Biotechnol. 32, 583–91. 
(96) Benigni, R., Bossa, C., Giuliani, A., and Tcheremenskaia, O. (2010) Exploring in vitro/in vivo 
correlation: lessons learned from analyzing phase I results of the US EPA’s ToxCast Project. J. 
Environ. Sci. Health. C. Environ. Carcinog. Ecotoxicol. Rev. 28, 272–86. 
(97) Benigni, R., Bossa, C., Tcheremenskaya, O., and Giuliani, A. (2010) In Vitro / In Vivo 
Relationship in the Light of Toxcast Phase 1. ALTEX Altern. zu Tierexperimenten 27, 269–274. 
(98) Abdelaziz, A., Sushko, Y., Novotarskyi, S., Körner, R., Brandmaier, S., and Tetko, I. V. (2015) 
Using Online Tool (iPrior) for Modeling ToxCastTM Assays Towards Prioritization of Animal 
Toxicity Testing. Comb. Chem. High Throughput Screen. 18, 420–38. 
(99) Thomas, R. S., Black, M. B., Li, L., Healy, E., Chu, T.-M., Bao, W., Andersen, M. E., and 
Wolfinger, R. D. (2012) A comprehensive statistical analysis of predicting in vivo hazard using high-
throughput in vitro screening. Toxicol. Sci. 128, 398–417. 
(100) Dix, D. J., Houck, K. A., Judson, R. S., Kleinstreuer, N. C., Knudsen, T. B., Martin, M. T., Reif, 
D. M., Richard, A. M., Shah, I., Sipes, N. S., and Kavlock, R. J. (2012) Incorporating biological, 
chemical, and toxicological knowledge into predictive models of toxicity. Toxicol. Sci. 130, 440–441. 
(101) Liu, J., Mansouri, K., Judson, R. S., Martin, M. T., Hong, H., Chen, M., Xu, X., Thomas, R. S., 
and Shah, I. (2015) Predicting hepatotoxicity using ToxCast in vitro bioactivity and chemical 
structure. Chem. Res. Toxicol. 28, 738−751. 
(102) Huang, R., Xia, M., Sakamuru, S., Zhao, J., Shahane, S. A., Attene-Ramos, M., Zhao, T., 
Austin, C. P., and Simeonov, A. (2016) Modelling the Tox21 10 K chemical profiles for in vivo 
toxicity prediction and mechanism characterization. Nat. Commun. 7, 10425. 
(103) Liam, R., Robinson, M., Palczewska, A., Palczewski, J., Kidley, N., Marchese Robinson, R. L., 
Palczewska, A., Palczewski, J., and Kidley, N. (2017) Comparison of the Predictive Performance and 
Interpretability of Random Forest and Linear Models on Benchmark Data Sets. J. Chem. Inf. Model. 
57, 1773−1792. 
(104) Cook, D., Brown, D., Alexander, R., March, R., Morgan, P., Satterthwaite, G., and Pangalos, 
M. N. (2014) Lessons learned from the fate of AstraZeneca’s drug pipeline: a five-dimensional 
framework. Nat. Rev. Drug Discov. 13, 419–431. 
 135 
(105) Kaplowitz, N. (2004) Drug-Induced Liver Injury. Clin. Infect. Dis. 38, S44–S48. 
(106) Vinken, M. (2015) Adverse Outcome Pathways and Drug-Induced Liver Injury Testing. Chem. 
Res. Toxicol. 28, 1391–7. 
(107) Russmann, S., Kullak-Ublick, G., and Grattagliano, I. (2009) Current Concepts of Mechanisms 
in Drug-Induced Hepatotoxicity. Curr. Med. Chem. 16, 3041–3053. 
(108) Michalopoulos, G. K. (2007) Liver regeneration. J. Cell. Physiol. 213, 286–300. 
(109) Shah, F., Leung, L., Barton, H. A., Will, Y., Rodrigues, A. D., Greene, N., and Aleo, M. D. 
(2015) Setting Clinical Exposure Levels of Concern for Drug-Induced Liver Injury (DILI) Using 
Mechanistic in vitro Assays. Toxicol. Sci. 147, 500–514. 
(110) Thompson, R. A., Isin, E. M., Li, Y., Weidolf, L., Page, K., Wilson, I., Swallow, S., Middleton, 
B., Stahl, S., Foster, A. J., Dolgos, H., Weaver, R., and Kenna, J. G. (2012) In vitro approach to assess 
the potential for risk of idiosyncratic adverse reactions caused by candidate drugs. Chem. Res. 
Toxicol. 25, 1616–1632. 
(111) Sakatis, M. Z., Reese, M. J., Harrell, A. W., Taylor, M. A., Baines, I. A., Chen, L., Bloomer, J. 
C., Yang, E. Y., Ellens, H. M., Ambroso, J. L., Lovatt, C. A., Ayrton, A. D., and Clarke, S. E. (2012) 
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 
compounds. Chem. Res. Toxicol. 25, 2067–2082. 
(112) Kostadinova, R., Boess, F., Applegate, D., Suter, L., Weiser, T., Singer, T., Naughton, B., and 
Roth, A. (2013) A long-term three dimensional liver co-culture system for improved prediction of 
clinically relevant drug-induced hepatotoxicity. Toxicol. Appl. Pharmacol. 268, 1–16. 
(113) O’Brien, P. J., Irwin, W., Diaz, D., Howard-Cofield, E., Krejsa, C. M., Slaughter, M. R., Gao, 
B., Kaludercic, N., Angeline, A., Bernardi, P., Brain, P., and Hougham, C. (2006) High concordance 
of drug-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model 
using high content screening. Arch. Toxicol. 80, 580–604. 
(114) Persson, M., Loye, A. F., Jacquet, M., Mow, N. S., Thougaard, A. V., Mow, T., and Hornberg, 
J. J. (2014) High-content analysis/screening for predictive toxicology: Application to hepatotoxicity 
and genotoxicity. Basic Clin. Pharmacol. Toxicol. 115, 18–23. 
(115) Persson, M., Løye, A. F., Mow, T., and Hornberg, J. J. (2013) A high content screening assay to 
predict human drug-induced liver injury during drug discovery. J. Pharmacol. Toxicol. Methods 68, 
302–313. 
(116) Bisgin, H. (2014) Toward predictive models for drug-induced liver injury in humans : are we 
there yet ? Biomarkers Med 8, 201–213. 
(117) Kumar, R., Sharma, A., and Varadwaj, P. K. (2011) A prediction model for oral bioavailability 
of drugs using physicochemical properties by support vector machine. J. Nat. Sci. Biol. Med. 2, 168–
73. 
(118) Khojasteh, S. C., Wong, H., and Hop, C. E. C. A. (2011) ADME Properties and Their 
Dependence on Physicochemical Properties, in Drug Metabolism and Pharmacokinetics Quick Guide, 
pp 165–181. Springer New York, New York, NY. 
(119) Chen, M., Borlak, J., and Tong, W. (2013) High lipophilicity and high daily dose of oral 
medications are associated with significant risk for drug-induced liver injury. Hepatology 58, 388–
396. 
(120) Chen, M., Suzuki, A., Borlak, J., Andrade, R. J., and Lucena, M. I. (2015) Drug-induced liver 
injury: Interactions between drug properties and host factors. J. Hepatol. 63, 503–514. 
 136 
(121) Nakayama, S., Atsumi, R., Takakusa, H., Kobayashi, Y., Kurihara, A., Nagai, Y., Nakai, D., 
and Okazaki, O. (2009) A zone classification system for risk assessment of idiosyncratic drug toxicity 
using daily dose and covalent binding. Drug Metab. Dispos. 37, 1970–1977. 
(122) ECHA. (2015) Guidance on information requirements and chemical safety assessment Chapter 
R.7a: Endpoint specific guidance. 
(123) OECD. (2008) Test No. 425: Acute Oral Toxicity: Up-and-Down Procedure, OECD Guidelines 
for the Testing of Chemicals, Section 4. 
(124) OECD. (2002) Test No. 420: Acute Oral Toxicity - Fixed Dose Procedure, OECD Guidelines 
for the Testing of Chemicals. 
(125) Stokes, W. S., Casati, S., Strickland, J., and Paris, M. (2008) Neutral red uptake cytotoxicity 
tests for estimating starting doses for acute oral toxicity tests. Curr. Protoc. Toxicol. 36, 20.4.1-
20.4.20. 
(126) Ducharme, N. A., Reif, D. M., Gustafsson, J.-A., and Bondesson, M. (2015) Comparison of 
toxicity values across zebrafish early life stages and mammalian studies: Implications for chemical 
testing. Reprod. Toxicol. 55, 3–10. 
(127) Russom, C. L., Lalone, C. A., Villeneuve, D. L., and Ankley, G. T. (2014) Development of an 
adverse outcome pathway for acetylcholinesterase inhibition leading to acute mortality. Environ. 
Toxicol. Chem. 33, 2157–2169. 
(128) Sachana, M., Munn, S., and Bal-Price, A. (2017) Adverse Outcome Pathway on binding of 
agonists to ionotropic glutamate receptors in adult brain leading to excitotoxicity that mediates 
neuronal cell death, contributing to learning and memory impairment. OECD Series on Adverse 
Outcome Pathways, No. 6. 
(129) Gong, P., Hong, H., and Perkins, E. J. (2015) Ionotropic GABA receptor antagonism-induced 
adverse outcome pathways for potential neurotoxicity biomarkers. Biomark. Med. 9, 1225–1239. 
(130) Russom, C. L., Lalone, C. A., Villeneuve, D. L., and Ankley, G. T. (2014) Development of an 
adverse outcome pathway for acetylcholinesterase inhibition leading to acute mortality. Environ. 
Toxicol. Chem. 33, 2157–2169. 
(131) Viney, J. L. (1995) Transgenic and gene knockout mice in cancer research. Cancer Metastasis 
Rev. 14, 77–90. 
(132) Wang, Y., Wang, Q., Wu, B., Li, Y., and Lu, G. (2013) Correlation between TCDD acute 
toxicity and aryl hydrocarbon receptor structure for different mammals. Ecotoxicol. Environ. Saf. 89, 
84–88. 
(133) Villalobos-Molina, R., Vázquez-Cuevas, F. G., López-Guerrero, J. J., Figueroa-García, M. C., 
Gallardo-Ortiz, I. A., Ibarra, M., Rodríguez-Sosa, M., Gonzalez, F. J., and Elizondo, G. (2008) 
Vascular α1D-adrenoceptors are overexpressed in aorta of the aryl hydrocarbon receptor null mouse: 
Role of increased angiotensin II. Auton. Autacoid Pharmacol. 28, 61–67. 
(134) Knapen, D., Vergauwen, L., Villeneuve, D. L., and Ankley, G. T. (2015) The potential of AOP 
networks for reproductive and developmental toxicity assay development. Reprod. Toxicol. 56, 52–
55. 
(135) Knapen, D., Angrish, M. M., Fortin, M. C., Katsiadaki, I., Leonard, M., Margiotta-Casaluci, L., 
Munn, S., O’Brien, J. M., Pollesch, N., Smith, L. C., Zhang, X., and Villeneuve, D. L. (2018) Adverse 
outcome pathway networks I: Development and applications. Environ. Toxicol. Chem. 37, 1723–
1733. 
 137 
(136) Villeneuve, D. L., Angrish, M. M., Fortin, M. C., Katsiadaki, I., Leonard, M., Margiotta-
Casaluci, L., Munn, S., O’Brien, J. M., Pollesch, N. L., Smith, L. C., Zhang, X., and Knapen, D. 
(2018) Adverse outcome pathway networks II: Network analytics. Environ. Toxicol. Chem. 37, 1734–
1748. 
(137) Perkins, E. J., Antczak, P., Burgoon, L., Falciani, F., Garcia-Reyero, N., Gutsell, S., Hodges, 
G., Kienzler, A., Knapen, D., McBride, M., and Willett, C. (2015) Adverse outcome pathways for 
regulatory applications: Examination of four case studies with different degrees of completeness and 
scientific confidence. Toxicol. Sci. 148, 14–25. 
(138) Garcia-Reyero, N. (2015) Are adverse outcome pathways here to stay? Environ. Sci. Technol. 
49, 3–9. 
(139) ICH. (2009) ICH harmonised tripartite guideline guidance on nonclinical safety studies for the 
conduct of human clinical trials and marketing authorization for pharmaceuticals. ICH Harmonised 
Tripartite Guideline. 
(140) Burden, N., Sewell, F., and Chapman, K. (2015) Testing Chemical Safety: What Is Needed to 
Ensure the Widespread Application of Non-animal Approaches? PLoS Biol. 13, e1002156. 
(141) Kuhn, M., and Johnson, K. (2013) Applied Predictive Modeling. Springer, New York. 
(142) Ahlberg, E., Carlsson, L., and Boyer, S. (2014) Computational derivation of structural alerts 
from large toxicology data sets. J. Chem. Inf. Model. 54, 2945–2952. 
(143) Aiken, L. S., and Stephen, G. (1991) Multiple regression: Testing and interpreting interactions. 
Sage Publications. 
(144) Lazic, S. E., Edmunds, N., and Pollard, C. E. (2017) Predicting drug safety and communicating 
risk: benefits of a Bayesian approach. Toxicol. Sci. 162, 89–98. 
(145) Judson, R., Elloumi, F., Setzer, R. W., Li, Z., and Shah, I. (2008) A comparison of machine 
learning algorithms for chemical toxicity classification using a simulated multi-scale data model. 
BMC Bioinformatics 9, 241. 
(146) Allen, C. H. G., Koutsoukas, A., Cortés-Ciriano, I., Murrell, D. S., Malliavin, T. E., Glen, R. C., 
and Bender, A. (2016) Improving the prediction of organism-level toxicity through integration of 
chemical, protein target and cytotoxicity qHTS data. Toxicol. Res. (Camb). 5, 883–894. 
(147) Li, X., Chen, L., Cheng, F., Wu, Z., Bian, H., Xu, C., Li, W., Liu, G., Shen, X., and Tang, Y. 
(2014) In silico prediction of chemical acute oral toxicity using multi-classification methods. J. Chem. 
Inf. Model. 54, 1061–1069. 
(148) Unterthiner, T., Mayr, A., Klambauer, G., and Hochreiter, S. (2015) Toxicity Prediction using 
Deep Learning. Front. Environ. Sci. 3, 80. 
(149) Dong, G., and Bailey, J. (2013) Contrast data mining : concepts, algorithms, and applications. 
CRC Press. 
(150) Kumbhare, T. A., and Chobe, S. V. (2014) An Overview of Association Rule Mining 
Algorithms. Int. J. Comput. Sci. Inf. Technol. 5, 927–930. 
(151) García-Borroto, M., Martínez-Trinidad, J. F., and Carrasco-Ochoa, J. A. (2012) A survey of 
emerging patterns for supervised classification. Artif. Intell. Rev. 42, 705–721. 
(152) Kuhn, M., Weston, S., Coulter, N., Culp, M. C., and Maintainer, R. Q. (2015) Package “C50” 
Decision Trees and Rule-Based Models code for C5.0, R package version 0.1.2. https://CRAN.R-
project.org/package=C50. 
 138 
(153) Quinlan, J. R. (John R., and Ross, J. (1993) C4.5 : programs for machine learning. Morgan 
Kaufmann Publishers. 
(154) Shannon, C. E. (1948) The mathematical theory of communication. Bell Syst. Tech. J. 27, 379–
423. 
(155) Yin, X. & Han, J. (2003) CPAR : Classification based on Predictive Association Rules, in 
Proceedings of the SIAM International Conference on Data Mining, pp 369–376. SIAM Press, San 
Francisco, CA. 
(156) Quinlan, J. R., and Cameron-Jones, R. M. (1993) FOIL: A midterm report. Springer, Berlin, 
Heidelberg. 
(157) Breiman, L. (2001) Random forests. Mach. Learn. 45, 5–32. 
(158) Breiman, L., Friedman, J., Stone, C. J., and Olshen, R. A. (1984) Classification and Regression 
Trees. Chapman & Hall/CRC, Taylor & Francis Group. 
(159) Svetnik, V., Liaw, A., Tong, C., Christopher Culberson, J., Sheridan, R. P., and Feuston, B. P. 
(2003) Random Forest: A Classification and Regression Tool for Compound Classification and 
QSAR Modeling. J. Chem. Inf. Comput. Sci. 43, 1947–1958. 
(160) Mitchell, J. B. O. (2014) Machine learning methods in chemoinformatics. WIREs Comput. Mol. 
Sci. 4, 468–481. 
(161) Klopman, G. (1984) Artificial intelligence approach to structure-activity studies. Computer 
automated structure evaluation of biological activity of organic molecules. J. Am. Chem. Soc. 106, 
7315–7321. 
(162) Fourches, D., Muratov, E., and Tropsha, A. (2010) Trust, but verify: on the importance of 
chemical structure curation in cheminformatics and QSAR modeling research. J. Chem. Inf. Model. 
50, 1189–1204. 
(163) Enoch, S. J. (2010) Recent Advances in QSAR Studies. Program. Springer Netherlands, 
Dordrecht. 
(164) Klingspohn, W., Mathea, M., ter Laak, A., Heinrich, N., and Baumann, K. (2017) Efficiency of 
different measures for defining the applicability domain of classification models. J. Cheminform. 9, 
44. 
(165) Worth, A. P., Van Leeuwen, C. J., and Hartung, T. (2004) The prospects for using (Q)SARs in a 
changing political environment--high expectations and a key role for the european commission’s joint 
research centre. SAR QSAR Environ. Res. 15, 331–343. 
(166) Hanser, T., Barber, C., Marchaland, J. F., and Werner, S. (2016) Applicability domain: towards 
a more formal definition. SAR QSAR Environ. Res. 27, 865–881. 
(167) Norinder, U., Carlsson, L., Boyer, S., and Eklund, M. (2015) Introducing conformal prediction 
in predictive modeling for regulatory purposes. A transparent and flexible alternative to applicability 
domain determination. Regul. Toxicol. Pharmacol. 71, 279–284. 
(168) Eklund, M., Norinder, U., Boyer, S., and Carlsson, L. (2013) The application of conformal 
prediction to the drug discovery process. Ann. Math. Artif. Intell. 74, 117–132. 
(169) Svensson, F., Norinder, U., and Bender, A. (2017) Modelling compound cytotoxicity using 
conformal prediction and PubChem HTS data. Toxicol. Res. (Camb). 6, 73–80. 
(170) Ji, C., Svensson, F., Zoufir, A., Bender, A., and Valencia, A. (2018) eMolTox: prediction of 
 139 
molecular toxicity with confidence. Bioinformatics 34, 2508–2509. 
(171) Norinder, U., Carlsson, L., Boyer, S., and Eklund, M. (2014) Introducing Conformal Prediction 
in Predictive Modeling. A Transparent and Flexible Alternative to Applicability Domain 
Determination. J. Chem. Inf. Model. 54, 1596–1603. 
(172) Vovk, V., Lindsay, D., Nouretdinov, I., and Gammerman, A. (2003) Mondrian Confidence 
Machine. Tech. Rep. 1–19. 
(173) EPA, U. S. (2016) Toxicity ForeCaster (ToxCastTM) Data, https://www.epa.gov/chemical-
research/toxicity-forecaster-toxcasttm-data (accessed 2017-07-19). 
(174) Kuhn, M. (2008) Building Predictive Models in R Using the caret Package. J. Stat. Softw. 28, 
1–26. 
(175) Meyer, D., Dimitriadou, E., Hornik, K., Andreas, Leisch, and Friedrich, W. (2015) Package 
‘e1071’: Misc Functions of the Department of Statistics, Probability Theory Group (Formerly: 
E1071), TU Wien. R package version 1.7-0.1. https://CRAN.R-project.org/package=e1071. 
(176)  R Core Team (2018). R: A language and environment for statistical computing. R Foundation 
for Statistical Computing, Vienna, Austria. URL https://www.R-project.org/. 
(177) Lê, S., Josse, J., and Husson, F. (2008) FactoMineR : An R package for multivariate analysis. J 
Stat Softw 25, 1–18. 
(178) Lantz, B. (2015) Machine Learning with R. Second Edi. Packt Publishing, Birmingham, UK. 
(179) Everitt, B., and Hothorn, T. (2011) An Introduction to Applied Multivariate Analysis with R. 
Springer-Verlag New York. 
(180) Lehman, A., O’Rourke, N., Hatcher, L., and Stepanski, E. (2013) JMP for Basic Univariate and 
Multivariate Statistics: Methods for Researchers and Social Scientists, Second Edi. SAS Institute Inc. 
(181) Warnes, G. R., Bolker, B., Bonebakker, L., Gentleman, R., Liaw, W., Lumley, T., Maechler, 
M., Magnusson, A., Moeller, S., Schwartz, M., and Venables, B. “gplots”: Various R Programming 
Tools for Plotting Data. R package version 3.0.1.1. https://CRAN.R-project.org/package=gplots. 
(182) Levin, E. R. (2005) Integration of the extranuclear and nuclear actions of estrogen. Mol. 
Endocrinol. 19, 1951–9. 
(183) Roy, A. K., Lavrovsky, Y., Song, C. S., Chen, S., Jung, M. H., Velu, N. K., Bi, B. Y., and 
Chatterjee, B. (1998) Regulation of Androgen Action. Vitam. Horm. 55, 309–352. 
(184) Lu, N. Z., Wardell, S. E., Burnstein, K. L., Defranco, D., Fuller, P. J., Giguere, V., Hochberg, 
R. B., McKay, L., Renoir, J.-M., Weigel, N. L., Wilson, E. M., McDonnell, D. P., and Cidlowski, J. 
A. (2006) International Union of Pharmacology. LXV. The Pharmacology and Classification of the 
Nuclear Receptor Superfamily: Glucocorticoid, Mineralocorticoid, Progesterone, and Androgen 
Receptors. Pharmacol. Rev. 58, 782–797. 
(185) Flamant, F., Baxter, J. D., Forrest, D., Refetoff, S., Samuels, H., Scanlan, T. S., Vennström, B., 
and Samarut, J. (2006) International Union of Pharmacology. LIX. The pharmacology and 
classification of the nuclear receptor superfamily: thyroid hormone receptors. Pharmacol. Rev. 58, 
705–11. 
(186) Patisaul, H. B., Fenton, S. E., and Aylor, D. (2018) Animal models of endocrine disruption. 
Best Pract. Res. Clin. Endocrinol. Metab. 32, 283–297. 
(187) Gore, A. C., Chappell, V. A., Fenton, S. E., Flaws, J. A., Nadal, A., Prins, G. S., Toppari, J., and 
 140 
Zoeller, R. T. (2016) EDC-2 : The Endocrine Society ’ s Second Scientific Statement on Endocrine-
Disrupting Chemicals. Endocr. Rev. 36, 1–150. 
(188) Dunand-Sauthier, I., Walker, C. A., Narasimhan, J., Pearce, A. K., Wek, R. C., and Humphrey, 
T. C. (2005) Stress-activated protein kinase pathway functions to support protein synthesis and 
translational adaptation in response to environmental stress in fission yeast. Eukaryot. Cell 4, 1785–
93. 
(189) Webster, M., Witkin, K. L., and Cohen-Fix, O. (2009) Sizing up the nucleus: nuclear shape, size 
and nuclear-envelope assembly. J. Cell Sci. 122, 1477–1486. 
(190) Shadel, G. S. (2008) Expression and maintenance of mitochondrial DNA: new insights into 
human disease pathology. Am. J. Pathol. 172, 1445–56. 
(191) Lodish, H., Berk, A., Zipursky, S. L., Matsudaira, P., Baltimore, D., and Darnell, J. (2000) Cell-
Cell Adhesion and Communication, in Molecular Cell Biology Forth Edi. W. H. Freeman, New York. 
(192) Eberwine, J. (1999) Regulation of Transcription by Transcription Factors, in Basic 
Neurochemistry: Molecular, Cellular and Medical Aspects 6th edi. Lippincott-Raven, Philadelphia. 
(193) Kim, M. T., Huang, R., Sedykh, A., Wang, W., Xia, M., and Zhu, H. (2016) Mechanism 
Profiling of Hepatotoxicity Caused by Oxidative Stress Using Antioxidant Response Element 
Reporter Gene Assay Models and Big Data. Environ. Health Perspect. 124, 634–41. 
(194) Wetmore, B. A., Wambaugh, J. F., Allen, B., Ferguson, S. S., Sochaski, M. A., Setzer, R. W., 
Houck, K. A., Strope, C. L., Cantwell, K., Judson, R. S., LeCluyse, E., Clewell, H. J., Thomas, R. S., 
and Andersen, M. E. (2015) Incorporating High-Throughput Exposure Predictions with Dosimetry-
Adjusted In Vitro Bioactivity to Inform Chemical Toxicity Testing. Toxicol. Sci. 148, 121–136. 
(195) Degoey, D. A., Chen, H. J., Cox, P. B., and Wendt, M. D. (2018) Beyond the Rule of 5: 
Lessons Learned from AbbVie’s Drugs and Compound Collection. J. Med. Chem. 61, 2636–2651. 
(196) Veber, D. F., Johnson, S. R., Cheng, H., Smith, B. R., Ward, K. W., and Kopple, K. D. (2002) 
Molecular Properties That Influence the Oral Bioavailability of Drug Candidates. J. Med. Chem. 45, 
2615–2623. 
(197) Martin, M. T., Judson, R. S., Reif, D. M., Kavlock, R. J., and Dix, D. J. (2009) Profiling 
Chemicals Based on Chronic Toxicity Results from the U.S. EPA ToxRef Database. Environ. Health 
Perspect. 117, 392–399. 
(198)  Standardizer was used for structure canonicalization and transformation, JChem 15.12.14.0, 
2015, ChemAxon (http://www.chemaxon.com). 
(199) Landrum, G. RDKit: Open source chemoinformatics; http://www.rdkit.org. 
(200) Berthold, M. R., Cebron, N., Dill, F., Gabriel, T. R., Kötter, T., Meinl, T., Ohl, P., Thiel, K., 
and Wiswedel, B. (2009) KNIME - the Konstanz information miner, in Data Analysis, Machine 
Learning and Applications, pp 319–326. Springer, Berlin, Heidelberg. 
(201)  Calculator Plugins: Calculator Plugins were used for structure property prediction and 
calculation, Marvin 15.12.14.0, 2015, ChemAxon (http://www.chemaxon.com). 
(202) ChemAxon. Instant JChem was used for structure database management, search and prediction, 
Instant JChem 15.12.14.0, 2015, ChemAxon (http://www.chemaxon.com). 
(203) Real, R., and Vargas, J. M. (1996) The probabilistic basis of Jaccard’s index of similarity. Syst. 
Biol. 45, 380–385. 
 141 
(204) Murtagh, F., and Legendre, P. (2014) Ward’s Hierarchical Agglomerative Clustering Method: 
Which Algorithms Implement Ward’s Criterion? J. Classif. 31, 274–295. 
(205) Wickham, H., and Chang, W. (2016) ‘ggplot2’: Elegant Graphics for Data Analysis. Springer-
Verlag New York. 
(206) Huang, R., Xia, M., Sakamuru, S., Zhao, J., Shahane, S. A., Attene-Ramos, M., Zhao, T., 
Austin, C. P., and Simeonov, A. (2016) Modelling the Tox21 10 K chemical profiles for in vivo 
toxicity prediction and mechanism characterization. Nat. Commun. 7, 10425. 
(207) Wienkers, L. C., and Heath, T. G. (2005) Predicting in vivo drug interactions from in vitro drug 
discovery data. Nat. Rev. Drug Discov. 4, 825–833. 
(208) Murugaiyan, G., Martin, S., and Saha, B. (2007) CD40-induced countercurrent conduits for 
tumor escape or elimination? Trends Immunol. 28, 467–473. 
(209) Zhai, Y., Shen, X. D., Gao, F., Zhao, A., Freitas, M. C., Lassman, C., Luster, A. D., Busuttil, R. 
W., and Kupiec-Weglinski, J. W. (2008) CXCL10 regulates liver innate immune response against 
ischemia and reperfusion injury. Hepatology 47, 207–214. 
(210) Schmitz, V., Dombrowski, F., Prieto, J., Qian, C., Diehl, L., Knolle, P., Sauerbruch, T., 
Caselmann, W. H., Spengler, U., and Leifeld, L. (2006) Induction of murine liver damage by 
overexpression of CD40 ligand provides an experimental model to study fulminant hepatic failure. 
Hepatology 44, 430–439. 
(211) Shu, U., Kiniwa, M., Wu, C. Y., Maliszewski, C., Vezzio, N., Hakimi, J., Gately, M., and 
Delespesse, G. (1995) Activated T cells induce interleukin-12 production by monocytes via CD40-
CD40 ligand interaction. Eur. J. Immunol. 25, 1125–1128. 
(212) Karthivashan, G., Arulselvan, P., and Fakurazi, S. (2015) Pathways involved in acetaminophen 
hepatotoxicity with specific targets for inhibition/downregulation. RSC Adv. 5, 62040–62051. 
(213) Bone-Larson, C. L., Hogaboam, C. M., Evanhoff, H., Strieter, R. M., and Kunkel, S. L. (2001) 
IFN-gamma-inducible protein-10 (CXCL10) is hepatoprotective during acute liver injury through the 
induction of CXCR2 on hepatocytes. J. Immunol. 167, 7077–7083. 
(214) Jaeschke, H., Williams, C. D., Ramachandran, A., and Bajt, M. L. (2012) Acetaminophen 
hepatotoxicity and repair: the role of sterile inflammation and innate immunity. Liver Int. 32, 8–20. 
(215) Saiman, Y., and Friedman, S. L. (2012) The role of chemokines in acute liver injury. Front. 
Physiol. 3, 213. 
(216) McMahan, R. H., Porsche, C. E., Edwards, M. G., and Rosen, H. R. (2016) Free fatty acids 
differentially downregulate chemokines in liver sinusoidal endothelial cells: Insights into non-
alcoholic fatty liver disease. PLoS One 11, e0159217. 
(217) Yamamoto, Y. (2006) Estrogen Receptor   Mediates 17 -Ethynylestradiol Causing 
Hepatotoxicity. J. Biol. Chem. 281, 16625–16631. 
(218) Mueller, K. M., Kornfeld, J.-W., Friedbichler, K., Blaas, L., Egger, G., Esterbauer, H., 
Hasselblatt, P., Schlederer, M., Haindl, S., Wagner, K.-U., Engblom, D., Haemmerle, G., Kratky, D., 
Sexl, V., Kenner, L., Kozlov, A. V, Terracciano, L., Zechner, R., Schuetz, G., Casanova, E., 
Pospisilik, J. A., Heim, M. H., and Moriggl, R. (2011) Impairment of hepatic growth hormone and 
glucocorticoid receptor signaling causes steatosis and hepatocellular carcinoma in mice. Hepatology 
54, 1398–409. 
(219) Thole, Z., Manso, G., Salgueiro, E., Revuelta, P., and Hidalgo, A. (2004) Hepatotoxicity 
induced by antiandrogens: A review of the literature. Urol. Int. 73, 289–295. 
 142 
(220) Zhang, J., Huang, W., Qatanani, M., Evans, R. M., and Moore, D. D. (2004) The constitutive 
androstane receptor and pregnane X receptor function coordinately to prevent bile acid-induced 
hepatotoxicity. J. Biol. Chem. 279, 49517–49522. 
(221) Lee, F. Y., de Aguiar Vallim, T. Q., Chong, H. K., Zhang, Y., Liu, Y., Jones, S. A., Osborne, T. 
F., and Edwards, P. A. (2010) Activation of the Farnesoid X Receptor Provides Protection against 
Acetaminophen-Induced Hepatic Toxicity. Mol. Endocrinol. 24, 1626–1636. 
(222) Collin, M., Abdelrahman, M., and Thiemermann, C. (2004) Endogenous ligands of PPAR-γ 
reduce the liver injury in haemorrhagic shock. Eur. J. Pharmacol. 486, 233–235. 
(223) Shan, W., Nicol, C. J., Ito, S., Bility, M. T., Kennett, M. J., Ward, J. M., Gonzalez, F. J., and 
Peters, J. M. (2007) Peroxisome proliferator-activated receptor-β/δ protects against chemically 
induced liver toxicity in mice. Hepatology 47, 225–235. 
(224) Osawa, Y., Oboki, K., Imamura, J., Kojika, E., Hayashi, Y., Hishima, T., Saibara, T., Shibasaki, 
F., Kohara, M., and Kimura, K. (2015) Inhibition of Cyclic Adenosine Monophosphate (cAMP)-
response Element-binding Protein (CREB)-binding Protein (CBP)/β-Catenin Reduces Liver Fibrosis 
in Mice. EBIOM 2, 1751–1758. 
(225) AlSharari, S. D., Al-Rejaie, S. S., Abuohashish, H. M., Ahmed, M. M., and Hafez, M. M. 
(2016) Rutin Attenuates Hepatotoxicity in High-Cholesterol-Diet-Fed Rats. Oxid. Med. Cell. Longev. 
2016, 1–11. 
(226) Dooley, S., and Ten Dijke, P. (2012) TGF-β in progression of liver disease. Cell Tissue Res. 
347, 245–256. 
(227) Wagner, M., Zollner, G., and Trauner, M. (2011) Nuclear receptors in liver disease. Hepatology 
53, 1023–1034. 
(228) Zuniga, S., Firrincieli, D., Housset, C., and Chignard, N. (2011) Vitamin D and the vitamin D 
receptor in liver pathophysiology. Clin. Res. Hepatol. Gastroenterol. 35, 295–302. 
(229) Saini, S. P. S., Zhang, B., Niu, Y., Jiang, M., Gao, J., Zhai, Y., Hoon Lee, J., Uppal, H., Tian, 
H., Tortorici, M. A., Poloyac, S. M., Qin, W., Venkataramanan, R., and Xie, W. (2011) Activation of 
liver X receptor increases acetaminophen clearance and prevents its toxicity in mice. Hepatology 54, 
2208–17. 
(230) Lemasters, J. J., Qian, T., Bradham, C. A., Brenner, D. A., Cascio, W. E., Trost, L. C., 
Nishimura, Y., Nieminen, A. L., and Herman, B. (1999) Mitochondrial dysfunction in the 
pathogenesis of necrotic and apoptotic cell death. J. Bioenerg. Biomembr. 31, 305–19. 
(231) Jaeschke, H., Gores, G. J., Cederbaum, A. I., Hinson, J. A., Pessayre, D., and Lemasters, J. J. 
(2002) Mechanisms of hepatotoxicity. Toxicol. Sci. 65, 166–176. 
(232) Vairetti, M., Ferrigno, A., Rizzo, V., Ambrosi, G., Bianchi, A., Richelmi, P., Blandini, F., and 
Armentero, M. T. (2012) Impaired hepatic function and central dopaminergic denervation in a rodent 
model of Parkinson’s disease: A self-perpetuating crosstalk? Biochim. Biophys. Acta - Mol. Basis Dis. 
1822, 176–184. 
(233) Veenman, L., and Gavish, M. (2012) The Role of 18 kDa Mitochondrial Translocator Protein 
(TSPO) in Programmed Cell Death, and Effects of Steroids on TSPO Expression. Curr. Mol. Med. 12, 
398–412. 
(234) Hatori, A., Yui, J., Xie, L., Yamasaki, T., Kumata, K., Fujinaga, M., Wakizaka, H., Ogawa, M., 
Nengaki, N., Kawamura, K., and Zhang, M. R. (2014) Visualization of acute liver damage induced by 
cycloheximide in rats using PET with [18F]FEDAC, a radiotracer for translocator protein (18 kDa). 
PLoS One 9, e86625. 
 143 
(235) Rincón-Sánchez, A. R., Covarrubias, A., Rivas-Estilla, A. M., Pedraza-Chaverrí, J., Cruz, C., 
Islas-Carbajal, M. C., Panduro, A., Estanes, A., and Armendáriz-Borunda, J. (2005) PGE2 alleviates 
kidney and liver damage, decreases plasma renin activity and acute phase response in cirrhotic rats 
with acute liver damage. Exp. Toxicol. Pathol. 56, 291–303. 
(236) Takano, M., Nishimura, H., Kimura, Y., Washizu, J., Mokuno, Y., Nimura, Y., and Yoshikai, 
Y. (1998) Prostaglandin E2 protects against liver injury after Escherichia coli infection but hampers 
the resolution of the infection in mice. J Immunol 161, 3019–3025. 
(237) Rudnick, D. A., Perlmutter, D. H., and Muglia, L. J. (2001) Prostaglandins are required for 
CREB activation and cellular proliferation during liver regeneration., in Proceedings of the National 
Academy of Sciences of the United States of America, pp 8885–8890. 
(238) Zhang, H., Liu, Y., Wang, L., Li, Z., Zhang, H., Wu, J., Rahman, N., Guo, Y., Li, D., Li, N., 
Huhtaniemi, I., Tsang, S. Y., Gao, G. F., and Li, X. (2013) Differential effects of estrogen/androgen 
on the prevention of nonalcoholic fatty liver disease in the male rat. J. Lipid Res. 54, 345–57. 
(239) Hanioka, N., Gonzalez, F. J., Lindberg, N. A., Liu, G., Gelboin, H. V., and Korzekwa, K. R. 
(1992) Site-directed mutagenesis of cytochrome P450s CYP2A1 and CYP2A2: influence of the distal 
helix on the kinetics of testosterone hydroxylation. Biochemistry 31, 3364–3370. 
(240) Williams, T. M., and Borghoff, S. J. (2000) Induction of Testosterone Biotransformation 
Enzymes following Oral Administration of Methyl tert-Butyl Ether to Male Sprague-Dawley Rats. 
Toxicol. Sci. 57, 147–155. 
(241) Olokpa, E., Bolden, A., and Stewart, L. V. (2016) The Androgen Receptor Regulates PPARγ 
Expression and Activity in Human Prostate Cancer Cells. J. Cell. Physiol. 231, 2664–72. 
(242) Olokpa, E., Moss, P. E., and Stewart, L. V. (2017) Crosstalk between the Androgen Receptor 
and PPAR Gamma Signaling Pathways in the Prostate. PPAR Res. 2017, 1–13. 
(243) Lin, H. Y., Yu, I. C., Wang, R. S., Chen, Y. T., Liu, N. C., Altuwaijri, S., Hsu, C. L., Ma, W. L., 
Jokinen, J., Sparks, J. D., Yeh, S., and Chang, C. (2008) Increased hepatic steatosis and insulin 
resistance in mice lacking hepatic androgen receptor. Hepatology 47, 1924–1935. 
(244) Daskalopoulos, E. P., Lang, M. A., Marselos, M., Malliou, F., and Konstandi, M. (2012) D2-
Dopaminergic Receptor-Linked Pathways: Critical Regulators of CYP3A, CYP2C, and CYP2D. Mol. 
Pharmacol. 82, 668–678. 
(245) Harkitis, P., Daskalopoulos, E. P., Malliou, F., Lang, M. A., Marselos, M., Fotopoulos, A., 
Albucharali, G., and Konstandi, M. (2015) Dopamine D2-receptor antagonists down-regulate 
CYP1A1/2 and CYP1B1 in the rat liver. PLoS One 10, e0128708. 
(246) Schwabe, R. F., Schnabl, B., Kweon, Y. O., and Brenner, D. A. (2001) CD40 Activates NF- B 
and c-Jun N-Terminal Kinase and Enhances Chemokine Secretion on Activated Human Hepatic 
Stellate Cells. J. Immunol. 166, 6812–6819. 
(247) Yamaguchi, J., Tanaka, T., Eto, N., and Nangaku, M. (2015) Inflammation and hypoxia linked 
to renal injury by CCAAT/enhancer-binding protein δ. Kidney Int. 88, 262–275. 
(248) Anderson, E. R., Taylor, M., Xue, X., Martin, A., Moons, D. S., Omary, M. B., and Shah, Y. M. 
(2012) The hypoxia-inducible factor-C/EBPα axis controls ethanol-mediated hepcidin repression. 
Mol. Cell. Biol. 32, 4068–77. 
(249) Jakobsen, J. S., Waage, J., Rapin, N., Bisgaard, H. C., Larsen, F. S., and Porse, B. T. (2013) 
Temporal mapping of CEBPA and CEBPB binding during liver regeneration reveals dynamic 
occupancy and specific regulatory codes for homeostatic and cell cycle gene batteries. Genome Res. 
23, 592–603. 
 144 
(250) Barchetta, I., Carotti, S., Labbadia, G., Gentilucci, U. V., Muda, A. O., Angelico, F., Silecchia, 
G., Leonetti, F., Fraioli, A., Picardi, A., Morini, S., and Cavallo, M. G. (2012) Liver vitamin D 
receptor, CYP2R1, and CYP27A1 expression: relationship with liver histology and vitamin D3 levels 
in patients with nonalcoholic steatohepatitis or hepatitis C virus. Hepatology 56, 2180–2187. 
(251) Petta, S., Grimaudo, S., Tripodo, C., Cabibi, D., Calvaruso, M., Di Cristina, A., Guarnotta, C., 
Macaluso, F. S. alvatore, Minissale, M. G. iovanna, Marchesini, G., and Craxì, A. (2015) The hepatic 
expression of vitamin D receptor is inversely associated with the severity of liver damage in genotype 
1 chronic hepatitis C patients. J. Clin. Endocrinol. Metab. 100, 193–200. 
(252) Chen, Y., and Goldstein, J. A. (2009) The transcriptional regulation of the human CYP2C 
genes. Curr. Drug Metab. 10, 567–78. 
(253) Cook, L. C., Hillhouse, A. E., Myles, M. H., Lubahn, D. B., Bryda, E. C., Davis, J. W., and 
Franklin, C. L. (2014) The role of estrogen signaling in a mouse model of inflammatory bowel 
disease: a Helicobacter hepaticus model. PLoS One 9, e94209. 
(254) Zeremski, M., Dimova, R., Astemborski, J., Thomas, D. L., and Talal, A. H. (2011) CXCL9 and 
CXCL10 chemokines as predictors of liver fibrosis in a cohort of primarily African-American 
injection drug users with chronic hepatitis C. J. Infect. Dis. 204, 832–6. 
(255) Jaeschke, H. (2007) Troglitazone hepatotoxicity: Are we getting closer to understanding 
idiosyncratic liver injury? Toxicol. Sci. 97, 1–3. 
(256) Masubuchi, Y. (2006) Metabolic and Non-Metabolic Factors Determining Troglitazone 
Hepatotoxicity: A Review. Drug Metab. Pharmacokinet. 21, 347–356. 
(257) Vansant, G., Pezzoli, P., Saiz, R., Birch, A., Duffy, C., Ferre, F., and Monforte, J. (2006) Gene 
Expression Analysis of Troglitazone Reveals Its Impact on Multiple Pathways in Cell Culture: A Case 
for In Vitro Platforms Combined with Gene Expression Analysis for Early (Idiosyncratic) Toxicity 
Screening. Int. J. Toxicol. 25, 85–94. 
(258) Ong, M. M. K., Latchoumycandane, C., and Boelsterli, U. A. (2007) Troglitazone-Induced 
Hepatic Necrosis in an Animal Model of Silent Genetic Mitochondrial Abnormalities. Toxicol. Sci. 
97, 205–213. 
(259) Jaeschke, H. (2007) Troglitazone hepatotoxicity: Are we getting closer to understanding 
idiosyncratic liver injury? Toxicol. Sci. 97, 1–3. 
(260) Bale, S., Vernetti, L., Senutovitch, N., Jindal, R., Hegde, M., Gough, A., Mccarty, W. J., Bakan, 
A., Bhushan, A., Shun, T. Y., Golberg, I., Debiasio, R., Osman Usta, B., Taylor, D. L., and Yarmush, 
M. L. (2014) In Vitro Platforms for Evaluating Liver Toxicity. Exp Biol Med 239, 1180–1191. 
(261) Giuliano, K. A., Gough, A. H., Taylor, D. L., Vernetti, L. A., and Johnston, P. A. (2010) Early 
safety assessment using cellular systems biology yields insights into mechanisms of action. J. Biomol. 
Screen. 15, 783–797. 
(262) Messner, S., Agarkova, I., Moritz, W., and Kelm, J. M. (2013) Multi-cell type human liver 
microtissues for hepatotoxicity testing. Arch. Toxicol. 87, 209–213. 
(263) Khetani, S., and Bhatia, S. (2007) Microscale culture of human liver cells for drug 
development. Nat. Biotechnol. 26, 120–6. 
(264) Hop, C. E. C. A. (2012) Role of ADME Studies in Selecting Drug Candidates : Dependence of 
ADME Parameters on Physicochemical Properties, in Encyclopedia of Drug Metabolism and 
Interactions. John Wiley & Sons, Inc., Hoboken, NJ, USA. 
(265) Ritchie, T. J., and Macdonald, S. J. F. (2009) The impact of aromatic ring count on compound 
 145 
developability - are too many aromatic rings a liability in drug design? Drug Discov. Today 14, 1011–
1020. 
(266) Trainor, G. L. (2007) The importance of plasma protein binding in drug discovery. Expert Opin. 
Drug Discov. 2, 51–64. 
(267) Pellegatti, M., Pagliarusco, S., Solazzo, L., and Colato, D. (2011) Plasma protein binding and 
blood-free concentrations: which studies are needed to develop a drug? Expert Opin. Drug Metab. 
Toxicol. 7, 1009–1020. 
(268) Faria, M., Garcia-Reyero, N., Padrós, F., Babin, P. J., Sebastián, D., Cachot, J., Prats, E., Arick, 
M., Rial, E., Knoll-Gellida, A., Mathieu, G., Le Bihanic, F., Escalon, B. L., Zorzano, A., Soares, A. 
M. V. M., and Raldúa, D. (2015) Zebrafish Models for Human Acute Organophosphorus Poisoning. 
Sci. Rep. 5, 15591. 
(269) Auer, J., and Bajorath, J. (2006) Emerging chemical patterns: A new methodology for 
molecular classification and compound selection. J. Chem. Inf. Model. 46, 2502–2514. 
(270) Nagata, K., Washio, T., Kawahara, Y., and Unami, A. (2014) Toxicity prediction from 
toxicogenomic data based on class association rule mining. Toxicol. Reports 1, 1133–1142. 
(271) Li, J., and Wong, L. (2002) Identifying good diagnostic gene groups from gene expression 
profiles using the concept of emerging patterns. Bioinformatics 18, 725–34. 
(272) Namasivayam, V., Hu, Y., Balfer, J., and Bajorath, J. (2013) Classification of compounds with 
distinct or overlapping multi-target activities and diverse molecular mechanisms using emerging 
chemical patterns. J. Chem. Inf. Model. 53, 1272–1281. 
(273) Bolton, E. E., Wang, Y., Thiessen, P. A., and Bryant, S. H. (2008) Chapter 12 – PubChem: 
Integrated Platform of Small Molecules and Biological Activities, in Annual Reports in 
Computational Chemistry, pp 217–241. 
(274) Mervin, L. H., Afzal, A. M., Drakakis, G., Lewis, R., Engkvist, O., and Bender, A. (2015) 
Target prediction utilising negative bioactivity data covering large chemical space. J. Cheminform. 7, 
51. 
(275) Borgelt, C., Meinl, T., and Berthold, M. (2005) MoSS: a program for molecular substructure 
mining, in Proceedings of the 1st international workshop on open source data miningRegulation of 
human metabolism by hypoxia-inducible factor, pp 6–15. 
(276) Winder, C., Azzi, R., and Wagner, D. (2005) The development of the globally harmonized 
system (GHS) of classification and labelling of hazardous chemicals. J. Hazard. Mater. 125, 29–44. 
(277) Shannon, P., Markiel, A., Ozier, O., Baliga, N. S., Wang, J. T., Ramage, D., Amin, N., 
Schwikowski, B., and Ideker, T. (2003) Cytoscape: A software Environment for integrated models of 
biomolecular interaction networks. Genome Res. 13, 2498–2504. 
(278) Fang, G., Wang, W., Oatley, B., Van Ness, B., Steinbach, M., and Kumar, V. (2011) 
Characterizing Discriminative Patterns. Comput. Res. Repos. abs/1102.4. 
(279) Cortina-Borja, M., Smith, A. D., Combarros, O., and Lehmann, D. J. (2009) The synergy factor: 
a statistic to measure interactions in complex diseases. BMC Res. Notes 2, 105. 
(280) Xu, Y., Pei, J., and Lai, L. (2017) Deep Learning Based Regression and Multiclass Models for 
Acute Oral Toxicity Prediction with Automatic Chemical Feature Extraction. J. Chem. Inf. Model. 57, 
2672–2685. 
(281) Li, X., Chen, L., Cheng, F., Wu, Z., Bian, H., Xu, C., Li, W., Liu, G., Shen, X., and Tang, Y. 
 146 
(2014) In silico prediction of chemical acute oral toxicity using multi-classification methods. J. Chem. 
Inf. Model. 54, 1061–9. 
(282) Sun, L., Zhang, C., Chen, Y., Li, X., Zhuang, S., Li, W., Liu, G., Lee, P. W., and Tang, Y. 
(2015) In silico prediction of chemical aquatic toxicity with chemical category approaches and 
substructural alerts. Toxicol. Res. (Camb). 4, 452–463. 
(283) Girvan, M., and Newman, M. E. J. (2002) Community structure in social and biological 
networks., in Proceedings of the National Academy of Sciences of the United States of America, pp 
7821–6. 
(284) Lau, A., and Tymianski, M. (2010) Glutamate receptors, neurotoxicity and neurodegeneration. 
Pflugers Arch. Eur. J. Physiol. 460, 525–542. 
(285) Hwang, J. Y., Kim, Y. H., Ahn, Y. H., Wie, M. B., and Koh, J. Y. (1999) N-methyl-D-aspartate 
receptor blockade induces neuronal apoptosis in cortical culture. Exp. Neurol. 159, 124–130. 
(286) Rahn, C. A., Bombick, D. W., and Doolittle, D. J. (1991) Assessment of mitochondrial 
membrane potential as an indicator of cytotoxicity. Fundam. Appl. Toxicol. 16, 435–448. 
(287) Bhhatarai, B., Wilson, D. M., Bartels, M. J., Chaudhuri, S., Price, P. S., and Carney, E. W. 
(2015) Acute Toxicity Prediction in Multiple Species by Leveraging Mechanistic ToxCast 
Mitochondrial Inhibition Data and Simulation of Oral Bioavailability. Toxicol. Sci. 147, 386–96. 
(288) Schep, L. J., Slaughter, R. J., and Beasley, D. M. G. (2009) Nicotinic plant poisoning. Clin. 
Toxicol. 47, 771–781. 
(289) Wolkove, N., and Baltzan, M. Amiodarone pulmonary toxicity. Can. Respir. J. 16, 43–8. 
(290) Ying, G. G. (2006) Fate, behavior and effects of surfactants and their degradation products in 
the environment. Environ. Int. 32, 417–431. 
(291) Lémery, E., Briançon, S., Chevalier, Y., Bordes, C., Oddos, T., Gohier, A., and Bolzinger, M.-
A. (2015) Skin toxicity of surfactants: Structure/toxicity relationships. Colloids Surfaces A 
Physicochem. Eng. Asp. 469, 166–179. 
(292) Ullrich, V., King, L. J., Wolf, C. R., and Nastainczyk, W. (1979) Carbenes and Free Radicals of 
Haloalkanes as Toxic Intermediates. Toxicology 131–138. 
(293) Weber, L. W. D., Boll, M., and Stampfl, A. (2003) Hepatotoxicity and mechanism of action of 
haloalkanes: Carbon tetrachloride as a toxicological model. Crit. Rev. Toxicol. 33, 105–136. 
(294) Eisentraeger, A., Brinkmann, C., Hollert, H., Sagner, A., Tiehm, A., and Neuwoehner, J. (2008) 
Heterocyclic compounds: Toxic effects using algae, daphnids, and the Salmonella/microsome test 
taking methodical quantitative aspects into account. Environ. Toxicol. Chem. 27, 1590–1596. 
(295) Pezdirc, M., Žegura, B., and Filipič, M. (2013) Genotoxicity and induction of DNA damage 
responsive genes by food-borne heterocyclic aromatic amines in human hepatoma HepG2 cells. Food 
Chem. Toxicol. 59, 386–394. 
(296) Goswami, D. G., Kumar, D., Tewari-Singh, N., Orlicky, D. J., Jain, A. K., Kant, R., Rancourt, 
R. C., Dhar, D., Inturi, S., Agarwal, C., White, C. W., and Agarwal, R. (2015) Topical nitrogen 
mustard exposure causes systemic toxic effects in mice. Exp. Toxicol. Pathol. 67, 161–170. 
(297) Colovic, M. B., Krstic, D. Z., Lazarevic-Pasti, T. D., Bondzic, A. M., and Vasic, V. M. (2013) 
Acetylcholinesterase Inhibitors: Pharmacology and Toxicology. Curr. Neuropharmacol. 11, 315–335. 
(298) Mcaninch, E. A., and Bianco, A. C. (2014) Thyroid hormone signaling in energy homeostasis 
 147 
and energy metabolism. Ann. N. Y. Acad. Sci. 1311, 77–87. 
(299) Biondi, B., Palmieri, E. A., Lombardi, G., and Fazio, S. (2002) Effects of Thyroid Hormone on 
Cardiac Function - The Relative Importance of Heart Rate, Loading Conditions, and Myocardial 
Contractility in the Regulation of Cardiac Performance in Human Hyperthyroidism. J. Clin. 
Endocrinol. Metab. 87, 968–974. 
(300) Mancini, A., Di Segni, C., Raimondo, S., Olivieri, G., Silvestrini, A., Meucci, E., and Currò, D. 
(2016) Thyroid Hormones, Oxidative Stress, and Inflammation. Mediators Inflamm. 2016, 6757154. 
(301) Takahashi, K., Furuya, F., Shimura, H., Kaneshige, M., and Kobayashi, T. (2014) Impaired 
oxidative endoplasmic reticulum stress response caused by deficiency of thyroid hormone receptor α. 
J. Biol. Chem. 289, 12485–93. 
(302) Dietrich, C. (2016) Antioxidant Functions of the Aryl Hydrocarbon Receptor. Stem Cells Int. 
2016, 1–10. 
(303) Uberti, F., Lattuada, D., Morsanuto, V., Nava, U., Bolis, G., Vacca, G., Squarzanti, D. F., 
Cisari, C., and Molinari, C. (2014) Vitamin D protects human endothelial cells from oxidative stress 
through the autophagic and survival pathways. J. Clin. Endocrinol. Metab. 99, 1367–1374. 
(304) Bosland, M. C., and Mahmoud, A. M. (2011) Hormones and prostate carcinogenesis: 
Androgens and estrogens. J. Carcinog. 10, 33. 
(305) Lee, C. (2017) Collaborative Power of Nrf2 and PPAR γ Activators against Metabolic and 
Drug-Induced Oxidative Injury. Oxid. Med. Cell. Longev. 2017, 1–14. 
(306) Yang, B., and Papoian, T. (2018) Preclinical approaches to assess potential kinase inhibitor-
induced cardiac toxicity: Past, present and future. J. Appl. Toxicol. 38, 790–800. 
(307) Kong, D., and Yamori, T. (2008) Phosphatidylinositol 3-kinase inhibitors: Promising drug 
candidates for cancer therapy. Cancer Sci. 99, 1734–1740. 
(308) Tokarska-Schlattner, M. (2005) Acute toxicity of doxorubicin on isolated perfused heart: 
response of kinases regulating energy supply. AJP Hear. Circ. Physiol. 289, H37–H47. 
(309) Barquilla, A., and Pasquale, E. B. (2015) Eph receptors and ephrins: therapeutic opportunities. 
Annu. Rev. Pharmacol. Toxicol. 55, 465–87. 
(310) Wu, B., Wang, S., De, S. K., Barile, E., Quinn, B. A., Zharkikh, I., Purves, A., Stebbins, J. L., 
Oshima, R. G., Fisher, P. B., and Pellecchia, M. (2015) Design and Characterization of Novel EphA2 
Agonists for Targeted Delivery of Chemotherapy to Cancer Cells. Chem. Biol. 22, 876–887. 
(311) Amato, K. R., Wang, S., Hastings, A. K., Youngblood, V. M., Santapuram, P. R., Chen, H., 
Cates, J. M., Colvin, D. C., Ye, F., Brantley-Sieders, D. M., Cook, R. S., Tan, L., Gray, N. S., and 
Chen, J. (2014) Genetic and pharmacologic inhibition of EPHA2 promotes apoptosis in NSCLC. J. 
Clin. Invest. 124, 2037–49. 
(312) Shen, H. M., and Liu, Z. G. (2006) JNK signaling pathway is a key modulator in cell death 
mediated by reactive oxygen and nitrogen species. Free Radic. Biol. Med. 40, 928–939. 
(313) Zhang, J., Min, R. W. M., Le, K., Zhou, S., Aghajan, M., Than, T. A., Win, S., and Kaplowitz, 
N. (2017) The role of MAP2 kinases and p38 kinase in acute murine liver injury models. Cell Death 
Dis. 8, e2903. 
(314) Moslehi, J. J., and Deininger, M. (2015) Tyrosine Kinase Inhibitor-Associated Cardiovascular 
Toxicity in Chronic Myeloid Leukemia. J. Clin. Oncol. 33, 4210–8. 
 148 
(315) Ashpole, N. M., Song, W., Brustovetsky, T., Engleman, E. A., Brustovetsky, N., Cummins, T. 
R., and Hudmon, A. (2012) Calcium/calmodulin-dependent protein kinase II (CaMKII) inhibition 
induces neurotoxicity via dysregulation of glutamate/calcium signaling and hyperexcitability. J. Biol. 
Chem. 287, 8495–8506. 
(316) Swaminathan, P. D., Purohit, A., Hund, T. J., and Anderson, M. E. (2012) Calmodulin-
dependent protein kinase II: Linking heart failure and arrhythmias. Circ. Res. 110, 1661–1677. 
(317) Gonano, L. A., Sepulveda, M., Rico, Y., Kaetzel, M., Valverde, C. A., Dedman, J., Mattiazzi, 
A., and Vila Petroff, M. (2011) Calcium-Calmodulin Kinase II Mediates Digitalis-Induced 
Arrhythmias. Circ. Arrhythmia Electrophysiol. 4, 947–957. 
(318) Chung, J. H., Biesiadecki, B. J., Ziolo, M. T., Davis, J. P., and Janssen, P. M. L. (2016) 
Myofilament calcium sensitivity: Role in regulation of in vivo cardiac contraction and relaxation. 
Front. Physiol. 7, 562. 
(319) Pagel, P. S., Haikala, H., Pentikäinen, P. J., Toivonen, M.-L., Nieminen, M. S., Lehtonen, L., 
Papp, J. G., and Warltier, D. C. (1996) Pharmacology of Levosimendan: A New Myofilament 
Calcium Sensitizer. Cardiovasc. Drug Rev. 14, 286–316. 
(320) Wilson, K., Guggilam, A., West, T. A., Zhang, X., Trask, A. J., Cismowski, M. J., de Tombe, 
P., Sadayappan, S., and Lucchesi, P. A. (2014) Effects of a myofilament calcium sensitizer on left 
ventricular systolic and diastolic function in rats with volume overload heart failure. Am. J. Physiol. 
Circ. Physiol. 307, H1605–H1617. 
(321) Parvatiyar, M. S., Pinto, J. R., Dweck, D., and Potter, J. D. (2010) Cardiac troponin mutations 
and restrictive cardiomyopathy. J. Biomed. Biotechnol. 2010, 1–9. 
(322) Chen, Z., Mou, R.-T., Feng, D.-X., Wang, Z., and Chen, G. (2017) The role of nitric oxide in 
stroke. Med. Gas Res. 7, 194–203. 
(323) Deng, S., Kruger, A., Schmidt, A., Metzger, A., Yan, T., Gödtel-Armbrust, U., Hasenfuss, G., 
Brunner, F., and Wojnowski, L. (2009) Differential roles of nitric oxide synthase isozymes in 
cardiotoxicity and mortality following chronic doxorubicin treatment in mice. Naunyn. 
Schmiedebergs. Arch. Pharmacol. 380, 25–34. 
(324) Liu, D., Zeng, X., Li, X., Mehta, J. L., and Wang, X. (2018) Role of NLRP3 inflammasome in 
the pathogenesis of cardiovascular diseases. Basic Res. Cardiol. 113, 5. 
(325) Reese, I., Ballmer-Weber, B., Beyer, K., Fuchs, T., Kleine-Tebbe, J., Klimek, L., Lepp, U., 
Niggemann, B., Saloga, J., Schäfer, C., Werfel, T., Zuberbier, T., and Worm, M. (2017) German 
guideline for the management of adverse reactions to ingested histamine. Allergo J. Int. 26, 72–79. 
(326) Taylor, S. L., Stratton, J. E., and Nordlee, J. A. (1989) Histamine poisoning (scombroid fish 
poisoning): an allergy-like intoxication. J. Toxicol. Clin. Toxicol. 27, 225–40. 
(327) Villalba, J. M., and Alcaín, F. J. (2012) Sirtuin activators and inhibitors. Biofactors 38, 349–59. 
(328) Kim, H.-S., Vassilopoulos, A., Wang, R.-H., Lahusen, T., Xiao, Z., Xu, X., Li, C., Veenstra, T. 
D., Li, B., Yu, H., Ji, J., Wang, X. W., Park, S.-H., Cha, Y. I., Gius, D., and Deng, C.-X. (2011) 
SIRT2 Maintains Genome Integrity and Suppresses Tumorigenesis through Regulating APC/C 
Activity. Cancer Cell 20, 487–499. 
(329) Schetter, A. J., and Harris, C. C. (2012) Tumor suppressor p53 (TP53) at the crossroads of the 
exposome and the cancer genome, in Proceedings of the National Academy of Sciences, pp 7955–
7956. 
(330) Zhu, W., Soonpaa, M. H., Chen, H., Shen, W., Payne, R. M., Liechty, E. A., Caldwell, R. L., 
 149 
Shou, W., and Field, L. J. (2009) Acute doxorubicin cardiotoxicity is associated with p53-induced 
inhibition of the mammalian target of rapamycin pathway. Circulation 119, 99–106. 
(331) Altucci, L., and Gronemeyer, H. (2001) Nuclear receptors in cell life and death. Trends 
Endocrinol. Metab. 12, 460–468. 
(332) Neto, M., Naval-Sánchez, M., Potier, D., Pereira, P. S., Geerts, D., Aerts, S., and Casares, F. 
(2017) Nuclear receptors connect progenitor transcription factors to cell cycle control. Sci. Rep. 7, 
4845. 
(333) Abd Elhalim, M. M., Ismail, N. S. M., M Yahya, S. M., Omar, Y. Y., Abd Rabou, A. A., 
Lasheen, D. S., Zawrah, M. F., and Elmegeed, G. A. (2017) Synthesis, Characterization, and 
Evaluation of Cytotoxic Effects of Novel Hybrid Steroidal Heterocycles as PEG Based Nanoparticles. 
Asian Pac. J. Cancer Prev. 18, 1937–1946. 
(334) Singh, H., Jindal, D. P., Yadav, M. R., and Kumar, M. (1991) Heterosteroids and drug research. 
Prog. Med. Chem. 28, 233–300. 
(335) Drocourt, L., Ourlin, J. C., Pascussi, J. M., Maurel, P., and Vilarem, M. J. (2002) Expression of 
CYP3A4, CYP2B6, and CYP2C9 is regulated by the vitamin D receptor pathway in primary human 
hepatocytes. J. Biol. Chem. 277, 25125–25132. 
(336) Matsunawa, M., Amano, Y., Endo, K., Uno, S., Sakaki, T., Yamada, S., and Makishima, M. 
(2009) The aryl hydrocarbon receptor activator benzo[a]pyrene enhances vitamin D3 catabolism in 
macrophages. Toxicol. Sci. 109, 50–58. 
(337) Vogel, C. F. A., William Chang, W. L., Kado, S., McCulloh, K., Vogel, H., Wu, D., Haarmann-
Stemmann, T., Yang, G. X., Leung, P. S. C., Matsumura, F., and Gershwin, M. E. (2016) Transgenic 
overexpression of aryl hydrocarbon receptor repressor (AhRR) and AhR-mediated induction of 
CYP1A1, cytokines, and acute toxicity. Environ. Health Perspect. 124, 1071–1083. 
(338) Diry, M., Tomkiewicz, C., Koehle, C., Coumoul, X., Bock, K. W., Barouki, R., and Transy, C. 
(2006) Activation of the dioxin/aryl hydrocarbon receptor (AhR) modulates cell plasticity through a 
JNK-dependent mechanism. Oncogene 25, 5570–5574. 
(339) Kamat, P. K., Kalani, A., Tyagi, S. C., and Tyagi, N. (2015) Hydrogen sulfide epigenetically 
attenuates homocysteine-induced mitochondrial toxicity mediated through NMDA receptor in mouse 
brain endothelial (bEnd3) cells. J. Cell. Physiol. 230, 378–394. 
(340) Kysenius, K., Brunello, C. A., and Huttunen, H. J. (2014) Mitochondria and NMDA receptor-
dependent toxicity of berberine sensitizes neurons to glutamate and rotenone injury. PLoS One 9, 
e107129. 
(341) Duarte, A. I., Santos, M. S., Seiça, R., and Oliveira, C. R. (2004) Oxidative stress affects 
synaptosomal gamma-aminobutyric acid and glutamate transport in diabetic rats: the role of insulin. 
Diabetes 53, 2110–6. 
(342) Duarte, A., Santos, M., Seiça, R., and Resende de Oliveira, C. (2000) Effect of Oxidative Stress 
on the Uptake of GABA and Glutamate in Synaptosomes Isolated from Diabetic Rat Brain. 
Neuroendocrinology 72, 179–186. 
(343) Wiens, S. C., and Trudeau, V. L. (2006) Thyroid hormone and gamma-aminobutyric acid 
(GABA) interactions in neuroendocrine systems. Comp. Biochem. Physiol. A. Mol. Integr. Physiol. 
144, 332–44. 
(344) Féron, F., Burne, T. H. J., Brown, J., Smith, E., McGrath, J. J., Mackay-Sim, A., and Eyles, D. 
W. (2005) Developmental Vitamin D3deficiency alters the adult rat brain. Brain Res. Bull. 65, 141–
148. 
 150 
(345) Cho, H., Nam, G. B., Lee, S. H., Earm, Y. E., and Ho, W. K. (2001) Phosphatidylinositol 4,5-
bisphosphate is acting as a signal molecule in alpha(1)-adrenergic pathway via the modulation of 
acetylcholine-activated K(+) channels in mouse atrial myocytes. J. Biol. Chem. 276, 159–64. 
(346) Martínez-Miguel, P., Valdivielso, J. M., Medrano-Andrés, D., Román-García, P., Cano-
Peñalver, J. L., Rodríguez-Puyol, M., Rodríguez-Puyol, D., and López-Ongil, S. (2014) The active 
form of vitamin D, calcitriol, induces a complex dual upregulation of endothelin and nitric oxide in 
cultured endothelial cells. Am. J. Physiol. Metab. 307, E1085–E1096. 
(347) Bhatt, S., Qin, J., Bennett, C., Qian, S., Fung, J. J., Hamilton, T. A., and Lu, L. (2014) All-trans 
retinoic acid induces arginase-1 and inducible nitric oxide synthase-producing dendritic cells with T 
cell inhibitory function. J. Immunol. 192, 5098–108. 
(348) Zhang, H., and Zhang, L. (2008) Role of protein kinase C isozymes in the regulation of alpha1-
adrenergic receptor-mediated contractions in ovine uterine arteries. Biol. Reprod. 78, 35–42. 
(349) Minneman, K. P. (1988) Alpha 1-adrenergic receptor subtypes, inositol phosphates, and sources 
of cell Ca2+. Pharmacol. Rev. 40, 87. 
(350) Kalaria, R. N., and Prince, A. K. (1985) Effects of thyroid deficiency on the development of 
cholinergic, GABA, dopaminergic and glutamate neuron markers and DNA concentrations in the rat 
corpus striatum. Int J Dev Neurosci. 3, 655–666. 
(351) Rowley, N. M., Madsen, K. K., Schousboe, A., and Steve White, H. (2012) Glutamate and 
GABA synthesis, release, transport and metabolism as targets for seizure control. Neurochem. Int. 61, 
546–558. 
(352) Seyfried, T. N., Glaser, G. H., and Yu, R. K. (1979) Thyroid hormone influence on the 
susceptibility of mice to audiogenic seizures. Science. 205, 598–600. 
(353) Martin, J. V, Padron, J. M., Newman, M. A., Chapell, R., Leidenheimer, N. J., and Burke, L. A. 
(2004) Inhibition of the activity of the native γ-aminobutyric acidA receptor by metabolites of thyroid 
hormones: correlations with molecular modeling studies. Brain Res. 1004, 98–107. 
(354) Accardi, M. V., Daniels, B. A., Brown, P. M. G. E., Fritschy, J. M., Tyagarajan, S. K., and 
Bowie, D. (2014) Mitochondrial reactive oxygen species regulate the strength of inhibitory GABA-
mediated synaptic transmission. Nat. Commun. 5, 3168. 
(355) Formenti, F., Constantin-Teodosiu, D., Emmanuel, Y., Cheeseman, J., Dorrington, K. L., 
Edwards, L. M., Humphreys, S. M., Lappin, T. R. J., McMullin, M. F., McNamara, C. J., Mills, W., 
Murphy, J. A., O’Connor, D. F., Percy, M. J., Ratcliffe, P. J., Smith, T. G., Treacy, M., Frayn, K. N., 
Greenhaff, P. L., Karpe, F., Clarke, K., and Robbins, P. A. (2010) Regulation of human metabolism 
by hypoxia-inducible factor, in Proceedings of the National Academy of Sciences of the United States 
of America, pp 12722–7. National Academy of Sciences. 
(356) Nilsson, G. E., and Lutz, P. L. (1993) Role of GABA in hypoxia tolerance, metabolic 
depression and hibernation—Possible links to neurotransmitter evolution. Comp. Biochem. Physiol. 
Part C Comp. Pharmacol. 105, 329–336. 
(357) Tannahill, G. M., Curtis, A. M., Adamik, J., Palsson-McDermott, E. M., McGettrick, A. F., 
Goel, G., Frezza, C., Bernard, N. J., Kelly, B., Foley, N. H., Zheng, L., Gardet, A., Tong, Z., Jany, S. 
S., Corr, S. C., Haneklaus, M., Caffrey, B. E., Pierce, K., Walmsley, S., Beasley, F. C., Cummins, E., 
Nizet, V., Whyte, M., Taylor, C. T., Lin, H., Masters, S. L., Gottlieb, E., Kelly, V. P., Clish, C., 
Auron, P. E., Xavier, R. J., and O’Neill, L. A. J. (2013) Succinate is an inflammatory signal that 
induces IL-1β through HIF-1α. Nature 496, 238–42. 
(358) Hu, H., Takano, N., Xiang, L., Gilkes, D. M., Luo, W., and Semenza, G. L. (2014) Hypoxia-
 151 
inducible factors enhance glutamate signaling in cancer cells. Oncotarget 5, 8853–68. 
(359) Binny, D. (2017) Biochemical abnormalities in OPC poisoning and its prognostic significance. 
IOSR J. Dent. Med. Sci. 16, 2279–861. 
(360) Cha, Y. S., Kim, H., Go, J., Kim, T. H., Kim, O. H., Cha, K. C., Lee, K. H., and Hwang, S. O. 
(2014) Features of myocardial injury in severe organophosphate poisoning. Clin. Toxicol. 52, 873–
879. 
(361) Duffy, P. A., Betton, G., Horner, S., Horner, J., Cotton, P., McMahon, N., Lawrence, C., Prior, 
H., Armstrong, D., Philp, K., and Roberts, R. A. (2007) Biomarkers for safety and toxicology: Drug 
induced cardiac injury and dysfunction. Eur. J. Cancer Suppl. 5, 143–151. 
(362) Roongsritong, C., Warraich, I., and Bradley, C. (2004) Common causes of troponin elevations 
in the absence of acute myocardial infarction: incidence and clinical significance. Chest 125, 1877–
84. 
(363) Repplinger, D., Su, M. K., and McKinnon, K. (2014) Troponin elevations and organophosphate 
poisoning: Direct cardiac injury or demand ischemia? Clin. Toxicol. 52, 1298–1298. 
(364) Marchetti, C., Toldo, S., Chojnacki, J., Mezzaroma, E., Liu, K., Salloum, F. N., Nordio, A., 
Carbone, S., Mauro, A. G., Das, A., Zalavadia, A. A., Halquist, M. S., Federici, M., Van Tassell, B. 
W., Zhang, S., and Abbate, A. (2015) Pharmacologic Inhibition of the NLRP3 Inflammasome 
Preserves Cardiac Function After Ischemic and Nonischemic Injury in the Mouse. J. Cardiovasc. 
Pharmacol. 66, 1–8. 
(365) El-Sheikh, A., Hashem, A., Elgohary, M., Elfadl, A., and Lashin, H. (2017) Evaluation of the 
potential cardiotoxic effects in acute organophosphate toxicity as a prognostic factor. Tanta Med. J. 
45, 115. 
(366) Rameh, L. E., Tolias, K. F., Duckworth, B. C., and Cantley, L. C. (1997) A new pathway for 
synthesis of phosphatidylinositol-4,5-bisphosphate. Nature 390, 192–196. 
(367) Xie, H. Q., Xu, H. M., Fu, H. L., Hu, Q., Tian, W. J., Pei, X. H., and Zhao, B. (2013) AhR-
mediated effects of dioxin on neuronal acetylcholinesterase expression in vitro. Environ. Health 
Perspect. 121, 613–618. 
(368) Andrukhova, O., Slavic, S., Zeitz, U., Riesen, S. C., Heppelmann, M. S., Ambrisko, T. D., 
Markovic, M., Kuebler, W. M., and Erben, R. G. (2014) Vitamin D Is a Regulator of Endothelial 
Nitric Oxide Synthase and Arterial Stiffness in Mice. Mol. Endocrinol. 28, 53–64. 
(369) Gouni-Berthold, I., Krone, W., and Berthold, H. K. (2009) Vitamin D and cardiovascular 
disease. Curr. Vasc. Pharmacol. 7, 414–22. 
(370) Ghosh, R., Siddharth, M., Singh, N., Kare, P. K., Dev Banerjee, B., Wadhwa, N., and Tripathi, 
A. K. (2017) Organochlorine pesticide-mediated induction of NADPH oxidase and nitric-oxide 
synthase in endothelial cell. J. Clin. Diagnostic Res. 11, BC09-BC12. 
(371) Sahu, B., and Maeda, A. (2016) Retinol dehydrogenases regulate vitamin A metabolism for 
visual function. Nutrients 8, 746. 
(372) Marchitti, S. A., Brocker, C., Stagos, D., and Vasiliou, V. (2008) Non-P450 aldehyde oxidizing 
enzymes: the aldehyde dehydrogenase superfamily. Expert Opin. Drug Metab. Toxicol. 4, 697–720. 
(373) Sica, D. A. (2005) Alpha1-adrenergic blockers: current usage considerations. J. Clin. 
Hypertens. 7, 757–762. 
(374) Slivka, S. R., Meier, K. E., and Insel, P. A. (1988) α1-Adrenergic receptors promote 
 152 
phosphatidylcholine hydrolysis in MDCK-D1 cells. A mechanism for rapid activation of protein 
kinase C. J. Biol. Chem. 263, 12242–12246. 
(375) Wynne, B. M., McCarthy, C. G., Szasz, T., Molina, P. A., Chapman, A. B., Webb, R. C., Klein, 
J. D., and Hoover, R. S. (2018) Protein kinase Cα deletion causes hypotension and decreased vascular 
contractility. J. Hypertens. 36, 510–519. 
(376) Lei, B., Schwinn, D. A., and Morris, D. P. (2013) Stimulation of α1a Adrenergic Receptors 
Induces Cellular Proliferation or Antiproliferative Hypertrophy Dependent Solely on Agonist 
Concentration. PLoS One 8, e72430. 
(377) Sun, J., Carlsson, L., Ahlberg, E., Norinder, U., Engkvist, O., and Chen, H. (2017) Applying 
Mondrian Cross-Conformal Prediction to Estimate Prediction Confidence on Large Imbalanced 
Bioactivity Data Sets. J. Chem. Inf. Model. 57, 1591–1598. 
(378) Vovk, V., Gammerman, A., and Shafer, G. (2005) Algorithmic Learning in a Random World. 
Springer-Verlag Berlin. 
(379) Lovering, F. (2013) Escape from Flatland 2: Complexity and promiscuity. Medchemcomm 4, 
515–519. 
(380) Méndez-Lucio, O., and Medina-Franco, J. L. (2017) The many roles of molecular complexity in 
drug discovery. Drug Discov. Today 22, 120–126. 
(381) Hann, M. M., Leach, A. R., and Harper, G. (2001) Molecular Complexity and Its Impact on the 
Probability of Finding Leads for Drug Discovery. J. Chem. Inf. Comput. Sci. 41, 856–864. 
(382) Senger, M. R., Fraga, C. A. M., Dantas, R. F., and Silva, F. P. (2016) Filtering promiscuous 
compounds in early drug discovery: Is it a good idea? Drug Discov. Today 21, 868–872. 
(383) Johnson, I., and Hahsler, M. arulesCBA: Classification for Factor and Transactional Data Sets 
Using Association Rules. R package version 1.1.4. https://CRAN.R-project.org/package=arulesCBA. 
 153 
APPENDIX A 
 
 
 
Figure (A-1) Distribution of AC50 values in target-based assays 
 
 
Figure (A-2) Distribution of AC50 values in phenotypic-based assays 
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Table (A-1) Description of some assays, their source, class and target type. Further information on 
full assays annotations can be found in the ToxCast project website.  
 
Assay abbreviation Platform 
source 
Assay class Target 
type 
Description reference 
PXR/PXRE Attagene Target-based Nuclear receptor 
Pregnane X receptor/ 
pregnane X receptor 
element: involved in the 
regulation and expression 
of detoxification proteins 
1 
DR5 Attagene Target-based Nuclear receptor 
Response element of the 
retinoid acid 
receptor(ARE) that play 
an important role in the 
proliferation and 
differentiation of cells 
2 
PPARγ Attagene Target-based Nuclear receptor 
Peroxisome proliferator-
activated receptor gamma 
is responsible for lipid 
metabolism/storage and 
adipocyte differentiation 
3 
NRF2/ARE Attagene Target-based DNA binding 
Nuclear factor erythroid 
2-related factor 2 (Nrf2)-
antioxidant response 
element (ARE): plays a 
key role in sensing and 
regulating oxidative stress 
by activating the 
expression of hundreds of 
antioxidant and 
detoxifying genes 
4 
AP-1 Attagene Target-based DNA binding 
Activator protein-1 is a 
DNA binding protein that 
regulate the transcription 
of many proteins and it is 
involved in some disease 
pathways such as 
inflammatory responses 
5 
Eselectin Bioseek Target-based 
Cell 
adhesion 
molecule 
Selectin E protein plays a 
role in the adhesion of 
leukocytes at the site of 
injury as in inflammatory 
response 
6 
hLADR Bioseek Target-based 
Cell 
adhesion 
molecule 
Histocompatibility 
complex, class II, DR 
alpha protein involved in 
cell adhesion in immune 
response 
7 
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Continue Table (A-1)      
IL-8 Bioseek Target-based cytokine 
Chemokine (C-X-C 
motif) ligand 8 protein 
that promotes 
angiogenesis 
8 
MCP-1 Bioseek Target-based cytokine 
Chemokine (C-C motif) 
ligand 2 protein that is 
involved in 
neuroinflammatory 
response 
9 
uPAR Bioseek Target-based cytokine 
Plasminogen activator, 
urokinase receptor protein 
that regulate the activation 
of plasminogen system 
10 
VCAM-1 Bioseek Target-based 
Cell 
adhesion 
molecule 
Vascular cell adhesion 
molecule 1 protein that 
induce endothelial 
adhesion 
11 
IP-10 Bioseek Target-based Cytokine 
Chemokine (C-X-C 
motif) ligand 10 protein 
that activate T cell –
endothelial adhesion and 
angiogenesis inhibition 
12,13 
CollagenIII  Bioseek Target-based 
Cell 
adhesion 
molecule 
Collagen, type III, alpha 1 
protein is a structural 
protein in connective 
tissues 
14 
SRB Bioseek Phenotypic-based 
Not 
applicable 
Quantification of  the total 
protein levels in the 
system 
15 
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APPENDIX B 
 
 
Figure (B-1) Distribution of rule model accuracy based on 5-fold repeated cross-validation 
performed in 100 trials. The average accuracy of models at 15mg/kg/day and 500mg/kg/day 
are 87% and 82%, respectively. Potent toxic compounds were detected at higher accuracy than 
less potent toxic compounds. 
 
  
 
Figure (B-2) Distribution of rule accuracy (left) and coverage (right). The average accuracy of 
original models is higher than the corresponding modified rule set at both thresholds. Modified 
rules set at toxicity threshold of 15mg/kg/day have higher accuracy (~75%).  Coverage here 
represents the number of compounds comply with the rule and correctly classified as toxic. At 
toxicity threshold of 500mg/kg/day, the overall coverage increased in the modified rule to 
around two folds in comparison to the original rule set. The average of coverage at 
15mg/kg/day is not significantly different from the original set, however, it is more dispersed.
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Bioactivity cutoffs of assays in selected rules 
Bioactivity cutoffs are points in the continuous variables of assay measurements were split 
during the rule search process. These splitting points reflects the potency level in an assay that 
can best discriminate between toxic and non-toxic compounds. As the cutoff level varied by 
assay type, it can be inappropriate to set an arbitrary bioactivity cutoff to discretize assay 
measurements when analyzing in vitro–in vivo associations. For example, according to Figure 
B-3, compounds that are active in Cytochrome P assays at AC50 values of 50µM can be non-
toxic, whereas, compounds possessing the same potency level against phenotypic or nuclear 
receptor assays can be toxic. 
Additionally, potency cutoffs in assays differ with the potency of in vivo toxicity. Overall, the 
potent toxicants, i.e. at 15mg/kg/day, required higher potencies in vitro. The difference was 
most significant for phenotypic assays, as low potent toxicants exerted as double overall AC50 
cutoffs as potent toxins.    
 
 
 
Figure (B-3) The distribution of split points of bioactivity conditions in prioritized rules. As 
the in vitro measurements were taken from half maximal activity concentrations (AC50) of 
dose-response curves, the split point of a bioactivity condition represents the potency cutoff 
that discriminates between toxic and non-toxic compounds. This bioactivity cutoff is lowest 
for cytochrome activity and highest for nuclear receptors and phenotypic activities. 
Consequently, hepatotoxic compounds exert high potency against Cytochrome P enzymes and 
moderate activities in nuclear receptor and phenotypic bioassays. This cutoff is also slightly 
lower among potent toxicants (LEL level of 15mg/kg/day). 
 
1µM
10µM
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Figure (B-4) Number of rules matched by toxic and non-toxic compounds at levels of 
15mg/kg/day (A) and 500mg/kg/day (B). Toxic compounds match significantly more rules 
than non-toxic compounds at both levels. Troglitazone (C), an antidiabetic drug withdrawn 
from the market, had matched two rules at 15mg/kg/day and 10 rules at 500mg/kg/day (Red 
dashed line).  This is equivalent to average liability of toxic compounds at 15mg/kg/day level 
and higher than average at 500mg/kg/day, which indicate the likelihood of troglitazone to be 
hepatotoxic (see Table S9 for detailed rules). 
 
 
 
Figure (B-5) Change in error rates (accuracy deterioration) in percentage as a result of 
removing physicochemical properties from prioritized rules, at each toxicity threshold. Rules 
at threshold of 15mg/kg/day had a greater overall deterioration in accuracy from removing 
physicochemical properties than rules at 500mg/kg/day. 
A) B
) 
C) 
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Table (B-1) Histopathology endpoints on liver from ToxRefDB 
(CHR=chronic/cancer; MGR=multigenerational reproductive; DEV=Prenatal developmental; 
SUB=Subchronic; SAC=Subacute; REP=reproductive fertility) 
 
CHR_rat_SystemicCarcinogenic_adult_PathologyNonProliferative_AccessoryDigestive_Liver 
CHR_rat_SystemicCarcinogenic_adult_PathologyProliferative_AccessoryDigestive_Liver 
CHR_rat_SystemicCarcinogenic_adult_PathologyGross_AccessoryDigestive_Liver 
CHR_rat_SystemicCarcinogenic_adult_PathologyNeoplastic_AccessoryDigestive_Liver 
SUB_rat_SystemicCarcinogenic_adult_PathologyNonProliferative_AccessoryDigestive_Liver 
SUB_rat_SystemicCarcinogenic_adult_PathologyGross_AccessoryDigestive_Liver 
SUB_rat_SystemicCarcinogenic_adult_OrganWeight_AccessoryDigestive_Liver 
SUB_rat_SystemicCarcinogenic_adult_PathologyProliferative_AccessoryDigestive_Liver 
DEV_rat_SystemicCarcinogenic_adult_PathologyGross_AccessoryDigestive_Liver 
MGR_rat_SystemicCarcinogenic_adult_PathologyNonProliferative_AccessoryDigestive_Liver 
MGR_rat_SystemicCarcinogenic_adult_PathologyGross_AccessoryDigestive_Liver 
MGR_rat_SystemicCarcinogenic_juvenile_PathologyNonProliferative_AccessoryDigestive_Liver 
CHR_rat_SystemicCarcinogenic_adult_AccessoryDigestive_Liver 
SUB_rat_SystemicCarcinogenic_adult_AccessoryDigestive_Liver 
DEV_rat_SystemicCarcinogenic_adult_AccessoryDigestive_Liver 
MGR_rat_SystemicCarcinogenic_adult_AccessoryDigestive_Liver 
MGR_rat_SystemicCarcinogenic_juvenile_AccessoryDigestive_Liver 
 
 
Table (B-2) List of assays used in analysis 
ACEA_T47D_80hr_Negative BSK_LPS_PGE2_up 
ACEA_T47D_80hr_Positive BSK_LPS_SRB_down 
APR_HepG2_CellCycleArrest_1h_up BSK_LPS_TissueFactor_down 
APR_HepG2_CellCycleArrest_24h_dn BSK_LPS_TNFa_down 
APR_HepG2_CellCycleArrest_24h_up BSK_LPS_VCAM1_down 
APR_HepG2_CellCycleArrest_72h_dn BSK_SAg_CD38_down 
APR_HepG2_CellCycleArrest_72h_up BSK_SAg_CD40_down 
APR_HepG2_CellLoss_24h_dn BSK_SAg_CD69_down 
APR_HepG2_CellLoss_72h_dn BSK_SAg_Eselectin_down 
APR_HepG2_MicrotubuleCSK_1h_dn BSK_SAg_IL8_down 
APR_HepG2_MicrotubuleCSK_24h_dn BSK_SAg_MCP1_down 
APR_HepG2_MicrotubuleCSK_24h_up BSK_SAg_MIG_down 
APR_HepG2_MicrotubuleCSK_72h_dn BSK_SAg_PBMCCytotoxicity_down 
APR_HepG2_MicrotubuleCSK_72h_up BSK_SAg_PBMCCytotoxicity_up 
APR_HepG2_MitoMass_1h_dn BSK_SAg_Proliferation_down 
APR_HepG2_MitoMass_1h_up BSK_SAg_SRB_down 
APR_HepG2_MitoMass_24h_dn NVS_ADME_hCYP19A1 
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APR_HepG2_MitoMass_24h_up NVS_ADME_hCYP1A1 
APR_HepG2_MitoMass_72h_dn NVS_ADME_hCYP1A2 
APR_HepG2_MitoMass_72h_up NVS_ADME_hCYP2B6 
APR_HepG2_MitoMembPot_1h_dn NVS_ADME_hCYP2C18 
APR_HepG2_MitoMembPot_24h_dn NVS_ADME_hCYP2C19 
APR_HepG2_MitoMembPot_72h_dn NVS_ADME_hCYP2C9 
APR_HepG2_MitoMembPot_72h_up NVS_ADME_hCYP2D6 
APR_HepG2_MitoticArrest_1h_up NVS_ADME_hCYP2J2 
APR_HepG2_MitoticArrest_24h_up NVS_ADME_hCYP3A4 
APR_HepG2_MitoticArrest_72h_up NVS_ADME_rCYP2A1 
APR_HepG2_NuclearSize_1h_dn NVS_ADME_rCYP2A2 
APR_HepG2_NuclearSize_24h_dn NVS_ADME_rCYP2B1 
APR_HepG2_NuclearSize_24h_up NVS_ADME_rCYP2C11 
APR_HepG2_NuclearSize_72h_dn NVS_ADME_rCYP2C12 
APR_HepG2_NuclearSize_72h_up NVS_ADME_rCYP2C13 
APR_HepG2_OxidativeStress_1h_up NVS_ADME_rCYP2C6 
APR_HepG2_OxidativeStress_24h_up NVS_ADME_rCYP2D1 
APR_HepG2_OxidativeStress_72h_up NVS_ADME_rCYP2D2 
APR_HepG2_p53Act_24h_up NVS_ADME_rCYP3A1 
APR_HepG2_p53Act_72h_up NVS_ADME_rCYP3A2 
APR_HepG2_StressKinase_1h_up NVS_ENZ_hAChE 
APR_HepG2_StressKinase_24h_dn NVS_ENZ_hBACE 
APR_HepG2_StressKinase_24h_up NVS_ENZ_hDUSP3 
APR_HepG2_StressKinase_72h_dn NVS_ENZ_hES 
APR_HepG2_StressKinase_72h_up NVS_ENZ_hGSK3b 
ATG_Ahr_CIS_up NVS_ENZ_hMMP7 
ATG_AP_1_CIS_up NVS_ENZ_hPDE4A1 
ATG_BRE_CIS_up NVS_ENZ_hPDE5 
ATG_CAR_TRANS_up NVS_ENZ_oCOX1 
ATG_C_EBP_CIS_up NVS_ENZ_oCOX2 
ATG_CMV_CIS_up NVS_ENZ_rabI2C 
ATG_CRE_CIS_up NVS_ENZ_rAChE 
ATG_DR4_LXR_CIS_up NVS_ENZ_rMAOAC 
ATG_DR5_CIS_up NVS_ENZ_rMAOAP 
ATG_E2F_CIS_up NVS_ENZ_rMAOBC 
ATG_E_Box_CIS_up NVS_ENZ_rMAOBP 
ATG_EGR_CIS_up NVS_GPCR_g5HT4 
ATG_ERa_TRANS_up NVS_GPCR_gH2 
ATG_ERE_CIS_up NVS_GPCR_gMPeripheral_NonSelective 
ATG_FoxA2_CIS_up NVS_GPCR_gOpiateK 
ATG_FXR_TRANS_up NVS_GPCR_h5HT5A 
ATG_GLI_CIS_up NVS_GPCR_h5HT6 
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ATG_HIF1a_CIS_up NVS_GPCR_h5HT7 
ATG_HSE_CIS_up NVS_GPCR_hAdoRA1 
ATG_IR1_CIS_up NVS_GPCR_hAdoRA2a 
ATG_LXRa_TRANS_up NVS_GPCR_hAdra2C 
ATG_LXRb_TRANS_up NVS_GPCR_hDRD1 
ATG_M_06_CIS_up NVS_GPCR_hDRD2s 
ATG_M_19_CIS_up NVS_GPCR_hM1 
ATG_M_19_TRANS_up NVS_GPCR_hM2 
ATG_M_32_CIS_up NVS_GPCR_hM3 
ATG_M_32_TRANS_up NVS_GPCR_hM4 
ATG_M_61_CIS_up NVS_GPCR_hNK2 
ATG_MRE_CIS_up NVS_GPCR_hOpiate_mu 
ATG_Myc_CIS_up NVS_GPCR_p5HT2C 
ATG_NFI_CIS_up NVS_GPCR_rabPAF 
ATG_NF_kB_CIS_up NVS_GPCR_rmAdra2B 
ATG_NRF1_CIS_up NVS_GPCR_rOpiate_NonSelective 
ATG_NRF2_ARE_CIS_up NVS_IC_rCaBTZCHL 
ATG_NURR1_TRANS_up NVS_IC_rCaDHPRCh_L 
ATG_Oct_MLP_CIS_up NVS_IC_rNaCh_site2 
ATG_p53_CIS_up NVS_MP_hPBR 
ATG_Pax6_CIS_up NVS_MP_rPBR 
ATG_PBREM_CIS_up NVS_NR_bER 
ATG_PPARa_TRANS_up NVS_NR_bPR 
ATG_PPARg_TRANS_up NVS_NR_cAR 
ATG_PPRE_CIS_up NVS_NR_hAR 
ATG_PXRE_CIS_up NVS_NR_hCAR_Antagonist 
ATG_PXR_TRANS_up NVS_NR_hER 
ATG_RARa_TRANS_up NVS_NR_hFXR_Antagonist 
ATG_RARb_TRANS_up NVS_NR_hGR 
ATG_RARg_TRANS_up NVS_NR_hPPARa 
ATG_RORE_CIS_up NVS_NR_hPPARg 
ATG_RXRb_TRANS_up NVS_NR_hPR 
ATG_Sox_CIS_up NVS_NR_hPXR 
ATG_Sp1_CIS_up NVS_NR_hTRa 
ATG_SREBP_CIS_up NVS_NR_mERa 
ATG_STAT3_CIS_up NVS_NR_rAR 
ATG_TA_CIS_up NVS_OR_gSIGMA_NonSelective 
ATG_TAL_CIS_up NVS_TR_gDAT 
ATG_TGFb_CIS_up NVS_TR_hDAT 
ATG_THRa1_TRANS_up NVS_TR_hNET 
ATG_VDRE_CIS_up NVS_TR_hSERT 
ATG_Xbp1_CIS_up NVS_TR_rSERT 
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BSK_3C_Eselectin_down NVS_TR_rVMAT2 
BSK_3C_HLADR_down OT_AR_ARELUC_AG_1440 
BSK_3C_ICAM1_down OT_AR_ARSRC1_0480 
BSK_3C_IL8_down OT_AR_ARSRC1_0960 
BSK_3C_MCP1_down OT_ERa_EREGFP_0120 
BSK_3C_MIG_down OT_ERa_EREGFP_0480 
BSK_3C_Proliferation_down OT_ER_ERaERa_0480 
BSK_3C_SRB_down OT_ER_ERaERa_1440 
BSK_3C_Thrombomodulin_up OT_ER_ERaERb_0480 
BSK_3C_TissueFactor_down OT_ER_ERaERb_1440 
BSK_3C_uPAR_down OT_ER_ERbERb_0480 
BSK_3C_VCAM1_down OT_ER_ERbERb_1440 
BSK_3C_Vis_down OT_FXR_FXRSRC1_0480 
BSK_4H_Eotaxin3_down OT_FXR_FXRSRC1_1440 
BSK_4H_MCP1_down OT_NURR1_NURR1RXRa_0480 
BSK_4H_Pselectin_down OT_PPARg_PPARgSRC1_1440 
BSK_4H_SRB_down Tox21_AhR 
BSK_4H_uPAR_down Tox21_AR_BLA_Agonist_ratio 
BSK_4H_VCAM1_down Tox21_AR_BLA_Antagonist_ratio 
BSK_4H_VEGFRII_down Tox21_AR_BLA_Antagonist_viability 
BSK_BE3C_HLADR_down Tox21_ARE_BLA_agonist_ratio 
BSK_BE3C_IL1a_down Tox21_AR_LUC_MDAKB2_Agonist 
BSK_BE3C_IP10_down Tox21_AR_LUC_MDAKB2_Antagonist 
BSK_BE3C_MIG_down Tox21_Aromatase_Inhibition 
BSK_BE3C_MMP1_down Tox21_AutoFluor_HEK293_Cell_blue 
BSK_BE3C_MMP1_up Tox21_AutoFluor_HEK293_Cell_green 
BSK_BE3C_PAI1_down Tox21_AutoFluor_HEK293_Cell_red 
BSK_BE3C_SRB_down Tox21_AutoFluor_HEK293_Media_blue 
BSK_BE3C_SRB_up Tox21_AutoFluor_HEK293_Media_green 
BSK_BE3C_TGFb1_down Tox21_AutoFluor_HEK293_Media_red 
BSK_BE3C_tPA_down Tox21_AutoFluor_HEPG2_Cell_blue 
BSK_BE3C_uPA_down Tox21_AutoFluor_HEPG2_Cell_green 
BSK_BE3C_uPAR_down Tox21_AutoFluor_HEPG2_Media_blue 
BSK_BE3C_uPAR_up Tox21_AutoFluor_HEPG2_Media_green 
BSK_CASM3C_HLADR_down Tox21_AutoFluor_HEPG2_Media_red 
BSK_CASM3C_IL6_down Tox21_ELG1_LUC_Agonist 
BSK_CASM3C_IL6_up Tox21_ERa_BLA_Agonist_ratio 
BSK_CASM3C_IL8_down Tox21_ERa_BLA_Antagonist_ratio 
BSK_CASM3C_IL8_up Tox21_ERa_BLA_Antagonist_viability 
BSK_CASM3C_LDLR_down Tox21_ERa_LUC_BG1_Agonist 
BSK_CASM3C_LDLR_up Tox21_ERa_LUC_BG1_Antagonist 
BSK_CASM3C_MCP1_down Tox21_ESRE_BLA_ratio 
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BSK_CASM3C_MCSF_down Tox21_ESRE_BLA_viability 
BSK_CASM3C_MIG_down Tox21_FXR_BLA_agonist_ratio 
BSK_CASM3C_Proliferation_down Tox21_FXR_BLA_agonist_viability 
BSK_CASM3C_SAA_down Tox21_FXR_BLA_antagonist_ratio 
BSK_CASM3C_SRB_down Tox21_FXR_BLA_antagonist_viability 
BSK_CASM3C_Thrombomodulin_up Tox21_GR_BLA_Agonist_ratio 
BSK_CASM3C_uPAR_down Tox21_GR_BLA_Antagonist_ratio 
BSK_CASM3C_VCAM1_down Tox21_GR_BLA_Antagonist_viability 
BSK_hDFCGF_CollagenIII_down Tox21_HSE_BLA_agonist_ratio 
BSK_hDFCGF_EGFR_down Tox21_HSE_BLA_agonist_viability 
BSK_hDFCGF_IL8_down Tox21_MitochondrialToxicity_ratio 
BSK_hDFCGF_IP10_down Tox21_MitochondrialToxicity_viability 
BSK_hDFCGF_MCSF_down Tox21_NFkB_BLA_agonist_ratio 
BSK_hDFCGF_MIG_down Tox21_NFkB_BLA_agonist_viability 
BSK_hDFCGF_MMP1_down Tox21_p53_BLA_p1_ratio 
BSK_hDFCGF_MMP1_up Tox21_p53_BLA_p1_viability 
BSK_hDFCGF_PAI1_down Tox21_p53_BLA_p2_ratio 
BSK_hDFCGF_Proliferation_down Tox21_p53_BLA_p2_viability 
BSK_hDFCGF_SRB_down Tox21_p53_BLA_p3_ratio 
BSK_hDFCGF_TIMP1_down Tox21_p53_BLA_p3_viability 
BSK_hDFCGF_VCAM1_down Tox21_p53_BLA_p4_ratio 
BSK_KF3CT_ICAM1_down Tox21_p53_BLA_p4_viability 
BSK_KF3CT_IL1a_down Tox21_p53_BLA_p5_ratio 
BSK_KF3CT_IP10_down Tox21_p53_BLA_p5_viability 
BSK_KF3CT_MCP1_down Tox21_PPARd_BLA_agonist_ratio 
BSK_KF3CT_MMP9_down Tox21_PPARd_BLA_Agonist_viability 
BSK_KF3CT_SRB_down Tox21_PPARd_BLA_antagonist_ratio 
BSK_KF3CT_SRB_up Tox21_PPARd_BLA_antagonist_viability 
BSK_KF3CT_TGFb1_down Tox21_PPARg_BLA_Agonist_ratio 
BSK_KF3CT_TIMP2_down Tox21_PPARg_BLA_antagonist_ratio 
BSK_KF3CT_uPA_down Tox21_PPARg_BLA_antagonist_viability 
BSK_LPS_CD40_down Tox21_TR_LUC_GH3_Agonist 
BSK_LPS_Eselectin_down Tox21_TR_LUC_GH3_Antagonist 
BSK_LPS_IL1a_down Tox21_VDR_BLA_agonist_ratio 
BSK_LPS_IL8_down Tox21_VDR_BLA_Agonist_viability 
BSK_LPS_MCP1_down Tox21_VDR_BLA_antagonist_ratio 
BSK_LPS_MCSF_down Tox21_VDR_BLA_antagonist_viability 
BSK_LPS_PGE2_down  
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Table (B-3) List of physicochemical used in analysis 
Physicochemical property Source 
SlogP RDKit 
SMR RDKit 
LabuteASA RDKit 
TPSA RDKit 
AMW RDKit 
ExactMW RDKit 
NumLipinskiHBA RDKit 
NumLipinskiHBD RDKit 
NumRotatableBonds RDKit 
NumHBD RDKit 
NumHBA RDKit 
NumAmideBonds RDKit 
NumHeteroAtoms RDKit 
NumHeavyAtoms RDKit 
NumAtoms RDKit 
NumRings RDKit 
NumAromaticRings RDKit 
NumSaturatedRings RDKit 
NumAliphaticRings RDKit 
NumAromaticHeterocycles RDKit 
NumSaturatedHeterocycles RDKit 
NumAliphaticHeterocycles RDKit 
NumAromaticCarbocycles RDKit 
NumSaturatedCarbocycles RDKit 
NumAliphaticCarbocycles RDKit 
FractionCSP3 RDKit 
HallKierAlpha RDKit 
Strongest.acidic.pKa ChemAxon 
Strongest.basic.pKa ChemAxon 
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Table (B-4) Rules matching Troglitazone describing toxicity at level of 500mg/kg/day 
Rules Condition 1 Condition 2 Condition 3 Rule accuracy 
Compound 
coverage 
1 ATG_p53_CIS_up <= 2.122144 Tox21_MitochondrialToxicity_viability <= 2.5 - 0.95 51 
2 APR_HepG2_MitoMass_24h_up <= 2.319333 OT_AR_ARSRC1_0480 <= 2.5 NumLipinskiHBA > 1 0.92 66 
3 ATG_PPARg_TRANS_up <= 1.694441 OT_AR_ARSRC1_0480 <= 2.5 NumRings > 0 0.87 78 
4 OT_AR_ARSRC1_0480 <= 1.806514 NumHeavyAtoms <= 33 NumAromaticCarbocycles > 0 0.86 83 
5 BSK_SAg_SRB_down <= 2.10206 NumHeavyAtoms <= 33 NumAromaticCarbocycles > 0 0.81 100 
6 BSK_BE3C_uPA_down <= 2.06236 NumHeavyAtoms <= 33 NumAromaticHeterocycles <= 0 0.79 53 
7 BSK_SAg_CD40_down <= 1.341604 NumHeteroAtoms > 1 NumHeavyAtoms <= 32 0.77 90 
8 BSK_3C_IL8_down <= 1.336627 BSK_LPS_CD40_down <= 1.572855 - 0.75 56 
9 APR_HepG2_CellCycleArrest_72h_dn <= 2.791415 
Tox21_FXR_BLA_antagonist_ratio <= 
2.40309 - 0.75 96 
10 OT_FXR_FXRSRC1_0480 <= 2.073822 NumHeavyAtoms <= 33 
NumAromaticCarbocycles 
> 0 0.75 113 
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Table (B-5) Rules matching Troglitazone describing toxicity at level of 15mg/kg/day 
Rules Condition 1 Condition 2 Condition 3 Rule accuracy 
Compound 
coverage 
1 BSK_4H_MCP1_down <= 1.422321 NumRotatableBonds <= 6 NumAliphaticCarbocycles 
<=0 
0.81 40 
2 BSK_hDFCGF_IP10_down <= 
1.726166 
Tox21_MitochondrialToxicity_viability 
<= 1.581255 
 0.89 25 
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APPENDIX C 
 
Table (C-1) Tox21 assays used in emerging patterns in Chapter 5 and 6.  
 
Assay description Uniprot Pubchem Assay ID 
1. qHTS assay for small molecule agonists of the p53 signaling pathway P04637 651631 
2. qHTS assay for small molecule agonists of the p53 signaling pathway 
- cell viability 
NA 651633 
3. qHTS assay for small molecule agonists of the p53 signaling pathway: 
Summary 
P04637 720552 
4. qHTS assay for small molecules that induce genotoxicity in human 
embryonic kidney cells expressing luciferase-tagged ATAD5 
Q96QE3 651632 
5. qHTS assay for small molecules that induce genotoxicity in human 
embryonic kidney cells expressing luciferase-tagged ATAD5 - cell 
viability 
NA 651634 
6. qHTS assay for small molecules that induce genotoxicity in human 
embryonic kidney cells expressing luciferase-tagged ATAD5: Summary 
Q96QE3 720516 
7. qHTS assay for small molecule disruptors of the mitochondrial 
membrane potential - cell viability 
NA 720634 
8. qHTS assay for small molecule disruptors of the mitochondrial 
membrane potential 
NA 720635 
9. qHTS assay for small molecule disruptors of the mitochondrial 
membrane potential: Summary 
NA 720637 
10. qHTS assay to test for compound auto fluorescence at 460 nm (blue) 
in HEK293 cells 
NA 720678 
11. qHTS assay to test for compound auto fluorescence at 460 nm (blue) 
in HEK293 cell free culture 
NA 720681 
12. qHTS assay to test for compound auto fluorescence at 460 nm (blue) 
in HepG2 cell free culture 
NA 720685 
13. qHTS assay to test for compound auto fluorescence at 460 nm (blue) 
in HepG2 cells 
NA 720687 
14. qHTS assay to identify small molecule agonists of the glucocorticoid 
receptor (GR) signaling pathway 
P04150 720691 
15. qHTS assay to identify small molecule antagonists of the 
glucocorticoid receptor (GR) signaling pathway 
P04150 720692 
16. qHTS assay to identify small molecule antagonists of the 
glucocorticoid receptor (GR) signaling pathway - cell viability counter 
screen 
NA 720693 
17. qHTS assay to identify small molecule agonists of the glucocorticoid 
receptor (GR) signaling pathway: Summary 
P04150 720719 
18. qHTS assay to identify small molecule antagonists of the 
glucocorticoid receptor (GR) signaling pathway: Summary 
P04150 720725 
19. qHTS assay to identify small molecule antagonists of the androgen  
receptor (AR) signaling pathway - cell viability counter screen 
NA 743033 
20. qHTS assay to identify small molecule antagonists of the androgen 
receptor (AR) signaling pathway 
P10275 743035 
21. qHTS assay to identify small molecule agonists of the androgen 
receptor (AR) signaling pathway 
P10275 743036 
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22. qHTS assay to identify small molecule antagonists of the androgen  
receptor (AR) signaling pathway using the MDA cell line - cell viability 
counter screen 
NA 743041 
23. qHTS assay to identify small molecule antagonists of the androgen  
receptor (AR) signaling pathway using the MDA cell line 
P10275 743042 
24. qHTS assay to identify small molecule agonists of the androgen 
receptor (AR) signaling pathway: Summary 
P10275 743053 
25. qHTS assay to identify small molecule antagonists of the androgen 
receptor (AR) signaling pathway using the MDA cell line: Summary 
P10275 743054 
26. qHTS assay to identify small molecule antagonists of the androgen 
receptor (AR) signaling pathway: Summary 
P10275 743063 
27. qHTS assay to identify small molecule antagonists of the thyroid 
receptor (TR) signaling pathway - cell viability counter screen 
NA 743064 
28. qHTS assay to identify small molecule antagonists of the thyroid 
receptor (TR) signaling pathway 
NA 743065 
29. qHTS assay to identify small molecule antagonists of the thyroid 
receptor (TR) signaling pathway: Summary 
NA 743067 
30. qHTS assay to identify small molecule antagonists of the estrogen 
receptor alpha (ER-alpha) signaling pathway 
P03372 743069 
31. qHTS assay to identify small molecule antagonists of the estrogen 
receptor alpha (ER-alpha) signaling pathway - cell viability counter 
screen 
NA 743074 
32. qHTS assay to identify small molecule agonists of the estrogen 
receptor alpha (ER-alpha) signaling pathway 
P03372 743075 
33. qHTS assay to identify small molecule agonists of the estrogen 
receptor alpha (ER-alpha) signaling pathway: Summary 
P03372 743077 
34. qHTS assay to identify small molecule antagonists of the estrogen 
receptor alpha (ER-alpha) signaling pathway: Summary 
P03372 743078 
35. qHTS assay to identify small molecule antagonists of the estrogen 
receptor alpha (ER-alpha) signaling pathway using the BG1 cell line 
P03372 743080 
36. qHTS assay to identify small molecule antagonists of the estrogen 
receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - 
cell viability counter screen 
NA 743081 
37. qHTS assay to identify aromatase inhibitors P11511 743083 
38. qHTS assay to identify aromatase inhibitors - cell viability counter 
screen 
NA 743084 
39. qHTS assay to identify small molecule that activate the aryl 
hydrocarbon receptor (AhR) signaling pathway 
P35869 743085 
40. qHTS assay to identify small molecule that activate the aryl 
hydrocarbon receptor (AhR) signaling pathway - cell viability counter 
screen 
NA 743086 
41. qHTS assay to identify small molecule antagonists of the estrogen 
receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: 
Summary 
P03372 743091 
42. qHTS assay to identify small molecule agonists of the peroxisome 
proliferator-activated receptor gamma (PPARg) signaling pathway 
P37231 743094 
43. qHTS assay to identify small molecule that activate the aryl 
hydrocarbon receptor (AhR) signaling pathway: Summary 
P35869 743122 
44. qHTS assay to identify aromatase inhibitors: Summary P11511 743139 
45. qHTS assay to identify small molecule agonists of the peroxisome 
proliferator-activated receptor gamma (PPARg) signaling pathway: 
Summary 
P37231 743140 
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46. qHTS assay to identify small molecule antagonists of the retinoid-
related orphan receptor gamma (ROR-gamma) signaling pathway - cell 
viability counter screen 
NA 1159520 
47. qHTS assay to identify small molecule antagonists of the retinoid-
related orphan receptor gamma (ROR-gamma) signaling pathway 
P51450 1159521 
48. qHTS assay to identify small molecule antagonists of the retinoid-
related orphan receptor gamma (ROR-gamma) signaling pathway: 
Summary 
P51450 1159523 
49. qHTS assay to identify small molecule agonists of the AP-1 
signaling pathway - cell viability counter screen 
NA 1159525 
50. qHTS assay to identify small molecule agonists of the AP-1 
signaling pathway 
P05412 1159526 
51. qHTS assay to identify small molecule agonists of the RXR 
signaling pathway 
P19793 1159527 
52. qHTS assay to identify small molecule agonists of the AP-1 
signaling pathway: Summary 
P05412 1159528 
53. qHTS assay to identify small molecule agonists of the RXR 
signaling pathway - cell viability counter screen 
NA 1159529 
54. qHTS assay to identify small molecule agonists of the RXR 
signaling pathway: Summary 
P19793 1159531 
55. qHTS assay to identify small molecule antagonists of the retinoid 
acid receptor (RAR) signaling pathway - cell viability counter screen 
NA 1159551 
56. qHTS assay to identify small molecule antagonists of the retinoic 
acid receptor (RAR) signaling pathway 
P10276 1159552 
57. qHTS assay to identify small molecule antagonists of the retinoic 
acid receptor (RAR) signaling pathway: Summary 
P10276 1159555 
58. qHTS assay to identify small molecule agonists of the constitutive 
androstane receptor (CAR) signaling pathway - cell viability counter 
screen 
NA 1224836 
59. qHTS assay to identify small molecule antagonists of the constitutive 
androstane receptor (CAR) signaling pathway - cell viability counter 
screen 
NA 1224837 
60. qHTS assay to identify small molecule antagonists of the constitutive 
androstane receptor (CAR) signaling pathway 
Q14994 1224838 
61. qHTS assay to identify small molecule agonists of the constitutive 
androstane receptor (CAR) signaling pathway 
Q14994 1224839 
62. qHTS assay to identify small molecule agonists of the thyroid 
stimulating hormone receptor (TSHR) signaling pathway 
P16473 1224843 
63. qHTS assay to identify small molecule agonists of the hypoxia (HIF-
1) signaling pathway - cell viability counter screen 
NA 1224844 
64. qHTS assay to identify small molecule agonists of H2AX NA 1224845 
65. qHTS assay to identify small molecule agonists of the hypoxia (HIF-
1) signaling pathway 
Q16665 1224846 
66. qHTS assay to identify small molecule agonists of H2AX - cell 
viability counter screen 
NA 1224847 
67. qHTS assay to identify small molecule agonists of the constitutive 
androstane receptor (CAR) signaling pathway: Summary 
Q14994 1224892 
68. qHTS assay to identify small molecule antagonists of the constitutive 
androstane receptor (CAR) signaling pathway: Summary 
Q14994 1224893 
69. qHTS assay to identify small molecule agonists of the hypoxia (HIF-
1) signaling pathway: Summary 
Q16665 1224894 
70. qHTS assay to identify small molecule agonists of the thyroid 
stimulating hormone receptor (TSHR) signaling pathway: Summary 
P16473 1224895 
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71. qHTS assay to identify small molecule agonists of H2AX: Summary NA 1224896 
72. qHTS assay to identify small molecule antagonists of the estrogen 
receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in 
the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen 
NA 1259241 
73. qHTS assay to identify small molecule antagonists of the androgen 
receptor (AR) signaling pathway using the MDA cell line in the 
presence of 0.5 nM R1881 - cell viability counter screen 
NA 1259242 
74. qHTS assay to identify small molecule antagonists of the androgen 
receptor (AR) signaling pathway using the MDA cell line in the 
presence of 0.5 nM R1881 
P10275 1259243 
75. qHTS assay to identify small molecule antagonists of the estrogen 
receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in 
the presence of 0.1 nM 17-beta-estradiol 
P03372 1259244 
76. qHTS assay to identify small molecule antagonists of the androgen 
receptor (AR) signaling pathway using the MDA cell line in the 
presence of 0.5 nM R1881: Summary 
P10275 1259247 
77. qHTS assay to identify small molecule antagonists of the estrogen 
receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in 
the presence of 0.1 nM 17-beta-estradiol: Summary 
P03372 1259248 
78. qHTS assay to identify small molecule agonists of the NFkB 
signaling pathway 
P19838 1159509 
79. qHTS assay to identify small molecule agonists of the NFkB 
signaling pathway - cell viability counter screen 
NA 1159515 
80. qHTS assay to identify small molecule agonists of the endoplasmic 
reticulum stress response signaling pathway 
P18850 1159516 
81. qHTS assay to identify small molecule agonists of the endoplasmic 
reticulum stress response signaling pathway - cell viability counter 
screen 
NA 1159517 
82. qHTS assay to identify small molecule agonists of the NFkB 
signaling pathway: Summary 
P19838 1159518 
83. qHTS assay to identify small molecule agonists of the endoplasmic 
reticulum stress response signaling pathway: Summary 
P18850 1159519 
84. qHTS assay to identify small molecule antagonists of the peroxisome 
proliferator-activated receptor gamma (PPARg) signaling pathway 
P37231 743191 
85. qHTS assay to identify small molecule antagonists of the peroxisome 
proliferator-activated receptor gamma (PPARg) signaling pathway - cell 
viability counter screen 
NA 743194 
86. qHTS assay to identify small molecule antagonists of the peroxisome 
proliferator-activated receptor gamma (PPARg) signaling pathway: 
Summary 
P37231 743199 
87. qHTS assay for small molecule agonists of the antioxidant response 
element (ARE) signaling pathway 
Q16236 743202 
88. qHTS assay for small molecule agonists of the antioxidant response 
element (ARE) signaling pathway - cell viability counter screen 
NA 743203 
89. qHTS assay for small molecule activators of the heat shock response 
signaling pathway - cell viability counter screen 
NA 743209 
90. qHTS assay for small molecule activators of the heat shock response 
signaling pathway 
P04792 743210 
91. qHTS assay to identify small molecule agonists of the peroxisome 
proliferator-activated receptor delta (PPARd) signaling pathway - cell 
viability counter screen 
NA 743211 
92. qHTS assay to identify small molecule agonists of the peroxisome 
proliferator-activated receptor delta (PPARd) signaling pathway 
Q03181 743212 
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93. qHTS assay to identify small molecule antagonists of the peroxisome 
proliferator-activated receptor delta (PPARd) signaling pathway - cell 
viability counter screen 
NA 743213 
94. qHTS assay to identify small molecule antagonists of the peroxisome 
proliferator-activated receptor delta (PPARd) signaling pathway 
Q03181 743215 
95. qHTS assay to identify small molecule antagonists of the farnesoid-
X-receptor (FXR) signaling pathway 
Q96RI1 743217 
96. qHTS assay to identify small molecule agonists of the farnesoid-X-
receptor (FXR) signaling pathway - cell viability counter screen 
NA 743218 
97. qHTS assay for small molecule agonists of the antioxidant response 
element (ARE) signaling pathway: Summary 
Q16236 743219 
98. qHTS assay to identify small molecule agonists of the farnesoid-X-
receptor (FXR) signaling pathway 
Q96RI1 743220 
99. qHTS assay to identify small molecule antagonists of the farnesoid-
X-receptor (FXR) signaling pathway - cell viability counter screen 
NA 743221 
100. qHTS assay to identify small molecule agonists of the vitamin D 
receptor (VDR) signaling pathway 
P11473 743222 
101. qHTS assay to identify small molecule antagonists of the vitamin D 
receptor (VDR) signaling pathway 
P11473 743223 
102. qHTS assay to identify small molecule agonists of the vitamin D 
receptor (VDR) signaling pathway - cell viability counter screen 
NA 743224 
103. qHTS assay to identify small molecule antagonists of the vitamin D 
receptor (VDR) signaling pathway - cell viability counter screen 
NA 743225 
104. qHTS assay to identify small molecule antagonists of the 
peroxisome proliferator-activated receptor delta (PPARd) signaling 
pathway: Summary 
Q03181 743226 
105. qHTS assay to identify small molecule agonists of the peroxisome 
proliferator-activated receptor delta (PPARd) signaling pathway: 
Summary 
Q03181 743227 
106. qHTS assay for small molecule activators of the heat shock 
response signaling pathway: Summary 
P04792 743228 
107. qHTS assay to identify small molecule agonists of the farnesoid-X-
receptor (FXR) signaling pathway: Summary 
Q96RI1 743239 
108. qHTS assay to identify small molecule antagonists of the farnesoid-
X-receptor (FXR) signaling pathway: Summary 
Q96RI1 743240 
109. qHTS assay to identify small molecule agonists of the vitamin D 
receptor (VDR) signaling pathway: Summary 
P11473 743241 
110. qHTS assay to identify small molecule antagonists of the vitamin D 
receptor (VDR) signaling pathway: Summary 
P11473 743242 
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Figure (C-1) The correlation between the two synergy measures used in the study, mutual 
information (MI) and synergy factor. Threshold for MI-based synergy was set to 0.001 value. 
Pairs which did not exert MI synergy has shown synergy factor values less than 1.5.  
 
 
 
 
 
Figure (C-2) Percentage distribution of feature classes in each cluster as well as single 
condition feature rules in toxic (a) and non-toxic (b) networks. In toxic network, single feature 
rules and cluster 1, were more occupied by cell viability, nuclear receptor activity and structural 
features. The remaining clusters had mainly target-specific features such as enzymes, kinases, 
ion channels and GPCR. Clusters of non-toxic network had more diverse distribution of classes 
compared to toxic network.  
 
 
 
 
 
 
 
 
a) b) 
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Figure (C-3) Similarity between target-specific pairs using Gene Ontology (GO) (a) molecular 
functions and (b) biological processes with respect to the synergy of the pair. Synergistic pairs 
show almost zero similarity in function and biological processes. However, not all dissimilar 
pair are synergistic.  
 
 
 
 
 
 
 
 
a) b) 
